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ABSTRACT  
The purpose of this study was to explore the medication related experiences of community dwelling 
adults with learning disabilities (LD). A narrative review was undertaken and found that current 
literature focused on measuring the prevalence of particular drug related issues, rather than on the 
views and experiences of the adult with LD.  
 
A qualitative methodology was adopted with a pragmatic case study approach in which each case 
study focused on a community dwelling adult with LD. The Patients Lived Experience with Medicines 
(PLEM) conceptual model was used as a theoretical framework for data collection and analysis. Data 
were collected from: semi-structured interviews with the adult with LD, where possible; semi-
structured interviews with relevant carers and care workers; available documents; and unstructured 
indirect observations of relevant artefacts by the researcher. Ethical approval was gained. 
 
One pilot and ten case studies were identified by local care providers. Using the PLEM conceptual 
model, the following medication related experiences were reported: 
1. Medication related burden: drugs adversely affecting cognitive ability and mental wellbeing 
are often intolerable, the daily routine can itself be a burden, changes to routine can be 
challenging, and the burden with medication is often assumed by the carers or care workers; 
2. Medication related beliefs: medication is seen as both beneficial and necessary, carers and 
care workers of adults with severe LD are the experts on the person being prescribed for, 
and enabling the coping skills of adults with mild-moderate LD is important; 
3. Medication taking practice: acceptance of medication was never truly unconditional.  
 
In conclusion, the medication related experiences of community dwelling adults with LD are 
multifaceted and often shared by or transferred to, any carer or care worker. The outcomes of this 
research could help support the education and training of health care professionals. 
 
Key words: learning disabilities; medicines; medication; patients lived experience with medicines 
(PLEM); medication related burden; medication related beliefs; medication taking practice   
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FOREWORD 
For the last 8 years I have been employed by NHS Grampian as a primary care Lead Pharmacist 
within Aberdeen City Health and Social Care Partnership (previously Community Health Partnership). 
Prior to that I worked for 10 years as a clinical pharmacist across a variety of GP practices within NHS 
Grampian where I advised the GP practice team on medication related issues, participated in multi-
disciplinary meetings, and ran clinics for patients with respiratory conditions as an independent 
prescriber. Whilst the core aspect of my current role is to work with GPs to ensure safe and cost-
effective prescribing, a significant part of my role is also spent working with social care colleagues on 
medication management issues. Over the years I have been involved in: producing an online 
resource (www.medicinemanagement.org) for medication administration training; rewriting our 
local medication management guidance (version 3 launched June 2017); and assisting our Adult 
Support and Protection team with some cases involving medication. Some of my work with social 
care colleagues has involved me working with several LD care providers to create medication 
management policies and review current practices. During these times I was struck by some of the 
complex and unique challenges that LD care providers faced with regards to supporting their clients 
with medicines. It was the lack of literature on the subject that then prompted me to undertake 
research that would document some of these challenges and therefore increase awareness amongst 
health and social care professionals and so improve the support for this group of patients/clients. At 
the same time, I was working with academic colleagues to undertake local, practice-based research 
in the areas of multi-compartment compliance aids1 2 3 4 and the homeless population5 6.  
 
                                                     
 
1 Stewart D, Smith KG, MacLeod J, Strath A, Paudyal V, Forbes-McKay K, Cunningham S, MacLure K. The experiences and 
beliefs of older people in Scottish very sheltered housing about using multi-compartment compliance aids. International 
journal of clinical pharmacy. 2018 Apr 1;40(2):394-402. 
 
2 Stewart D, McDonald C, MacLeod J, MacLure K, Gray G, McIntosh T. The behaviors and experiences of the community 
pharmacy team on the provision of multi-compartment compliance aids. Research in social and administrative pharmacy. 
2018 Apr 1;14(4):347-55. 
 
3 Counter D, Stewart D, MacLeod J, McLay JS. Multicompartment compliance aids in the community: the prevalence of 
potentially inappropriate medications. British journal of clinical pharmacology. 2017 Jul;83(7):1515-20. 
 
4 MacLure K, MacLeod J, Forbes-McKay K, Paudyal V, Cunningham S, Strath A, Lynch R, Stewart D. A case study 
investigation into the use of multi-compartment compliance aids in older people resident in very sheltered housing. The 
Patient-Patient-Centered Outcomes Research. 2016 Dec 1;9(6):583-90. 
 
5 Smith KG, Paudyal V, MacLure K, Forbes-McKay K, Buchanan C, Wilson L, MacLeod J, Smith A, Stewart D. Relocating 
patients from a specialist homeless healthcare centre to general practices: a multi-perspective study. Br J Gen Pract. 2018 
Feb 1;68(667):e105-13. 
 
6 Paudyal V, MacLure K, Buchanan C, Wilson L, Macleod J, Stewart D. ‘When you are homeless, you are not thinking about 
your medication, but your food, shelter or heat for the night’: behavioural determinants of homeless patients' adherence 
to prescribed medicines. Public health. 2017 Jul 1;148:1-8. 
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As I was developing my knowledge of research processes and opportunities through this 
collaborative work, the option of undertaking a Doctorate of Professional Practice (DPP) arose. 
Whilst a traditional PhD was also an option, the DPP had a greater focus on the impact of the 
research and was therefore of greater value to me as a clinician, and to the service I work within. 
Accordingly, the DPP was chosen as a means of developing personal research skills but with the 
expectation that the results could be of benefit to the local service.  
 
This thesis has been structured as follows: 
 Chapter 1 is a general introduction to the thesis including a narrative literature review and 
the aim and objectives of the research; 
 Chapter 2 outlines the methodology, research governance, theoretical framework and study 
design; 
 Chapter 3 summarises the ten cases which were studied in the research; 
 Chapters 4, 5 and 6 contain the results, structured under the three research objectives 
which reflect the conceptual model adopted as a theoretical framework; 
 Chapter 7 continues the results by outlining the newly identified sub-themes that were not 
listed within the aforementioned theoretical framework; 
 Chapter 8 summarises the outcome of the dissemination panel check which was employed 
to enhance the credibility of the results; 
 Chapter 9 discusses the overall results in terms of the theoretical framework used and then 
considers the reflexivity, transferability, strengths and limitations of the research; 
 Chapter 10 considers the impact of the research before providing a conclusion. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
 
 
 
 
 
 
‘You never really understand a person until you consider things from his point of view – until you 
climb into his skin and walk around in it.’ 
Atticus Finch in ‘To Kill a Mockingbird’ – Harper Lee  
2 
 
1.1 CHAPTER INTRODUCTION 
This chapter provides an introduction to the thesis. First of all, the concept of learning disabilities 
(LD) is explored through describing the current definitions and classification of LD; citing the 
estimated prevalence of LD; and outlining the models for understanding LD. Current UK and Scottish 
policies relating to LD are described as well as the recognised health needs of people with LD. A brief 
summary of social care provision, the role of carers and care workers, and of medication and 
polypharmacy within Scotland is then provided. Following on from this, the current evidence within 
the literature relating to adults with LD and medication is presented in six themed sections: general 
medication; antipsychotic medication; practical challenges to medication administration and 
management; carers, care workers and medication; pharmacist input to care; and clinical issues. 
Gaps within the literature are then noted and discussed. Finally, the aim and objectives of the 
research are stated.  
 
1.2 LEARNING DISABILITIES  
1.2.1 Definition- Learning Disability (LD) 
Learning disability (LD) is the term used in the United Kingdom (UK) to describe an individual who: 
has significant impairment of intellectual functioning (generally recognised as Intelligence Quotient 
(IQ) <70); and who has significant impairment of adaptive functioning; and where the age of onset 
was before adulthood (British Psychological Society 2000). The British Psychological Society (2000 
p.6) defines adaptive functioning as being impaired when, ‘The individual requires significant 
assistance to provide for his/her own survival (eating and drinking; keeping himself/herself clean, 
warm and clothed) and/or with his/her social/community adaptation (e.g. social problem solving and 
social reasoning).’ However, Emerson and Hatton (2014) do highlight that the definition of LD has 
varied hugely over time due to it being a profoundly social construct. 
 
Intellectual disability (ID) is the internationally recognised term for LD. It too is defined in terms of 
significant impairment to both intellectual functioning and adaptive functioning with symptoms 
beginning in childhood or adolescence (American Psychiatric Association 2017; American Association 
on Intellectual and Development Disabilities 2015). The definitions of LD and ID are so similar that 
those working and conducting research within this field see the terms as synonymous (Bhaumik et al 
2015). As this research was conducted solely in the UK, the term learning disability (LD) will be used 
throughout this thesis.  
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It should also be noted that the term ‘learning difficulties’, used within the UK educational system, is 
not synonymous with ID and LD. ‘Learning difficulties’ refers to those issues that can affect 
education such as: speech and language impairments; sensory impairments that give rise to learning 
problems, physical disabilities, medical problems or general behavioural difficulties; and specific 
learning problems such as dyslexia (Bhaumik et al 2015). Furthermore, the term developmental 
disability (DD) is an umbrella term that refers to both physical and/or learning disabilities that 
originated at birth or early childhood; will last throughout life, and; will severely restrict the 
individual's functioning in several major life activities (Center for Disease Control and Prevention 
2017).  The term ‘learning difficulties’ and ‘developmental disabilities’ are therefore broader 
categories than LD or ID.  
 
1.2.2 Causes of LD 
Not all the causes of LD are known (British Institute of Learning Disabilities 2011). Some of the more 
common causes are listed by the Foundation for People with Learning Disabilities (Mental Health 
Foundation 2017) and include: genetic conditions such as Fragile X; chromosomal abnormalities such 
as Down’s syndrome; very premature delivery; illness of mother during pregnancy; brain damage or 
abnormal development of the brain before, during, or after birth such as Cerebral Palsy; foetal 
alcohol syndrome; teratogenic drugs; neglect or a lack of mental stimulation early in life.  
 
1.2.3 Classification of LD 
Traditionally in the UK, LD was classified on the basis of intelligence: mild (IQ 50-70); moderate (IQ 
35-50); severe (IQ 20-35); or profound (IQ <20) (British Institute of Learning Disabilities 2011; British 
Psychological Society 2000). Due to the challenges of accurately measuring IQ, and recognising 
adaptive functioning as a key issue, the British Psychological Society (BPS) recommended that LD 
classification should refer not just to the IQ but also to the required adaptive or social functioning 
support that person requires (British Psychological Society 2000). The BPS states that intellectual 
functioning should be classified as either significant (IQ 55-69) or severe (IQ<55); and the level of 
support required in relation to adaptive functioning should then be referred to as intermittent 
(episodic), limited (consistent over time, time limited, but more regular than intermittent), extensive 
(regular and not time limited), or pervasive (high intensity across more than one environment). 
However, accurate classification of LD remains a challenge for health care professionals (HCPs) and 
likely to change in the future (Webb and Whitaker 2012). Furthermore, in practice it is often difficult 
to ascertain how any classification being used by carers, care workers or HCPs to describe an 
individual with LD was actually determined. 
4 
 
1.2.4 Prevalence of LD 
The 2011 Scottish Census recorded that 26,300 (0.5%) people in Scotland reported that they had a 
learning disability: 15,100 males and 11,200 females (National Records of Scotland, 2011). Public 
Health England (2016) estimated that in 2015 in England there were 1,087,100 (1.7%) people with 
learning disabilities, including 930,400 adults. The Royal College of Nursing (2013) cited a higher 
figure of ~1.5 million (2.3%) people having LD in the UK. From these data sources it can be estimated 
that 0.5-2.3% of the UK population has LD. This can be compared to a meta-analysis undertaken by 
Maulik et al (cited by Emerson and Hatton 2013) which calculated global prevalence of LD to be 
1.03%. This differences in prevalence data is most probably due to the heterogeneity of the 
population to which it refers and whether or not people with mild LD see, or declare, themselves as 
having LD (British Psychological Society 2000). The Scottish Government noted that research studies 
that tried to more accurately determine the prevalence of LD have been challenging, expensive and 
unsuccessful (Scottish Government 2013).  
 
1.2.5 Models of LD 
Emerson and Hatton (2014) outline the three main models for understanding LD: the medical model; 
the social model; and the biopsychosocial model.  
1. The medical model is deficit based and aims to first reduce the deficit and then care for this 
population. The goal is to reduce the poor health of people with LD whilst accepting that 
they will always be in poorer health than the remainder of the non-LD population. 
2. The social model makes a conceptual distinction between impairment and disability, and 
views experienced inequalities as an expression of societal oppression and exclusion. This 
then provides a framework for political change, achievement of civil rights, and 
empowerment. 
3. The biopsychosocial model was developed by the World Health Organization (World Health 
Organization 2001). It is more complex than the medical or social models and some consider 
it to be the medical model with the social model just grafted on. The biopsychosocial model 
is neutral on the goals of policy and practice. 
Furthermore, within social care, the work of both Sen and Nussbaum has encouraged a shift of focus 
from disability to capability (Nussbaum 2011; Sen 1999). Capabilities are not to be considered 
merely as skills or abilities but as a combination of personal attributes and the environment with a 
particular emphasis on what that person is able to do and to be (Nussbaum 2011; Sen 1999). Giving 
due consideration to capability, inclusion and empowerment is, therefore, important for both HCPs 
and researchers (Nind 2009; Dalton and McVilly 2004; Stalker 1998).  
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1.2.6 UK National Health Service (NHS) 
In 1948, the publicly owned National Health Service (NHS) was founded in each of the four home 
nations of the UK (England, Northern Ireland, Scotland and Wales) and to this day continues to 
provide health care to all UK citizens (GIG Cymru NHS Wales 2017; Health and Social Care Northern 
Ireland 2017; NHS Choices 2017; Scotland’s Health on the Web 2017; Scottish Government Health 
Directorates 2008). Although the NHS has evolved differently in the four home nations, each nation 
adheres to the central principle of the NHS being available to all through a taxation system where 
people pay into it according to their means (GIG Cymru NHS Wales 2017; Health and Social Care 
Northern Ireland 2017; NHS Choices 2017; Scotland’s Health on the Web 2017). 
 
1.2.7 UK Government Health Policies 
The National Health Service and Community Care Act (National Health Service and Community Care 
Act 1990) was the first major reform of the NHS since its inception (Emerson and Hatton 1994). The 
Act attempted to bridge the gap between health care services and local council social services and, 
where possible, move these services away from institutions and into communities. Emerson and 
Hatton (1994) noted that this meant that people with LD were no longer to be consigned to mental 
handicap hospitals for their lifetime, but instead included in the community and housed in smaller 
units of residential care. In Scotland these smaller units of residential care are known as 
independent living supported housing (Scottish Government 2017a). In 2001, the UK Department of 
Health issued a strategic White Paper with the four key principles of rights, independence, choice, 
and inclusion, and covered issues ranging from health to advocacy (Department of Health 2001).  
However, in May 2011, despite this clearly articulated strategy for improving the lives of people with 
LD, the British Broadcasting Corporation (BBC)’s Panorama television documentary revealed the 
shocking, criminal abuse of people with LD at a privately owned hospital in Winterbourne (BBC News 
2011). Many of the employees were subsequently prosecuted and an investigation into the abuse 
was led by the Care Quality Commission (CQC). One of the key recommendations from the CQC 
investigation was that only when it was clinically necessary should any person with LD live in a 
hospital setting (Department of Health 2012). Whilst medication was not a primary factor in the 
Winterbourne scandal, the subsequent reports highlighted concerns over the use of antipsychotic 
and other psychoactive medicines being used as a chemical restraint: 
‘We have heard deep concerns about over-use of antipsychotic and antidepressant 
medicines. Health professionals caring for people with learning disabilities should assess and 
keep under review the medicines requirements for each individual patient to determine the 
best course of action for that patient, taking into account the views of the person if possible 
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and their family and/or carer. Services should have systems and policies in place to ensure 
that this is done safely and in a timely manner and should carry out regular audits of 
medication prescribing and management, involving pharmacists, doctors and nurses.’ 
(Department of Health 2012 p.45) 
 
‘…antipsychotics and antidepressants are often prescribed in the absence of recorded 
diagnosis for which they are known to be effective...relatively few of the patients would have 
taken the initiative themselves to seek initial or continuing treatment. It is likely that carers 
would have been influential both in arranging consultations and in procuring and 
administering medications.’ (Public Health England 2015 p.7 & p.48) 
Within Scotland, ‘The Keys to Life’ is the current strategy document for improving the lives of people 
with LD (Scottish Government 2013). It relates to the United Nations Convention of the Rights of 
People with Disabilities (United Nations General Assembly 2007) and lists four outcomes for people 
with LD in Scotland: a healthy life; choice and control; independence; and active citizenship. The 
strategy notes that, ‘Independent living does not mean living by yourself, or fending for yourself. It 
means rights to practical assistance and support to participate in society and live an ordinary life.’ 
(Scottish Government 2013 p.54) 
 
The Scottish Chief Medical Officer’s three most recent reports, ‘Realistic Medicine’ (Scottish 
Government 2016); ‘Realising Realistic Medicine’ (Scottish Government 2017b); and ‘Practising 
Realistic Medicine’ (Scottish Government 2018), have begun a new conversation in health and social 
care on personalising care, managing clinical risk, reducing harm and waste and innovating to 
improve. Two key points are noted below: 
‘You should expect the doctor (or other health professional) to explore and understand what 
matters to you personally and what your goals are, to explain to you the possible treatments 
or interventions available with a realistic explanation of their potential benefits and risks for 
you as an individual, and to discuss the option and implications of doing nothing. You should 
expect to be given enough information and time to make up your mind. You should consider 
carefully the value to you of anything that is being proposed whether it be a treatment, 
consultation or diagnostic investigation and be prepared to offer challenge if you feel it 
appropriate.’ (Scottish Government 2017b p.4) 
‘We fail to measure what really matters in producing value-based care because we’ve been 
trained in a reductionist environment where people don’t trust measures that aren’t highly 
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objective and generalisable, when most things that contribute to value at the level of the 
individual are highly subjective and context specific, including their preferences. If we don’t 
measure whether services delivered are concordant with people’s preferences, we can’t 
measure that value creation.’ (Scottish Government 2017b p. 11) 
These views have been echoed by the Scottish Chief Pharmaceutical Officer in, ‘Achieving Excellence 
in Pharmaceutical Care – a Strategy for Scotland’ (Scottish Government 2017c). Adopting a person-
centred approach to improving the quality of care and achieving better health outcomes, in 
particular for people with multiple and complex long term conditions, is a key focus. Within the 
strategy, a specific commitment was made to support patients who are resident in care home 
settings or who require support from care workers and involve their carers, family or care workers in 
key decisions. 
 
1.2.8 Health Needs of People with LD 
People with LD are known to have increased medical needs and a higher incidence of: visual 
impairment; hearing impairment; epilepsy; dementia; psychiatric disorders; cardiovascular disease; 
gastro-intestinal problems; major physical disabilities of mobility; faecal and urinary incontinence; 
and obesity (Bhaumik et al 2015; O’Dwyer, Mestrovic and Henman 2015; Paton et al 2011; Van-
Schrojenstein, Lantman-De Valk and Walsh 2008; Peate and Fearns 2006; Munk and Repp 1994). 
Garvey and Vincent (2006) highlight that people with LD are 58 times more likely to die before 50 
years of age and are 2.5 times more likely to have a condition requiring medical attention than 
people without LD.  Furthermore, people with LD encounter all the major life threatening diseases 5-
10 years earlier than the rest of the population (Scottish Government 2013). Baxter et al (2006 p.95) 
also highlight that even minor health issues, ‘may be more significant for these people than the 
general population because of their impact on already limited social, communicative, and practical 
abilities.’ 
 
Swallowing difficulties (dysphagia, difficulties in chewing and swallowing, difficulties in maintaining a 
safe posture for eating and drinking) are often prevalent in people with severe LD and insertion of 
either a nasogastric (NG) tube or a percutaneous endoscopy gastrostomy (PEG) tube for feeding and 
medicine administration is often required (Bhaumik et al 2015; Shah 2008). 
 
Although it is known that people with LD have increased health needs, the Royal College of General 
Practitioners (2010) highlight the potential for diagnostic overshadowing as a result of attributing 
symptoms to the overall LD condition. Furthermore, people with LD can often have difficulty in 
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relating illness to dysfunction in their body, recognising relevant signs and symptoms, or 
communicating these to a HCP (Davis et al 2016; Van Schrojenstein Lantman-De Valk and Walsh 
2008; Straetmans et al 2007). Another key issue to note is that any person with severe LD relies 
completely on their carers to communicate and advocate their health needs (Scottish Government 
2013). 
 
1.2.9 Care Provision, Carers and Care Workers  
In Scotland, Local Authorities (LAs) and the NHS are the two public bodies primarily responsible for 
providing formal services to adults with LD (Scottish Government 2013). Whilst the NHS is 
responsible for providing an appropriate health care service, the LA is responsible for assessing the 
need for social care services. If social care support is then required, the LA will either commission the 
provision of that service or provide a direct payment to the adult or their carer in order for them to 
commission their preferred services (Social Care (Self-directed Support) (Scotland) Act 2013). Whilst 
LAs may also provide the commissioned support to some adults with LD, care is often delivered by 
private care providers and third sector organisations such as community groups, voluntary 
organisations, charities, social enterprises, and co-operatives (Scottish Government 2017d; Scottish 
Government 2017e).  
 
People who are employed by the LA, care providers or third sector organisations to provide care and 
support are referred to as care workers (Scottish Government 2010). However, much of the care 
provided to adults with LD, is provided by unpaid carers. The Scottish Government (2010) estimated 
that 7,793 adults with LD and autism known to LAs in Scotland lived with a carer. In their ‘Caring 
Together’ strategy, the Scottish Government (2010 p16) notes that, ‘a range of terms is used to 
describe a person who cares for another including: “unpaid carer”, “carer”, “family carer”, and 
“informal carer” …It is important that carers are not confused with paid workers, who are sometimes 
incorrectly called carers too; paid workers are care workers’. Whilst this distinction is clear to those 
who work in the care sector it is not as clear to HCPs and the general public, and it is common to 
hear both groups referred to collectively as ‘carers’. Within this thesis every attempt will be made to 
refer to both carers and care workers and differentiate between them where appropriate. 
 
Locally, the Aberdeen Care Provider forum, previously known as Care And Support Providers 
Aberdeen (CASPA), is linked with Aberdeen Council of Voluntary Organisations (ACVO), a third sector 
interface organisation (ACVO 2018). This forum includes LD care providers and LD charities, all of 
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whom support community dwelling adults with LD in the local area where this research was 
undertaken. 
 
1.3 MEDICINES, MEDICATION and POLYPHARMACY  
In the UK, the 2012 Human Medicines Regulations use the term ‘medicinal product’ to define: (a) 
any substance or combination of substances presented as having properties of preventing or 
treating disease in human beings; or (b) any substance or combination of substances that may be 
used by or administered to human beings with a view to restoring, correcting or modifying a 
physiological function by exerting a pharmacological, immunological or metabolic action, or making 
a medical diagnosis (The Human Medicines Regulations 2012). 
 
However, the term ‘medicinal product’ is rarely used by HCPs or patients; instead the terms 
medicine or medication are used. The Oxford English dictionary defines medicine as, ‘a drug or other 
preparation for the treatment or prevention of disease’, and medication as, ‘a drug or other form of 
medicine that is used to treat or prevent disease’ (English Oxford Living Dictionary 2018a; English 
Oxford Living Dictionary 2018b). Whilst it can be argued that there is a distinction between the 
terms, the two will be used interchangeably within this thesis to refer to substances that are legally 
defined as ‘medicinal products’. 
 
According to the National Institute for health and Care Excellence (NICE), medicines are the most 
common intervention in healthcare and are used to prevent, treat or manage many medical 
conditions (National Institute for Health and Care Excellence 2015b). Within Scotland, 103.4 million 
prescription items were dispensed in primary care between April 2016 and March 2017 at a gross 
ingredient cost of £1.3 billion (National Services Scotland Information Services Division 2017).  
Guthrie et al (2012) noted that in Scotland the number of people prescribed multiple medicines is 
growing year on year. They calculated that in 1995, 12% of patients were prescribed 5 or more drugs 
and 1.9% were prescribed 10 or more drugs and that by 2010 these figures had risen to 22% patients 
being prescribed 5 or more drugs and 5.8% bring prescribed 10 or more drugs. The term used to 
define this phenomena of multiple medicine use is ‘polypharmacy’ and within Scotland this is 
understood to refer to patients who take five or more medicines (Scottish Government Model of 
Care Polypharmacy Working Group 2015). However, as noted by Duerden, Avery and Payne (2013), 
there is a distinction between appropriate polypharmacy (when medicines use has been optimised 
and prescribed according to best evidence) and problematic polypharmacy (when the use of 
multiple medications is inappropriate, or where the intended benefit of the medication is not 
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realised). In addition, Straetmans et al (2007) noted that people with LD are prescribed more 
medication than the general population due to their increased health needs. 
 
1.4 LITERATURE REVIEW 
1.4.1 Aim 
To provide an overview, in the form of a narrative review, of the current literature relating to people 
with LD and their experience of medication and/or pharmaceutical care. As such, the included 
studies have not been critically appraised. However, key limitations of each study have been noted 
in Table 1.2. 
1.4.2 Process 
Several electronic databases were searched for articles relating to LD and medication administration, 
or LD and pharmaceutical care, including: Medline (medicines, pharmacy, and biomedical and 
forensic sciences); Cumulative Index of Nursing and Allied Health Literature (nursing and allied 
health care professionals); and International Pharmacy Abstracts (pharmaceutical sciences). Articles 
had to be readily available, written in English and published in an academic journal. No time 
restriction was placed on the articles. These searches were set up to run on a monthly alert basis 
throughout the time of the research project to highlight new journal articles. Relevant papers from 
these ongoing searches and other relevant papers identified from included article reference lists 
were also incorporated into the review. Associated terms were used for LD, medication and 
pharmaceutical care which are summarised in Table 1.1. American spellings were also included. 
Table 1.1 Summary of search terms 
Key Term Terms Used in Search 
Learning Disability  Learning disabilit*, difficult*, impairment 
Intellectual disabilit*, difficult*, impairment 
Developmental disabilit*, difficult*, impairment 
Mental retard* 
Medication Administration Med* organisation, adherence, compliance, optimisation 
Drug organisation, adherence, compliance, optimisation 
Prescription organisation, adherence, compliance, optimisation 
Pharmaceutical Care  Pharma* 
 
1.4.3 Results of Literature Searches 
Searching for LD and medication administration terms in July 2015 initially yielded 58 results. 
Furthermore, searching for LD and pharmaceutical care terms in July 2015 initially yielded 272 
results. A total of 330 potential studies were therefore initially identified in the electronic databases. 
However, 17 of these were duplicates and 264 were found to not be relevant to the topic of people 
with LD and medication. Furthermore, 25 articles were not available from the RGU library and 1 was 
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only available as an abstract. This provided a total of 23 studies for initial review. Over the course of 
the research, a further 6 papers were identified from the searches and incorporated into the 
literature review and a summary of these 29 papers can be found in Table 1.2. Other relevant papers 
identified from the article reference lists were also incorporated into the narrative review. 
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Table 1.2 Summary of papers included in the literature review 
Section 1: LD & General Medication 
Author(s) and 
Publication 
Year 
Country Aim of Study Population Intervention Key Findings Key Limitations 
Identified by Study 
and/or Researcher 
 
TOBI, H., SCHEERS, T., 
NETJES, K.A., 
MULDER, E.J., DE 
BILDT, A. and 
MINDERAA, R.B., 
2005 
Netherlands To investigate the 
chronic drug utilisation in 
children with ‘mental 
retardation’  
N=912  
Children (4-18y) with 
‘mental retardation’ 
attending a school for 
people with LD (or 
known to LD services) 
 
Comprehensive 
structured interview 
with 
parents/caregiver – 
no medical records 
accessed 
 
 ~22% used regular medication 
 47% used two or more drugs 
 9.6% used an antipsychotic  
 Prevalence of drug use 
increased with severity of 
mental retardation from 
about 17% to 49% (exception 
was the 6% of children with 
borderline LD- medication 
prevalence was 27%) 
Dependence on carers 
providing accurate 
information; only regular 
medicines included; 
exclusion of children with 
LD who did not attend 
specialist LD schools 
ZAAL, R.J., VAN DER 
KAAIJ, A.D., 
EVENHUIS, H.M. and 
VAN DEN BEMT, 
P.M., 2013 
Netherlands To determine the 
prevalence of older 
individuals with LD with 
at least one prescription 
error and identify 
potential risk factors for 
these prescription errors  
N=600  
Older (≥50 years) 
people with LD using 
one or more drugs 
(randomly selected 
from the study cohort 
of another study) 
Cross-sectional study; 
screening of 
medication for errors 
using consensus 
methodology; use of 
multivariate logistic 
regression to identify 
potential risk factors 
 
 47.5% had prescription errors  
 26.8% of these errors required 
a change of therapy 
 Age, level of LD, BMI, and 
frailty index are potential risk 
factors for errors 
 Polypharmacy and drugs for 
the nervous system are also 
associated with errors 
Instances when clinicians 
made an informed 
decision to continue with 
therapy despite an ‘error’ 
were not taken into 
account 
HAIDER, S.I., ANSARI, 
Z., VAUGHAN, L., 
MATTERS, H. and 
EMERSON, E., 2014 
Australia To analyse the 
prevalence of 
polypharmacy (5 or more 
medicines) and to 
evaluate the role of 
different factors 
associated with 
polypharmacy  
N=897 
Adults with LD living in 
the community in 
Victoria, Australia 
Telephone 
questionnaire with 
proxy of person with 
LD 
 76% of adults with LD used 
prescribed medicine 
 ~21% were exposed to 
polypharmacy in the last two 
weeks 
 Polypharmacy was significantly 
associated with older age, 
unemployment and inability to 
All information is self-
reported; no mention of 
literacy issues in 
recruitment; those with 
mild LD and no carer 
could not participate; 
whether the 
polypharmacy was 
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get help from family and 
friends 
appropriate or not was 
not determined 
FISH, R., HATTON, C. 
and CHAUHAN, U., 
2017 
 
UK To ask people with LD 
how they felt about the 
information they got 
with their medicines 
N=58 
Adults with LD (self-
advocates) attending a 
self advocacy 
conference in the 
north of England, UK 
Written questionnaire 
(easy-read) – option 
of carer assistance to 
complete 
 55% people received helpful 
info from health care 
professionals about their 
medicines; 29% people did not 
receive helpful information 
 Frequent themes: information 
not accessible; only given basic 
information; information only 
given to carer 
Not representative of 
general LD population; 
may have excluded those 
with lower health literacy 
Section 2: LD & Antipsychotic Medication 
Author(s) and 
Publication 
Year 
Country Aim of Study Population Intervention Key Findings Key Limitations 
Identified by Study 
and/or Researcher 
 
LOTT, I.T., 
MCGREGOR, M., 
ENGELMAN, L., 
TOUCHETTE, P., 
TOURNAY, A., 
SANDMAN, C., 
FERNANDEZ, G., 
PLON, L. and WALSH, 
D., 2004 
USA To describe the 
longitudinal prescribing 
practices for 
psychoactive 
medications  
N=2344 
People with LD and DD 
(resident in community 
settings) 
Descriptive study; 
computerised 
pharmacy records 
were accessed and 
reviewed over  17 
months 
 52% of all prescriptions were 
for psychoactive medications 
 62% were given prescriptions 
for more than one 
psychoactive medication; 36% 
received three or more 
No comparison to the 
general population; 
‘psychoactive’ includes 
antiepileptic medication 
and antidepressants as 
well as antipsychotics 
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PATON, C., FLYNN, A., 
SHINGLETON‐SMITH, 
A., MCINTYRE, S., 
BHAUMIK, S., 
RASMUSSEN, J., 
HARDY, S. and 
BARNES, T., 2011 
UK To determine if people 
with LD prescribed an 
antipsychotic had: the 
indication noted; the 
need for the 
antipsychotic reviewed 
annually; and side-
effects checked for 
annually 
 
N=2319 
Person with LD under 
the care of an LD 
consultant and 
prescribed an 
antipsychotic 
Data collection from 
the clinical records of 
individuals with LD 
 Indication in notes – 95% 
 Annual review done – 96% 
 Annual review inclusion of 
check for side-effects – 69% 
 
Not a true audit as 
standards did not include 
a stated target (only the 
criteria) 
DOAN, T., WARE, R., 
MCPHERSON, L., 
DOOREN, K., BAIN, C., 
CARRINGTON, S., 
EINFELD, S., TONGE, 
B. and LENNOX, N., 
2014 
Australia To investigate prevalence 
of, and factors associated 
with, psychotropic 
medication  
N=176  
Adolescents (11-19y) 
with LD living in the 
community & 
attending a special LD 
school or LD unit 
Cross-sectional, self-
reported information  
 
 20% taking psychotropics  
 9% taking psychostimulants 
 Male gender and major 
behaviour problems are 
associated with use of 
psychotropic medication 
Medication use was self-
reported (recall bias); 
possibility that incorrect 
indication was attributed 
by researcher 
MURRAY, M.L., HSIA, 
Y., GLASER, K., 
SIMONOFF, E., 
MURPHY, D.G., 
ASHERSON, P.J., 
EKLUND, H. and 
WONG, I.C., 2014 
UK To investigate the 
incidence and prevalence 
of psychotropic 
medication prescribing 
and neuropsychiatric 
related co-morbidities of 
<25s with autism 
spectrum disorder (ASD) 
diagnoses 
N= 561 
People <25 years with 
ASD 
 
 
A descriptive cohort 
study  
 9.7% prescribed hypnotics; 
7.9% psychostimulants; 7.3% 
antipsychotics  
 12.6% of the cohort had LD 
and/or DD 
Not all people with ASD 
have LD and not all 
people with LD have ASD; 
completeness of data set 
being used; measures 
prescription and not 
compliance 
SALDANA, S.N., 
KEESHIN, B.R., 
WEHRY, A.M., BLOM, 
T.J., SORTER, M.T., 
DELBELLO, M.P. and 
STRAWN, J.R., 2014 
USA To identify demographic 
and/or clinical predictors 
of antipsychotic 
prescribing in 
psychiatrically 
hospitalised children and 
adolescents  
N= 1427  
Children and 
adolescents discharged 
from an urban 
psychiatric service in a 
hospital over 9 months 
(not all had LD) 
 
 
Retrospective review 
of medical records; 
sub-analysis to 
determine predictors 
of antipsychotic 
A diagnosis of LD was predictive of 
antipsychotic prescribing at 
discharge; for 56% of the admission 
for people with LD was due to 
significant violence and aggression 
 
Only 4% participants had 
LD so sub-analysis 
potentially limited; 
lack of information in 
medical records  
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Section 3: LD and Practical Challenges to Administration  
Author(s) and 
Publication 
Year 
Country Aim of Study Population Intervention Key Findings Key Limitations 
Identified by Study 
and/or Researcher 
 
SHAH, T., TSE, A.P.Y., 
GILL, H., WONG, 
I.C.K., SUTCLIFFE, A., 
GRINGRAS, P., 
APPLETON, R. and 
TULEU, C., 2008 
UK To assess the 
compatibility and short-
term stability of 
melatonin capsules 
mixed in various foods 
and liquids 
n/a Measurement of 
melatonin 
concentration 
(mcg/ml) over a 6 
hour time period  
 
Melatonin mixed in either water, 
orange juice, semi-skimmed milk, 
strawberry yoghurt, and strawberry 
jam is stable for up to 6 hours 
 
Only applicable to 
melatonin and those 
food substances listed 
BUELOW, J.M. and 
SHORE, C.P., 2010 
USA To describe some of the 
factors associated with 
LD and epilepsy; to 
address the management 
challenges associated 
with these diagnoses 
Children with LD and 
epilepsy  
Description of 
challenges from 
personal experience 
 
Parental concerns: 
 Children cannot describe 
precisely how the medicines 
affect them 
 Difficulty in differentiating the 
cognitive adverse drug 
reactions from the actual anti-
epilpetic drug (AED) itself 
 the need to develop strategies 
to manage and remember to 
give medicines 
 interactions with health care 
professionals can be stressful 
Practical and insightful 
information but limited 
evidence base for 
statements 
HUNEKE, N.T., 
GUPTA, R., HALDER, 
N. and CHAUDRY, N., 
2012 
UK To audit current practice 
concerning consent to 
treatment in patients 
with LD  
N=45 Questionnaire (easy-
read format) sent to 
person and completed 
with the help of a 
carer.  
Overall, the patients’ knowledge of 
their medications was poor; doctors 
are providing information but 
delivery needs to be improved, and 
patients’ understanding and recall 
need to be checked more 
thoroughly 
Not a true audit as 
standards did not include 
a stated target (only the 
criteria); results filtered 
through the carer-
acquiescence? 
EPITROPAKIS, C. and 
DIPIETRO, E.A., 2015 
USA Design and 
implementation of a 
medication compliance 
protocol for paediatric 
patients with severe LD 
N=6  
Paediatric patients 
with severe LD in a 
neurobehavioural unit 
Implementation of 
medication 
compliance protocol 
based on applied 
Medication administration success 
rate of 83.3% after 4 weeks with the 
compliance protocol  
Small study; hard to 
follow the intervention 
details; no before and 
after so claim of success 
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behavioural analysis 
framework 
is unverifiable; few 
references to literature 
FLOOD, B. and 
HENMAN, M.C., 2015 
Ireland Case report – to  provide 
insight into the 
difficulties of insulin 
administration  and 
diabetes self-
management for a man 
with mild LD 
N=1 
Person with LD & 
diabetes 
Case report– but used 
a grounded theory 
approach to review 
the data 
 
Details of the medicine challenges 
faced 
 
No results section; very 
little info from the actual 
case study – more in 
intro and discussion; 
unsure of how grounded 
theory was actually used 
in the approach 
DAVIS, S.R., 
DURVASULA, S., 
MERHI, D., YOUNG, 
P.M., TRAINI, D. and 
ANTICEVICH, S.Z.B., 
2016 
Australia To explore the level of 
understanding of people 
with LD in relation to 
their asthma medication 
N=17 
People with mild LD 
who self-administer 
their asthma medicines 
Face-to-face 
interviews  
 
Level of autonomy for medication 
use varied, with motivation to self-
manage asthma influenced by the 
level of support that was practically 
available to individual participants 
 
Specific to asthma 
management; small 
numbers; limited to 
those who self-managed 
and were able to 
participate in an 
interview 
Section 4: Family or Carer Effect on Medication  
Author(s) and 
Publication 
Year 
Country Aim of Study Population Intervention Key Findings Key Limitations 
Identified by Study 
and/or Researcher 
 
RASARATNAM, R., 
CROUCH, K. and 
REGAN, A., 2004 
UK To investigate the 
influence of attitudes of 
carers of people with LD 
towards giving 
medication 
N=93 
Carers of people with 
LD (where the person 
with LD attends an 
outpatient clinic) 
Interview using the 
Rating of Attitude to 
Medication Scale 
interview schedule 
A disproportionate number of 
parents express a negative attitude 
in comparison with professional 
carers (46% vs. 11%) 
Many people with mild 
LD do not attend an LD 
outpatient clinic – so 
exclusion of this group in 
the study 
VAN DEN BEMT, 
P.M., ROBERTZ, R., 
DE JONG, A.L., VAN 
ROON, E.N. and 
LEUFKENS, H.G.M., 
2007 
Netherlands To identify the frequency 
of drug administration 
errors and determinants 
for these errors in an 
institutional setting 
N=46  
Children and adults 
with LD, resident in 
institutional setting 
 
Prospective, 
disguised, 
observational study 
with a case control 
design for identifying 
determinants for 
errors; each resident 
observed for 2 weeks 
 953 drug administrations 
observed 
 25% administrations had least 
one error  
 Determinants associated with 
errors were: ‘oral by feeding 
tube’ and ‘inhalation’; the 
units ‘adult full-time care’ and 
Short study period for 
each person; 
observations made 
during weekdays and 
only during the day; 
potential for participants 
to have modified their 
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‘children daytime care’; and 
the absence of a distribution 
robot 
behaviour knowing that 
they were being watched 
 
ERICKSON, S.R. and 
LEROY, B., 2015 
USA To measure health 
literacy (HL) of caregivers 
of adults with LD; to 
determine the 
association between HL 
and a medication 
administration task 
(MAT) assessment; to 
identify caregiver 
characteristics associated 
with higher HL and MAT 
scores 
N=47 
Adult caregivers of 
people with LD 
Cross-sectional study The lower the HL, the lower the 
medication administration ability; 
higher education was associated 
with greater HL 
Small sample and 
potential selection bias; 
sub-analysis on very 
small numbers; potential 
lack of instrument 
sensitivity 
HOM, C.L., 
TOUCHETTE, P., 
NGUYEN, V., 
FERNANDEZ, G., 
TOURNAY, A., PLON, 
L., HIMBER, P. and 
LOTT, I.T., 2015 
USA To determine factors 
affecting non-adherence 
with antiepileptic drugs 
(AED) medication in 
people with LD and 
epilepsy  
 
N=793 
People with LD and 
epilepsy who have 
been prescribed AEDs 
for >6 months.  
Retrospective 
examination of 
pharmacy records; 
calculation of 
medication possession 
ratio 
Compared with those living in group 
homes, individuals with LD living in 
family homes or in semi-
independent settings were 
significantly less adherent to AEDs 
(p < 0.0003) 
Did not note that 
measuring adherence 
through prescriptions 
ordered may not be the 
same as medicines 
actually taken 
JOOS, E., MEHUYS, E., 
VAN BOCXLAER, J., 
REMON, J.P., VAN 
WINCKEL, M. and 
BOUSSERY, K., 2015 
Belgium  To collect direct 
observational data on 
drug administration 
practices to residents 
with LD and enteral 
feeding tube (EFT) 
N=48 
People with LD living in 
a residential care 
facilities (RCF)  
Cross-sectional 
observational study of 
862 drug preparations 
and 268 
administrations in 48 
residents with EFT 
Deviations from medication 
preparation and medication 
administration guidance were 
observed 
 
Deviations not graded 
with respect to harm; 
potential for participants 
to have modified their 
behaviour knowing that 
they were being 
watched; observations 
limited to daytime 
weekdays 
JOOS, E., MEHUYS, E., 
VAN BOCXLAER, J., 
REMON, J.P., VAN 
WINCKEL, M. and 
BOUSSERY, K., 2016 
Belgium To investigate knowledge 
of EFT guidelines among 
staff of RCF for people 
with LD 
N=356 
Formal carers of 
people with LD living in 
RCF 
Self-administered 
questionnaire 
Mean self-perceived knowledge of 
medication administration via EFT 
was 6.7 (on a 0–10 scale); on 
average, 5.7 (SD 1.9) of 13 
questions were answered correctly; 
identification of a substantial lack of 
guideline knowledge 
Self selection of 
respondents (potential 
selection bias); 
questionnaire not 
formally validated 
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Section 5: Pharmacist Input to Care of People with LD 
Author(s) and 
Publication 
Year 
Country Aim of Study Population Intervention Key Findings Key Limitations 
Identified by Study 
and/or Researcher 
 
BROWN, R.O., 
DICKERSON, R.N., 
HAK, E.B., 
MATTHEWS, J.B. and 
HAK, L.J., 1997 
USA To assess the impact of a 
pharmacy service (for 
enteral feeds) on patient 
body weight  
 
N=24  
Non-ambulatory 
patients (children and 
adults) with severe LD 
receiving long term 
enteral feeding  
Review of the impact 
of pharmacist led 
interventions 
(educational and 
clinical); comparison 
to a control group  
Month 4:  body weight had 
increased from 101 ± 6% of 
baseline to 109 ± 7% (p<0.05).  
Month 7: body weight had 
increased to 116 ± 12% of baseline 
(p<0.0001).  
Small sample; unmatched 
groups; extreme dosages; 
all weight gain was fat; 
weight gain not linked to 
improved outcome  
BRAHM, N.C. and 
BROWN, R.C., 2004 
USA Description of a 
pharmacist-based 
consulting service for the 
developmentally 
disabled 
n/a n/a A pharmacist-based drug therapy 
consulting program provides 
valuable services to clinicians and 
patients.  
Lack of objective 
measurement; limited 
transferability  
BELL, J.S., 
KIRKPATRICK, C.M. 
and ALDERMAN, C.P., 
2015 
n/a n/a – editorial comment 
on paper by O'Dwyer, 
Meštrović, and 
Henman (2015) 
 
n/a n/a ‘There is an urgent need for the 
pharmacy profession to develop a 
research agenda to promote the 
quality use of medications in 
vulnerable patient groups.’ 
Editorial comment only 
O'DWYER, M., 
MEŠTROVIĆ, A. and 
HENMAN, M., 2015 
n/a To explore what type of 
pharmaceutical care 
interventions were being 
undertaken for people 
with LD and how 
pharmacists’ contributed 
to the care of people 
with LD as part of 
multidisciplinary teams 
n/a Narrative review of 8 
papers – found from 
systematic searches of 
electronic databases 
 
Some limited evidence to suggest 
benefit of pharmacist input but 
more research required. 
 
‘…little is known about their (people 
with LD) attitudes to medicines, 
their interactions with pharmacists 
and their ability to engage in the 
health care process in primary care.’ 
 
‘There were no studies of patients’ 
or carers’ views of pharmacists’ 
contribution to care.’ 
Focus was on pharmacist 
interventions only but no 
other limitations of note 
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Section 6: Clinical Issues  
Author(s) and 
Publication 
Year 
Country Aim of Study Population Intervention Key Findings Key Limitations 
Identified by Study 
and/or Researcher 
 
BRAHM, N.C., FAST, 
G.A. and BROWN, 
R.C., 2008 
USA Case study of a patient 
with LD and ASD whose 
behavioral problems 
were improved with 
buspirone 
 
N=1     
33-year-old, white, 
nonverbal, profoundly 
intellectually-impaired 
woman  
 
Addition of buspirone 
after discontinuation 
of: sertraline, 
aripiprazole, 
clozapine, risperidone 
and naltrexone 
Described therapy changes led to a 
reduction in target behaviors of 
self-injury, property destruction, 
and physical aggression 
No case study 
methodology referenced; 
limited transferability 
 
CARPAY, J.A., 
AALBERS, K., 
GRAVELAND, G.A. 
and ENGELSMAN, M., 
2009 
Netherlands 
 
To assess the long-term 
usefulness of new AEDs 
(lamotrigine, topiramate, 
levetiracetam, 
gabapentin and 
pregabalin) in 
institutionalised patients 
with LD  
N=118 
People with LD 
(resident in 
institutions) with 
epilepsy and 
current/past use of 
AEDs  
 
Retrospective study 
using data from the 
medical files and the 
pharmacy databases  
 The most frequently used new 
AEDs were lamotrigine (68%) 
and levetiracetam (58%) 
 The 3-year retention rate was 
highest for lamotrigine (70%), 
and lowest for gabapentin 
(33%) 
 Discontinuation due to lack of 
efficacy was: 61% - topiramate; 
60% - lamotrigine; 42% - 
levetiracetam 
 Discontinuation due to adverse 
events was: 42% - 
levetiracetam; 33% - 
topiramate; 28% - lamotrigine 
Retrospective, open, 
non-randomised design 
makes definite 
attribution of the effect 
or side-effect to the drug 
and comparison between 
AEDs impossible 
FERGUSON, L. and 
MURPHY, G.H., 2014 
UK To investigate the 
capacity of individuals 
with LD to make 
decisions about their 
medications, and to 
evaluate whether the 
provision of training 
(information) sessions on 
medications would 
increase their capacity 
N=28 
Adults with mild-
moderate LD on 
regular Epilim 
(valproate), metformin 
or haloperidol. 
Evaluation of three 
training sessions 
(using validated tools)  
Training had improved the capacity 
of the participants to give informed 
consent to taking their medications; 
increased levels of receptive 
language ability correlated with 
greater ability to give informed 
consent to taking medication 
Small numbers; no 
control; not blinded for 
assessors 
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ERICKSON, S.R. and 
KORNEXL, K., 2016 
USA To characterise and 
compare the screening, 
treatment, and control of 
BP in patients with DD to 
patients without DD 
N=183 
Adults with DD living in 
a community setting 
Retrospective cross-
sectional study from 
existing database  
Both groups had similar outcomes 
for hypertension therapy; those 
with uncontrolled BP in the DD 
group tended to have higher 
systolic BP; significantly more DD 
patients had a history of stroke 
Groups not equal with 
respect to gender; sub-
analysis with respect to 
type of DD not possible 
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1.4.4 Analysis  
In their recent literature review on a similar subject, ‘Pharmacists' medicines-related interventions 
for people with intellectual disabilities: a narrative review’, O’Dwyer, Mestrovic and Henman (2015) 
noted that a systematic review was precluded because of the heterogeneity of published studies. A 
scoping review of the 29 papers identified in this review against Critical Appraisal Skills Programme 
(CASP) checklists resulted in a similar conclusion (CASP UK 2016). As shown in Table 1.2, each paper 
was reviewed by considering the population, the intervention, the outcome and the key limitations.  
Six main themes within the literature were then identified by the researcher: general medication 
issues; antipsychotic medication; practical challenges to medication administration and 
management; carer and care worker issues; and general clinical issues. A narrative review of the 
literature was then undertaken to provide a foundation for the proposed research. 
1.4.5 Narrative Review  
General Medication Issues 
People with LD are often on medication that was initiated in childhood (Tobi et al 2005). It is 
estimated that people with LD are 27% more likely to be prescribed regular medication than the 
general population and that people with LD are prescribed four times more regular medicines than 
the general population (Straetmans et al 2007). In their study of community dwelling adults with LD 
in Australia (n=897), Haider et al (2014) estimated that 76% of adults with LD had used prescribed 
medication and that ~21% off adults with LD in their study were exposed to polypharmacy (5 or 
more medicines) in the last two weeks. This contrasts to a similar sized study by O’Dwyer et al 
(2016) where it was estimated that 53.7% of Irish adults with LD (aged 40 years and over) were 
exposed to polypharmacy (five or more medicines). Both these figures can be contrasted again with 
a study conducted in Scotland by Payne et al (2014) which found that 21.6% of the general adult 
population were receiving four or more medicines and incidence of polypharmacy increased with 
age (36% in those aged 60-69 years; 70.4% in those aged ≥ 80 years). It should be noted that none of 
these studies ascertained if the polypharmacy was inappropriate or appropriate. However, in their 
study of people ≥50 years with LD who were taking one or more medicines, Zaal et al (2013) noted 
that 47.5% had prescription errors with 26.8% requiring a change of therapy. 
 
In addition to being prescribed more medicines than the general population and experiencing 
similar, or indeed higher, rates of polypharmacy, Bhaumik et al (2015) suggested that compared 
with the general population, people with LD have: altered sensitivities to drugs; different effects 
from drugs; different optimum doses; and more adverse drug reactions.  This issue was also raised 
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by Saldana et al (2014) in relation to polypharmacy in the LD population and by Hefti and Blanco 
(2017) in respect to individuals with Down’s syndrome.  
Fish, Hatton and Chauhan (2017) highlighted that people with LD are often not receiving information 
about their medicines in a way that they can understand. In addition, the participants highlighted a 
desire for more direct involvement in consultations, whilst still involving their carer(s). 
 
 Antipsychotic Medication 
Antipsychotic drugs are licensed for the short term management of severe anxiety or disturbance, 
and for the long term management of schizophrenia and other psychoses (Joint Formulary 
Committee 2016). Antipsychotics have often been used in patients with LD to treat challenging 
behaviour, sometimes in the absence of a diagnosis of psychoses (Bhaumik et al 2015; National 
Institute for Health and Care Excellence 2015a).  
 
However, the prescribing of antipsychotics for challenging behaviour is now a contentious ethical 
issue due to them being perceived as a ‘chemical straitjacket’ (Bhaumik et al 2015; Public Health 
England 2015; Department of Health 2012). Best practice now dictates that antipsychotics should 
only be considered if: psychological or other interventions alone do not produce change within an 
agreed time; or treatment for any co-existing mental or physical health problem do not lead to a 
reduction in the behaviour; or the risk to the person or others is very severe (National Institute for 
Health and Care Excellence 2015a). As a result of this intensified focus on antipsychotics, much of 
research on people with LD in relation to medication has therefore focused on the use of 
antipsychotic medication for challenging behaviour (Ferguson and Murphy 2014).  
Public Health England (2015), using a database that included 7.8% of the English population, 
estimated that 16.6% of people with LD in England were being prescribed an antipsychotic between 
April 2009 and March 2012. Another recent UK study by Sheehan et al (2015), noted that the rate of 
prescription of antipsychotics in people with LD was almost twice that of the general population. 
They also noted that of the people with LD who had a record of challenging behaviour, 47% had 
been prescribed antipsychotic medication yet only 12% had a concurrent diagnosis of severe mental 
illness. Furthermore, in a study of psychiatrically hospitalised children and adolescents in the USA, 
Saldana et al (2014) noted that a diagnosis of LD was actually a predictor of antipsychotic 
prescribing. 
A further two studies also estimated the prevalence of psychoactive (antipsychotics, antidepressants 
and antiepileptic) medication: Lott et al (2004) determined that 52% of people with LD and 
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developmental delay were prescribed psychoactive medication; Doan et al (2014) determined that 
20% of adolescents with LD were prescribed psychoactive medication.  
Practical Challenges to Medication Administration and Management 
Bhaumik et al (2015) and Crossley and Withers (2009) noted that people with LD can encounter 
problems in taking oral medicines for a variety of physical, medical and psychological reasons, some 
of which are noted below:  
 Physical: oral palate malformations, dry mouth, unpleasant taste, and texture of medicines; 
 Medical: dysphagia, reflux; 
 Psychological: concern over size of tablet and choking, dislike for tablets, reaction to 
changes in tablet appearance, unwillingness to embrace changes to medicines or the 
medicine routine. 
Often a personalised medicine administration plan is required to maximise the success of medicine 
administration, as demonstrated by Epitropikas and Dipietro (2015). 
 
Monitoring the side effects of medication is another challenge as patients with LD do not usually 
volunteer such information due to their communication difficulties, or are only able to express the 
information in idiosyncratic ways (Bhaumik et al 2015; O’Dwyer, Mestrovic and Henman 2015; 
Stenfert-Kroese, Dewhurst and Holmes 2001). Furthermore, side-effects can be mistaken for 
challenging behaviour or just a part of the disability (Buelow and Shore 2010; Raghaven and Patel 
2010). 
 
Health literacy is defined as, ‘the cognitive and social skills which determine the motivation and 
ability of individuals to gain access to, understand and use information in ways which promote and 
maintain good health’ (Nutbeam 1998 p.263). It is a known issue for the general population and 
relevant to the LD population (Ngoh 2009; Schwartzberg et al 2007; Davis et al 2006). People with LD 
often have poorer health literacy and so rely on their caregivers, family, respite staff or HCPs for 
appropriate (and ongoing) support and education, as demonstrated in the studies by Davis et al 
(2006) and Flood and Henman (2015). In one study, lack of medication knowledge resulted in a 
belief amongst people with milder LD that because their carers knew more about their medicines 
than they did, then their carers should make all the decisions on their behalf (Crossley and Withers 
2009). In addition, for people with milder LD, problems with memory and understanding of time 
were highlighted as having the potential to adversely affect their ability to independently manage 
their medication (Bond and Hurst 2010; Arscott, Stenfert Kroese and Daganan 2000). 
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Williams and Evans (2013) raised the interesting point that society has a tendency to overprotect 
people with LD even though this has the potential to damage their development, self-esteem and 
community participation. They noted that, ‘…it will be an even greater safeguard of the person’s 
welfare if they can learn to practise safety themselves, and to learn this there must be some exposure 
to the hazards’ (Williams and Evans 2013 p.91). Whilst written generally, it is applicable to the area 
of medicine administration and management for people with milder LD.  
 
Carer and Care Worker Issues   
Support with medication administration and decision-making is often necessary for people with LD 
(Hom et al 2015; Ferguson and Murphy 2014; Haider et al 2014; Rasaratnam, Couch and Regan 
2004). However, as highlighted by Christian et al (1999), the skills, knowledge and decision-making 
ability of the caregiver is then crucial. Donley, Chan and Webber (2012) also noted that care 
workers, who often have limited training and qualifications, are expected to be able to interpret and 
communicate the complex needs of the person with LD that they are supporting. 
 
Van der Bemt et al (2007) noted that 25% of all drug administrations in an institution for people with 
LD were associated with at least one error. Joos et al (2015) observed deviations from medication 
preparation and medication administration guidance by care workers administering medicines via 
PEG tubes for people with LD in a residential facility.  In a later study they identified a substantial 
lack of guideline knowledge amongst staff with regards to administration of medicines via a PEG 
tube (Joos et al 2016).  
 
Rasaratnam, Couch and Regan (2004) found that parents were more likely than care workers to 
express a negative attitude towards medication. In addition, carers and care workers highlighted 
that communication with HCPs was often stressful, they often felt excluded from decision-making, 
and that concerns were often ignored (Redley et al 2013; Buelow et al 2006). This issue was 
summarised succinctly by Keywood and Flynn (2006 p. 360), ‘People with learning disabilities 
frequently experience unnoticed deteriorating health and suffering, they report considerable 
difficulty in gaining access to health services and are frequently reliant on relatives and support staff 
who have little option but to become battle-weary health advocates.’ 
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Pharmacist Input to Care 
In their narrative literature, O’Dwyer, Mestrovic and Henman (2015) concluded that there was 
limited available evidence to suggest the benefit of pharmacist input within the care of people with 
LD and therefore more research was required. This echoed the conclusion of Davis (2014) who 
concluded there was a lack of published evidence to support pharmacist-led medication reviews for 
people with LD living in the community.  Flood and Henman (2015 p.235) commented that people 
with LD, ‘…are a complex group of patients who may be “invisible” to pharmacists. Pharmacists may 
have little knowledge or experience of the challenges faced by this group...’. Blasi, Kendall and Spark 
(2006) cited that a lack of inter-professional collaboration may also inhibit the input of pharmacists 
in the care of people with LD.   
 
General Clinical Issues  
Bhaumik et al (2015) noted the challenges doctors often face in diagnosing psychiatric and 
behavioural problems in people with LD (due to different presentations and communication 
difficulties) and the feeling of vulnerability when prescribing an antipsychotic for the unlicensed 
indication of challenging behaviour. 
 
Van Schrojenstein Lantman-De Valk and Walsh (2008) noted the problem of unrecognised and 
untreated physical and mental health problems for people with LD. This was quantified in a study by 
Baxter et al (2006) who found that 51% of people with LD included in their study had new needs 
recognised during a pro-active health check. Baxter et al (2006) also highlighted that because of 
their already impaired social, communicative, and practical abilities, even relatively minor conditions 
such as blocked ear wax or vision difficulties had a significant impact on quality of life for a person 
with LD.  
 
O’Dwyer, Mestrovic and Henman (2015) also noted that little is actually known about people with 
LD’s attitudes towards their medication. Furthermore, ascertaining the real level of capacity and 
understanding, and being assured of truly shared decision-making is a challenge for all HCPs and 
prescribers when caring for people with mild to moderate LD (Ferguson and Murphy 2014; Stenfert 
Kroese, Dewhurst and Holmes 2001; Arscott, Stenfert Kroese and Dagnan 2000). 
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1.4.6 Summary of the Narrative Literature Review 
In summary, the published literature relating to people with LD and their experience of medication 
and pharmaceutical care noted that people with LD:  
 are prescribed more medicines and experience more polypharmacy than the general 
population; 
 are more likely to be prescribed antipsychotic medicines than the general population; 
 have poorer health literacy than the general population; 
 are more vulnerable to experiencing clinical and practical problems with their medication; 
 experience more challenges in communicating their views on medication; 
 may have sub-optimal medicine regimens; 
 often rely on carers to support them with their medication.  
In addition, the literature notes how medication related pressures and challenges are transferred to 
the carers of people with LD or their HCPs.  Only two identified studies explored the views of people 
with LD in relation to medication (Bond and Hurst 2010; Crossley and Withers 2009); a further two 
studies explored their level of understanding about their medication (Davis et al 2006; Arscott, 
Stenfert Kroese and Dagnan 2000). Four studies explored the views of carers of people with LD in 
relation to medication (Redley et al 2013; Donley, Chan and Webber 2012; Buelow et al 2006; 
Rasaratnam, Crouch and Regan 2004). 
1.4.7 Gaps in the Literature and Reason for this Research 
The Scottish Government’s Realising Realistic Medicine (Scottish Government 2017b), Achieving 
Excellence in Pharmaceutical Care – a Strategy for Scotland (Scottish Government 2017c), and Keys 
to Life (Scottish Government 2013) policy documents all ask HCPs to provide care in more 
meaningful and personalised ways.  In order to do this, HCPs require an increased understanding of 
the reality for patients in incorporating medication into their lives (Mohammed, Moles and Chen 
2016; O’Dwyer Mestrovic and Henman 2015). Despite people with LD experiencing more 
polypharmacy and medication related problems (O’Dwyer et al 2016; Bhaumik et al 2015; Haider et 
al 2014; Zaal et al 2013; Straetmans et al 2007), the majority of studies from the literature review 
focused on quantifying drug related issues, not understanding the experiences of the person with LD 
in relation to medication. In order for both prescribers and pharmacists to provide tailored and 
meaningful support to people with LD in relation to medication, and thereby improve patient care, a 
greater understanding of the experiences of medication of people with learning disabilities is 
required (Bell, Kirkpatrick and Alderman 2015; Flood and Henman 2015; Hollins and Tuffrey-Wijne 
2013). The results of this review echo the conclusion of the narrative review, ‘Pharmacists' 
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medicines-related interventions for people with intellectual disabilities: a narrative review’, by 
O’Dwyer Mestrovic and Henman (2015). 
1.5 RESEARCH AIM AND OBJECTIVES  
1.5.1 Aim 
The purpose of this study is to explore and describe the medication related experiences of 
community dwelling adults with LD. 
 
1.5.2 Objectives 
 
1. To explore and describe the medication related burden experienced by adults with LD; 
2. To explore and describe the medication related beliefs of adults with LD; 
3. To explore and describe the medication taking practice of adults with LD. 
 
1.6 CHAPTER SUMMARY 
This chapter provided an introduction to the thesis. First of all, the concept of learning disabilities 
(LD) was explored through describing the current definitions and classification of LD; citing the 
estimated prevalence of LD; and outlining the models for understanding LD. Current UK and Scottish 
policies relating to LD were described as well as the recognised health needs of people with LD. A 
brief summary of social care provision, the role of carers and care workers and of medication and 
polypharmacy within Scotland was provided. Following on from this, the current evidence within the 
literature relating to adults with LD and medication was presented in six themed sections: general 
medication; antipsychotic medication; practical challenges to medication administration and 
management; carers, care workers and medication; pharmacist input to care; and clinical issues. 
Gaps within the literature were then noted and discussed. Finally, the aim and objectives of the 
research were stated.  
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CHAPTER 2: METHODOLOGY, RESEARCH GOVERNANCE AND STUDY DESIGN  
 
 
 
 
 
 
 
‘For us truth is always partial, fragmentary, the view from somewhere and not, as philosophers 
sometimes say, “the view from nowhere”.’ 
The View from Nowhere - Thomas Nagel 
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2.1 CHAPTER INTRODUCTION 
First of all, this chapter provides a brief outline of research worldviews; epistemology, ontology, 
axiology and methodology within these worldviews; and the most common methodological 
approaches. A general overview of qualitative methodology and then a more specific overview of 
case study methodology will then be provided. Strategies for qualitative data collection, data 
analysis and for promoting trustworthiness, reflexivity and transferability throughout the research 
process are then evidenced. Then, this chapter will consider both the general then the specific 
research governance requirements when involving adults with incapacity in research. Issues of 
pertinent legislation, informed consent, inclusion, literacy, health literacy, involvement of significant 
others, capability and establishing relational boundaries will be discussed. Legislation surrounding 
the storage of data will also be outlined. Following on from this overview of theory and legislation, 
this chapter will outline how this theory has been applied within the design of this study and outline 
how this study has sought to adhere to the various methodological and research governance 
requirements. 
 
2.2 RESEARCH WORLDVIEWS 
Underpinning all research is the belief and approach of the researcher which is referred to in 
various, and often interchangeable, terms: worldview (Creswell 2014); paradigm (Bowling 2014; 
Denzin and Lincoln 2013; Kuhn 2012; Lincoln and Guba 1985); philosophical assumptions (Creswell 
2013; Creswell and Clark 2011); interpretive framework (Creswell 2013). Creswell (2014 p.6) 
describes a worldview as, ‘…a general philosophical orientation about the world and the nature of 
research that a researcher brings to a study’. Many worldviews have been defined (Denzin and 
Lincoln 2013), and Creswell (2013) notes that the number is ever expanding. However, Creswell 
(2013) cites post-positivism, constructivism, the transformative framework and pragmatism as being 
the four most commonly used within health and social sciences: 
 Post-positivism, also known as the scientific or traditional quantitative approach, is 
deterministic and reduces ideas to variables that can be tested; knowledge is developed 
through careful observation and measurement and laws, theories or hypotheses are 
tested and verified. 
 Constructivism, also known as the qualitative approach, seeks an understanding of the 
lived world and looks for complexity of participants’ views; meanings are negotiated 
historically and socially and a theory (or pattern of meaning from the data) is generated. 
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 The transformative framework is intertwined with politics and addresses issues of power 
and justice; the researcher(s) work with participants at all stages of the research and 
ultimately seek to make a change that benefits the group being researched. 
 Pragmatism is orientated to the ‘real world’ and will use quantitative or qualitative or 
mixed (quantitative and qualitative) methods, as required and focuses on finding 
solutions to problems. 
 
2.3 ONTOLOGY, EPISTEMOLOGY, AXIOLOGY and METHODOLOGY 
However, worldviews are better described in terms of their ontology (the nature of reality); their 
epistemology (what counts as knowledge and how knowledge claims are justified); their axiology 
(the role of values in research); and their methodology (the process of research), (Creswell 2014; 
Creswell 2013). A summary of the four common worldviews found within health and social sciences 
(taken and adapted from Creswell 2013, and Creswell and Clark 2011) can be found in Table 2.1. 
 
Table 2.1 Four common worldviews within health and social sciences 
 Post-Positivism Constructivism  Transformative Pragmatism 
 
Epistemology 
Objective; 
approximation of 
reality through 
research and 
statistics; minimal 
interaction with 
participants 
Subjective evidence 
from participants; 
enters world of 
researched; co-
constructs reality with  
participants 
Multiple ways of knowing 
reality; collaboration 
Gather data in the 
way that best 
answers the 
question(s)  
Ontology Single reality; reject 
or fail to reject a 
hypothesis 
Multiple realities 
constructed through 
lived experiences 
Political reality; 
negotiated with 
participants 
Single and multiple 
realities  
Axiology Researcher bias 
must be minmised 
(if not eliminated) 
and controlled 
Biased; researcher is 
open about their bias 
Biases are negotiated 
with participants  
Uses multiple 
stances (biased and 
unbiased) 
Methodology Quantitative, 
deductive logic; 
testing of theory 
Qualitative, inductive 
logic; emergent theory 
Emphasis on 
collaboration, 
participating politically, 
questioning of methods, 
highlighting of concerns 
and issues 
Mixed qualitative 
and/or quantitative 
approaches in data 
collection and 
analysis 
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2.4 METHODOLOGICAL APPROACHES 
There are three main methodological approaches within research: quantitative, qualitative and a 
combination of both quantitative and qualitative known as mixed methods. 
 
2.4.1 Quantitative 
Quantitative approaches seek to explain the relationship between variables or predict the results of 
related variables following from a priori theory (Bowling 2014; Creswell and Clark 2011). The 
predicted relationship is then presented as a hypothesis (null or directional) which the research 
proceeds to test through experimental designs (randomised controlled trials or quasi-experiments) 
or through non-experimental designs (surveys - cross-sectional or longitudinal), (Creswell 2014). It is 
reductionist, logical and empirical and the numerical data is analysed using appropriate statistical 
procedures (Creswell 2014).  
 
2.4.2 Qualitative 
In contrast, qualitative research focuses on exploring phenomena in their natural setting and seeking 
to understand the meanings that people attribute to their world (Creswell 2013; Denzin and Lincoln 
2013). In doing so, the researcher explores and gains detailed understanding of the experiences or 
meanings of an individual or a particular group (Bowling 2014; Ritchie and Lewis 2003). Lincoln and 
Guba (1985) note that the natural setting is essential because the phenomena of study take their 
meaning not just from themselves but from their context. Giangreco and Taylor (2003 p.135) state 
that, ‘Qualitative methods are ideally suited to providing an understanding of context and a detailed 
description of how practices actually work’. Rather than approaching the topic with a theory, 
qualitative research seeks to generate or develop a theory through interpreting the meaning(s) that 
others have of the world (Creswell 2013; Ritchie and Lewis 2003). Interestingly, Creswell (2013) 
notes that researchers can actually approach qualitative methodology through a post-positivist 
interpretive framework and view qualitative inquiry as a series of logically related steps, adhere to 
rigorous methods of data collection and analysis, and present findings in a structure similar to 
quantitative studies.  
 
Within a qualitative approach there are many methodologies that can be employed and Creswell 
(2014) highlights the following as the most common in health and social sciences: narrative 
(describing the experiences of individuals through story); phenomenology (describing the common 
meaning of a concept or phenomenon through the lived experience for a group of people); 
grounded theory (building a theory from the constant comparison, in depth repeat interviewing, 
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coding and analysis of layers of observational data); ethnography (describing the shared culture of a 
group through long term observation and conversation); and case study (providing in-depth 
understanding of a single unit or entity such as a person, process, organisation). 
 
2.4.3 Mixed Methods 
A mixed methods approach employs both quantitative and qualitative approaches in the research 
process and would be considered appropriate when either: one data source is insufficient; results 
require explanation; exploratory finding require generalisation; the study requires enhancement 
with a second method; a particular theoretical stance is required; and/or multiple phases or projects 
would best address the research questions (Creswell and Clark 2011). Creswell and Clark (2011) 
continue to detail six recognised mixed methods designs, each of which detail the approach 
(qualitative and/or quantitative) for each phase and then how each phase of data collection and 
analysis informs the next: convergent parallel, explanatory sequential, exploratory sequential, 
embedded, transformative, and multiphase. 
 
2.5 CASE STUDIES  
Case studies are described by Luck, Jackson and Usher (2006 p.104) as a, ‘detailed, intensive study of 
a particular contextual, and bounded, phenomena that is undertaken in real life situations.’ Yin 
(2014) notes there are three key aspects to case studies: a clearly defined focus; looking at a 
phenomenon in depth; and looking at this phenomenon within the real world. According to Thomas 
(2011), case studies can be classed according to subject, purpose, approach and process as detailed 
in Table 2.2. 
 
Table 2.2 Case study classification (Thomas 2011) 
Subject Purpose Approach Process 
Special (or outlier) 
Key 
Local knowledge 
Intrinsic 
Instrumental 
Evaluative 
Explanatory 
Exploratory 
Testing a theory 
Building a theory 
Illustrative 
Descriptive 
Interpretative 
Experimental 
Single (retrospective, 
snapshot or diachronic) 
 
Multiple (nested, parallel or 
sequential) 
  
How researchers select their cases will depend on the subject, purpose, approach and process, but 
as with all research, case selection will be restricted by available resources, including access and 
time (Yin 2014; Stake 1995). Case study methodology allows the researcher to collate multiple case 
studies or to merely select one case that is either extreme, critical or paradigmatic (Flyvbjerg 2006). 
Due to the strong connection with quantitative methodology, both Yin (2014) and Thomas (2011) 
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advise that case study researchers avoid using the term ‘sample’.  Instead, Yin (2014) and Thomas 
(2011) recommend the use of the term ‘selection’ to prevent confusion and unfounded criticism. 
Eisenhardt (1989) also highlights that for case studies it is neither necessary,, or even preferable, to 
choose cases randomly. However, Yin (2014) does note that non-random selection has the potential 
to create bias. Meyer (2001) stresses that case study researchers must be aware of the possible 
accusation of lack of rigour in case selection and therefore the need to be explicit about the choices 
made and the justification behind them. 
 
If considering multiple case studies, Yin (2014) stresses the importance of focusing on replication 
and not sampling logic. He states that each case must be carefully selected so that it either predicts 
similar results (literal replication), or contrasting results for anticipated reasons (theoretical 
replication). Yin (2014) also recommends 2-3 case studies for literal replication; 4-6 cases studies for 
theoretical replication; and 6-10 case studies as an aggregation to allow for convincing support for 
the original propositions. As an alternative strategy, Eisenhardt (1989) suggests that researchers 
should stop adding cases when theoretical saturation is reached.  
 
Establishment of boundaries in case study design is essential (Yin 2014; Baxter and Jack 2008). 
Boundaries are similar to quantitative inclusion and exclusion criteria for sample selection; the 
difference is that the breadth and depth of the study is also referred to in the boundaries. 
 
Yin (2014); Thomas (2011); Baxter and Jack (2008); and Luck, Jackson and Usher (2006) all note that 
one of the strengths of a case study approach is the inclusion of a variety of data sources. Luck, 
Jackson and Usher (2006) list some of these data sources as: direct observations; participant 
observations; survey, questionnaire; documentation; archival records; interviews (both structured 
and unstructured); written accounts by participants; physical artefacts; and researcher description of 
the context. It is the researcher’s responsibility to identify and incorporate the available and most 
appropriate data sources into the research design. As with all methodologies, case studies have 
noted advantages and disadvantages which are summarised in Table 2.3. 
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Table 2.3 Advantages and disadvantages of case studies  
 
 
 
 
 
 
 
 
 
Advantages of 
case studies 
Can be used within any worldview because all methods are acceptable (Luck, Jackson 
and Usher 2006) 
Can incorporate multiple sources of evidence (Baxter and Jack 2008; Yin 2014) 
Research design and data collection procedures can be tailored to the research 
questions (Meyer 2001) 
Allows for single or multiple realities (Yin 2014) 
Can be conducted in real-life settings (Luck, Jackson and Usher 2006) 
Has the flexibility to combine seemingly contradictory methods, allow for differing 
views and enable complex interrelated phenomena to be interpreted (Luck, Jackson 
and Usher 2006)  
Can be used to accomplish a wide variety of aims including providing description, 
testing theory and generating theory (Eisenhardt 1989) 
Takes a holistic approach to understanding phenomena as opposed to reducing it to a 
set of interrelating variables (Baxter and Jack 2008; Thomas 2011) 
‘Context-dependent knowledge and experience are at the very heart of expert 
activity…It is only because of experience with cases that one can at all move from being 
a beginner to being an expert.’ (Flyvbjerg 2006 p.223) 
 
 
 
 
 
Disadvantages of 
case studies 
Cases studies cannot assess prevalence of a phenomena (Yin 2014) 
No case study research design requirements have been stipulated and so there are no 
predefined standards of what constitutes a good case study (Meyer 2001; Yin 2014)  
Case studies are only generalisable to theoretical propositions and not to populations 
or universes. They do not represent a sample; only analytical and not statistical 
generalisations can be made (Jenson and Rodgers 2001 as cited by Luck, Jackson and 
Usher 2006; Yin 2014) 
Case studies are often considered to lack rigour (Meyer 2001; Luck, Jackson and Usher 
2006) 
The result of a case study can be a long and potentially unreadable document (Yin 
2014) 
 
2.6 QUALITATIVE DATA COLLECTION  
Unlike quantitative data, qualitative data is non-numerical data from a variety of sources such as 
observations, documents and interviews (Bowling 2014; Creswell 2013; Merriam 2009).  
 
2.6.1 Observations and Field Notes   
Bowling (2014) notes that in natural science, systematic observation is the classic method of 
enquiry. The author stresses that observation is not just merely watching but the gathering of 
information through use of the senses. This additional data on behaviour, actions and inactions, 
activities and interactions can provide the researcher with greater insight into more complex 
situations which may not always be articulated or even understood by the participants. Eisenhardt 
(1989) recommends that field notes be a running commentary and include the researcher’s 
impressions, learning points, cross-case comparison thoughts, hunches and anecdotes. Thomas 
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(2011) notes that researchers may choose to observe in a structured manner (systematically looking 
for particular kinds of behaviour) or in an unstructured manner (informally from within the 
situation).  Bowling (2014) recommends the following to researchers planning to incorporate 
observations into their fieldwork: decide what to observe and the clear definition of all variables of 
interest; keep separate observational notes; organise observations by time and keep in 
chronological order; record raw behaviour, not just the interpretation of the behaviour; write field 
notes up in full at the end of each observational session to prevent memory bias; and record feelings 
or impressions separately. Referencing Merriam (1988), Bowling (2014) suggests the following 
structure for observational notes: setting; participants; activities and interactions; frequency and 
duration; and subtle factors. 
 
As well as the time consuming nature of observation, another significant drawback of observational 
data is the effect of being studied upon those being studied. This is commonly known as the 
‘Hawthorne effect’, as described by Roethlisberger and Dickson 1939, cited by Bowling 2014. 
Furthermore, as noted by Gillham (2000), research has shown that observation can be both fallible 
and highly selective. However, Stake (1995) stresses the need for qualitative researchers to find the 
uniqueness and complexity of the case.  Accordingly, the case study researcher must exert discipline 
and effort to become an accurate and balanced observer whose observations enrich the case study.   
Regardless of whether the researcher chooses to include observations in the case study, field notes 
must always be created. Merriam (2009) states that field notes should include three things: verbal 
descriptions of the setting, the people, the activities; direct quotations or at least the substance of 
what people said; and the observer’s comments. 
 
2.6.2 Documents  
Including the analysis of available documents within the case study allows the researcher to include 
records of activity that the researcher could not observe directly and to relate formal reality to the 
informal reality (Gillham 2000; Stake 1995). Meyer (2001) also comments on the practical advantage 
of using documents to save time in interviews with regards to ascertaining certain facts. Thomas 
(2011) highlights the need to carefully read each document for meaning and substance and Gillham 
(2000) notes that the importance of the document will ultimately depend on the relevance to the 
research question. The potential issues Yin (2014) associates with documents are: problems with 
retrievability; biased selectivity if collection is incomplete; reporting bias; and the fact that access 
may be withheld. However, Stake (1995) also points out that it is also possible that the person 
recording may have been a better observer of the situation than the researcher. 
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2.6.3 Interviews 
A research interview is not to be considered a conversation between equal partners but an 
interaction defined and controlled, to varying degrees, by the researcher (Kvale and Brinkmann 
2009). Merriam (2009) notes that interviewing becomes necessary because observation alone does 
not allow the researcher to understand their feelings and interpretation of the world around them. 
Whilst technique is important, Kvale and Brinkmann (2009) note that interview mastery is achieved 
when the interviewer thinks less of the technique and more of the interviewee and the knowledge 
sought. Baxter and Jack (2008), Ritchie and Lewis (2003), and Meyer (2001) all stress the importance 
of the researcher creating and maintaining trust and rapport with the interviewee in order to elicit 
accurate information in an interview. 
 
Interviews can be conducted in person, over the phone or through digital technology such as 
Facetime and Skype; interviews can be one-to-one or in a group. The interview itself can be 
described as: structured (set questions); semi-structured (set questions to give rise to more in depth 
probes); or unstructured (few, if any, set questions), (Bowling 2014; Thomas 2011). In addition, Yin 
(2014) describes case study interviews as being either: prolonged (two or more hours); shorter 
(approximately one hour, more focused, and following case study protocol); or a survey (structured 
questionnaire). Furthermore, Khan et al (1991) highlight that within the interview, the actual 
questions themselves can also be described as: structured; semi-structured; or unstructured. 
However, Nind (2009) highlights four potential issues with interviews for people with LD: 
inarticulateness, linked to low self-esteem, anxiety and language skills; unresponsiveness in open 
questioning; difficulty generalising from experience; and conceptual difficulty around time. In 
addition, Atkinson (2004 p696) notes that for some people with LD there is the issue of memory and 
that, ‘Some areas of life have been forgotten – some were never known’. 
 
2.7 QUALITATIVE DATA ANALYSIS  
2.7.1 Strategies 
Within qualitative research there is no one particular way to approach data analysis (Bradley, Curry 
and Devers 2007); instead it must be custom-built (Creswell 2013). Hsiu and Shannon (2005) present 
three general strategies for approaching content analysis in qualitative data: conventional content 
analysis where categories flow from the data (inductive); directed content analysis in order to 
validate or extend conceptually a theoretical framework or theory; and summative content analysis 
with the counting and comparison of keywords or content followed by interpretation of the 
underlying content. In comparison, Miles and Huberman (1994) define their strategies according to 
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how the researcher decided upon their coding lists: a priori - creation of a provisional ‘start list’ of 
codes (master and sub) prior to fieldwork from a conceptual framework; inductive - no pre-coding 
until all the data is collected; and partway between a priori and inductive - creation of a general 
accounting scheme for codes that is not content specific but points to the general domains in which 
codes can be developed inductively. Whether one researcher undertaking all the coding alone is 
sufficient, or preferable, to a team of coders is debated within the literature (Bradley, Curry and 
Devers 2007). 
 
Gale et al (2013) recommend the framework method (thematic analysis) as a systematic and flexible 
approach that can be used inductively or deductively and note that is not aligned to any particular 
worldview. The deductive approach involves using themes and codes that are pre-selected from 
previous literature, theories or specifics of the research questions (Gale et al 2013). Using a 
deductive framework approach to content analysis is easy to follow, allows for inclusion of non-
interview data and demonstrates a systematic approach to analysis (Gale et al 2013). However, 
researchers may be tempted to begin quantifying results, find evidence that is supportive rather 
than non-supportive of the theory, or be blinded to contextual aspects of the phenomenon (Gale et 
al 2013; Hsui and Shannon 2005). 
 
2.7.2 Procedure for Analysis 
Patton (2002 p.433) notes that within qualitative data analysis, ‘no absolute rules exist except 
perhaps this: Do your very best with your full intellect to fairly represent the data and communicate 
what the data reveal given the purpose of the study.’ Whilst there is no one procedure for analysing 
qualitative data, Gale et al (2013) recommended a 7-step procedure for qualitative data analysis 
within a framework approach which is detailed in Figure 2.1. 
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Figure 2.1 Qualitative data analysis procedure within a framework approach   
 
Transcription, the act of changing audible talk to written words, requires reduction, interpretation 
and representation in order to make the data both readable and meaningful (Bailey 2008). Gale et al 
(2013) also note that within framework analysis, whilst it is ideal to transcribe the interview 
verbatim, it is not necessary to record all the conventions of dialogue transcription because it is 
what is said, rather than how it is said, that is of greatest interest. They further note that throughout 
the procedure the researcher must, ‘strike a balance between reducing the data on the one hand 
and retaining the original meanings and “feel” of the interviewees’ words on the other’ (Gale et al 
2013 p5). Oliver, Serovich and Mason (2005) highlight the complexities of interview transcription 
and note that when the informational content is the main interest, it can be considered appropriate 
to ‘denaturalise’ data through correcting of grammar and the removing of involuntary noises.  
 
2.7.3 Timing 
Gale et al (2013), Merriam (2009), and Silverman (2005) highlight that, in contrast to quantitative 
researchers, qualitative researchers must see data collection and analysis as a simultaneous activity 
in order to produce more trustworthy findings. As such, data analysis must begin immediately after 
the first interview, occur throughout data collection and then be finally refined once data collection 
is complete. Qualitative researchers must constantly remind themselves of the explicit purpose of 
the study and the conceptual lens that is being used whilst at the same time being open and 
responsive to the unexpected (Miles and Huberman 1994).   
1
• Transcription
2
• Familiarisation with the interview
3
• Coding
4
• Developing a working analytical framework
5
• Applying the analytical framework
6
• Charting data into the framework matrix
7
• Interpreting the data
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2.8 MAXIMISING THE QUALITY OF QUALITATIVE RESEARCH  
2.8.1 Trustworthiness 
Within quantitative research, validity and reliability are the criteria used to judge the quality of the 
research (Creswell 2014; Gray 2013; Silverman 2005). For research to be considered valid, it must 
have measured what it was intended to measure and various types of validity can be measured 
(internal, external, criterion, construct, content, predictive, statistical) and presented as evidence of 
the quality of the research (Gray 2013). For research to be considered reliable, the means of 
measurement within the research must be consistent. Reliability can also be measured in many ways 
such as stability, equivalence, internal consistency, inter-judge reliability, and intra-judge reliability 
(Gray 2013). Preventing bias and errors during conceptualisation of the research idea, and then 
during the design and process of the study, is paramount to ensuring validity and reliability (Bowling 
2014). Some of the more common types of bias and error, as outlined by Bowling (2014), are listed 
in Table 2.4.  
 
However, Shenton (2004) and Lincoln and Guba (1985) propose alternative terminology for use 
within qualitative work that is different to, and distanced from, the positivist paradigm. These terms 
are credibility, transferability, dependability and confirmability and are detailed in Table 2.5.  
 
Case study research can be used under a variety of paradigms and within quantitative, qualitative 
and mixed methods approaches, and so it is prudent to maintain a degree of flexibility when 
deciding on the terminology and approach to assessing quality. Furthermore, Birt et al (2016), 
Barbour (2001), and Sandelowski (1993), all caution on the over-zealous and uncritical adoption of 
trustworthiness strategies because of the potential to cause as many problems as they solve. Carlson 
(2010 p.1110) suggests that, ‘…trustworthiness is gained when researchers show that their data were 
ethically and mindfully collected, analysed, and reported’. Birt et al (2016), Barbour (2005), and 
Sandelowski (1993) also warn of potential problems with member checking (validation) of data 
because of: participants forgetting the information they provided; the changing nature of 
interpretations of phenomena over time by participants; the potential ethical issue of returning data 
to participants; the dilemma of anticipating and assimilating the disconfirming voices; and deciding 
who has ultimate responsibility for the overall interpretation. Barbour (2005) also suggests the use 
of dissemination focus groups as a possible alternative to member checking. This involves the 
researcher convening a group, providing feedback about the preliminary findings, and using the 
opportunity not just to validate the existing data but to generate more data. 
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Table 2.4 Common types of bias and error (Bowling 2014) 
Origin Bias or Error Description or example 
Researcher 
Conceptual bias Faulty logic in relation to the research problem, 
interpretations and conclusions 
Design bias Faulty design, method, sampling, procedures or analysis 
Handling of outliers Failure to discard an unusual value in a small sample or 
excluding unusual values inappropriately  
Interviewer bias Consciously or subconsciously causing participants to 
respond in a certain way e.g. asking leading questions 
Measurement decay Changing the way a measurement is taken throughout the 
research process  
Observer bias Difference between the actual situation and the one 
recorded  
Response set Having a lack of variety in questions that cause the 
participant to just say yes regardless of content; linked to 
participant response style bias  
Sampling bias The sample does not represent the population being 
studied  
Selection bias The characteristics of the sample differ from those of the 
wider population  
Systematic error All the various biases or errors in a study resulting in an 
estimate not being a true value 
Participant  
Acquiescence Participants are most likely to endorse, rather than 
disagree, with a statement 
Evaluation apprehension Participants giving answers they think are expected, rather 
than what they actually think, as a result of ‘exam anxiety’  
Mood bias Participants with depression may not accurately describe 
their situation 
Reactive ‘Hawthorne’ effect Participants changing their behavior due to the knowledge 
that they are being studied  
Recall (memory) bias Participants selective memory in relation to past events  
Reporting bias  Participants failing to provide the information requested  
Response style bias Saying yes to items regardless of content; linked to 
researcher response set bias 
Social desirability bias Participants wanting to present themselves at their best  
Other 
Non-response bias Differences in the characteristics between the responders 
and the non-responders not being known or accounted for  
Publication bias Results demonstrating a statistically significant outcome 
are more likely to be published than those that do not; 
positive results more likely to be published than negative 
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Table 2.5 Trustworthiness in qualitative research (Shenton 2004; Lincoln and Guba 1985) 
Term Description Similar to Examples of how this can be achieved 
Credibility The level to which the 
findings accurately reflect 
(are congruent with) 
reality 
Internal validity  Use well recognised research methods 
 Develop familiarity with individuals or 
organisation being researched  
 Random sampling of individuals serving 
as informants 
 Employ tactics to ensure honesty in 
informants  
 Triangulation - noted as fundamental to 
case study research (Yin 2014; Thomas 
2011; Stake 1995; Eisenhardt 1989) 
 Frequent debriefing 
 Peer scrutiny of project 
 Reflective commentary 
 Member checks of data (validation) 
 Description of the background, 
qualifications and experience of 
researcher 
 Rich, thick description of phenomenon 
Transferability The level to which the 
findings of the research 
can be applied (by the 
reader) to another group 
External validity 
(generalisability) 
 Provide background data 
 Establish context of study 
 Provide detailed descriptions of 
phenomenon (to allow for comparison)  
Dependability The level to which the 
research could be 
replicated accurately by 
another researcher  
Reliability  Use ‘overlapping’ methods 
 Provide a detailed description of 
methodology (to allow study to be 
repeated)  
Confirmability The level to which the 
findings are the result of 
the experiences and 
ideas if the informants 
(rather than that of the 
researcher)  
Objectivity  Use of triangulation (to reduce 
investigator bias)  
 Admission of researcher’s beliefs and 
assumptions 
 Acknowledge shortcoming(s) in methods 
and their effect(s) 
 In-depth descriptions of methods  
 Provision of an audit trail 
 
2.8.2 Reflexivity 
Mays and Pope (2000) define reflexivity as the awareness of the researcher to the ways in which 
both they personally, and the research process generally, shaped and influenced the collected data; 
Malterud (2001) uses the metaphor, ‘the knower’s mirror’. Within qualitative research, this issue is 
not whether the researcher has affected the process or indeed how to prevent any influence. 
Instead reflexivity is about acknowledging and sharing the effect of the researcher, on all aspects of 
the research. Encouraging dialogue between researchers so beliefs are made transparent; writing a 
reflexive journal to record logistics, decisions and reflections of values and interests; and reporting 
beliefs and values pre and post data collection are all considered ways to enhance reflexivity 
(Silverman 2005; Ahern 1999). When reviewing qualitative research Malterud (2001 p.485) suggests 
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assessing reflexivity by asking the question, ‘Are the researcher’s motives, background, perspectives 
and preliminary hypotheses presented, and is the effect of these issues sufficiently dealt with?’ 
 
2.9 RESEARCH GOVERNANCE – GENERAL CONSIDERATIONS  
NHS Research Scotland (2017) defines research governance as the setting of standards to improve 
research quality and to safeguard the public. Enhancing ethical and scientific quality, promoting 
good practice, reducing adverse incidents, ensuring lessons are learned, and preventing poor 
performance and misconduct are all considered (NHS Research Scotland 2017). Within their policy 
framework for health and social care research, the NHS Health Research Authority (HRA) outline the 
principles that apply to all health and social care research and the responsibilities of those involved 
(NHS Health Research Authority 2017a). These principles and responsibilities are summarised in 
Table 2.6. In addition, the Medical Research Council (MRC) provides online guidance on consent and 
how to prepare documents to support the process (Medical Research Council 2016). Finally, the 
university’s policies on research governance and integrity, and research ethics, support students in 
ensuring that the safety, rights, dignity and well-being of the participant and themselves are 
maintained; and that the research adheres to all relevant codes of good practice and policy (Robert 
Gordon University 2016a). As part of the research governance and integrity policy, all research 
involving human participants must be referred to the university’s Research Integrity and Ethics Sub-
committee for review before research can proceed (Robert Gordon University 2016a). It should also 
be noted that if any research involved NHS Grampian then approval from the North of Scotland 
Research Ethics Committee would also be required (Robert Gordon University 2016a).  
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Table 2.6 Principles and responsibilities in research (NHS Health Research Authority 2017a) 
Principle Summary 
1 The safety and well-being of the individual prevail over the interests of science and society.  
2 All the people involved in managing and conducting a research project are qualified by education, 
training and experience, or otherwise competent under the supervision of a suitably qualified person, 
to perform their tasks.  
3 Research projects are scientifically sound and guided by ethical principles in all their aspects.  
4 Patients, service users and the public are involved in the design, management, conduct and 
dissemination of research, unless otherwise justified.  
5 Research is designed, reviewed, managed and undertaken in a way that ensures integrity, quality and 
transparency.  
6 The design and procedure of the research are clearly described and justified in a research proposal or 
protocol, where applicable conforming to a standard template and/or specified contents.  
7 The researchers and sponsor familiarise themselves with relevant legislation and guidance in respect of 
managing and conducting the research. 
8 Before the research project is started, any anticipated benefit for the individual participant and other 
present and future recipients of the health or social care in question is weighed against the foreseeable 
risks and inconveniences once they have been mitigated.  
9 A research project is started only if a research ethics committee and any other relevant approval body 
have favourably reviewed the research proposal or protocol and related information, where their 
review is expected or required.  
10 In order to avoid waste, information about research projects (other than those for educational 
purposes) is made publicly available before they start (unless a deferral is agreed by or on behalf of the 
research ethics committee).  
11 Other than research for educational purposes and early phase trials, the findings, whether positive or 
negative, are made accessible, with adequate consent and privacy safeguards, in a timely manner after 
they have finished, in compliance with any applicable regulatory standards, i.e. legal requirements or 
expectations of regulators. In addition, where appropriate, information about the findings of the 
research is available, in a suitable format and timely manner, to those who took part in it, unless 
otherwise justified.  
12 Research participants are afforded respect and autonomy, taking account of their capacity to 
understand. Where there is a difference between the research and the standard practice that they 
might otherwise experience, research participants are given information to understand the distinction 
and make a choice, unless a research ethics committee agrees otherwise. Where participants’ explicit 
consent is sought, it is voluntary and informed. Where consent is refused or withdrawn, this is done 
without reprisal. 
13 Adequate provision is made for insurance or indemnity to cover liabilities which may arise in relation to 
the design, management and conduct of the research project.  
14 All information collected for or as part of the research project is recorded, handled and stored 
appropriately and in such a way and for such time that it can be accurately reported, interpreted and 
verified, while the confidentiality of individual research participants remains appropriately protected. 
Data and tissue collections are managed in a transparent way that demonstrates commitment to their 
appropriate use for research and appropriate protection of privacy.  
15 Sanctions for non-compliance with these principles may include appropriate and proportionate 
administrative, contractual or legal measures by funders, employers, relevant professional and 
statutory regulators, and other bodies.  
 
  
45 
 
2.10 RESEARCH GOVERNANCE CONSIDERATIONS SPECIFIC TO THE INCLUSION OF ADULTS WITH 
INCAPACITY  
2.10.1 Introduction 
According to the British Medical Association’s Medical Ethics Department (2009 p.4), a person is 
considered to lack capacity if, ‘he or she is incapable of acting, making decisions, communicating 
decisions, understanding decisions or retaining the memory of decisions due either to a mental 
disorder or to a physical disability which prevents communication.’ Furthermore, incapacity is not to 
be viewed as an ‘all-or-nothing’ concept but dependent on the nature of the decision that needs to 
be made (British Medical Association Medical Ethics Department 2009). In their policy framework for 
health and social care research, the NHS HRA state that persons, ‘who are not able to consent for 
themselves should be included in research, provided that you do this in line with relevant legal 
frameworks and ethical principles’ (NHS Health Research Authority 2017a).  The following section 
outlines the relevant legislation and ethical issues noted in the literature that require consideration 
when undertaking research inclusive of adults with LD who lack capacity or have only limited 
capacity. 
 
2.10.2 Adults with Incapacity Legislation (Scotland)  
The Adults with Incapacity (Scotland) Act (2000), provides a framework for safeguarding the welfare, 
and for managing the finances, of adults who lack capacity due to mental disorder or inability to 
communicate (Adults with Incapacity (Scotland) Act 2000). The Act sets down five general principles 
which must underpin any intervention, that is, any decision being taken on their behalf by other 
people: 
1. The intervention must benefit the adult; 
2. The adult’s wishes, so far as they can be ascertained, must be taken into account; 
3. The views of relevant others, so far as it is reasonable and practical to do so, must be taken 
into account; 
4. The adult’s freedom should be restricted as little as possible while still achieving the desired 
benefit; 
5. The adult must be encouraged to use any residual capacity.  
The Adults with Incapacity (Scotland) Act 2000 makes provision for a legally recognised proxy 
decision maker to be appointed by one of three routes: power of attorney; guardianship; and person 
appointed by a court order (The Office of the Public Guardian in Scotland, 2016): 
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Power of Attorney – Continuing and Welfare  
Continuing power of attorney gives power over the granter’s property and finances. 
Continuing power of attorney may start immediately and continue in the event of the 
granter’s incapacity, or the granter may stipulate that it only begins when they become 
incapable. Welfare power of attorney gives power over decisions that need to be taken 
about the granter’s welfare and health care. In contrast to continuing power of attorney, 
welfare power of attorney can only begin when the granter becomes incapable and has 
been medically certified as such. In order to grant either continuing or welfare power of 
attorney, the granter must have capacity. 
 
Guardianship 
Someone who has already lost capacity, or who has never had capacity, cannot appoint a 
power of attorney (welfare or continuing). Guardianship is a court appointment that 
authorises a person to act and make decisions on behalf of someone over the age of 16 
years with incapacity who is not able to look after their own affairs. The Court will agree the 
powers to be included in the guardianship order and these can be financial, welfare-related 
or a combination of both.  
 
Person Appointed by a Court Order  
Anyone with an interest can make an application for an intervention order. This is a court 
appointment which authorises a person to act and take a one-off action or make decisions 
on behalf of an adult with incapacity. The order allows the person appointed to do certain 
one-off things such as sign legal documents or sell the adult’s house or sign forms agreeing 
where someone can live. If powers are required on an on-going basis then 
guardianship would be more appropriate. 
 
Section 51 of the Adults with Incapacity (Scotland) Act 2000 outlines the authority for research and 
states that all research involving adults with incapacity must: have been approved by an ethics 
committee; entail no foreseeable risk, or only a minimal foreseeable risk, to the adult; impose no, or 
minimal, discomfort on the adult; and obtain consent from any guardian or welfare attorney who 
has power to consent to the adult’s participation in research, or where there is no such guardian or 
welfare attorney, from the adult’s nearest relative. Of note, is the fact that research involving adults 
with incapacity is not prohibited. When undertaking research that involves an individual who lacks 
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capacity, all aspects of Section 51 of the Adults with Incapacity (Scotland) Act 2000 must be adhered 
to. 
 
2.10.3 Informed Consent 
For consent to be considered both legal and ethical it must be given voluntarily with no undue 
influence, by an individual with capacity, who has been adequately informed (NHS Health Research 
Authority 2017b). In addition, consent must be seen not as a one-off event but an iterative and on-
going process (NHS Health Research Authority 2017b). The Medical Research Council (2007) states 
very clearly that a person is deemed unable to consent to take part in research if they cannot: 
understand the information relevant to the decision; retain the information long enough to make 
the decision; use or weigh that information as part of the process for making the decision; and 
communicate their decision. When considering consent in people with LD there will be two groups 
of individuals: those who lack the capacity to consent; and those who are able enough, possibly with 
a degree of support, to provide their own consent.  
 
If an individual lacks capacity to consent then, as per Section 51 of the Adults with Incapacity Act 
(Scotland) 2000, the person’s legal representative (welfare power of attorney or welfare guardian or 
person appointed by a court order) or relative can be approached and be asked to provide consent. 
When this occurs, the NHS Health Research Authority (2017b) stipulates that the legal 
representative must be given sufficient information about the research and then be told that they: 
are being asked to give consent on behalf of the incapacitated adult; are free to decide whether or 
not they wish to make this decision; and are being asked to consider what the adult would want; and 
should set aside their own personal views when making this decision. Dalton and McVilly (2004 p.63) 
recommend that, ‘…where a nominated family member of legal guardian does not have regular 
contact with the potential participant, collective decision making processes, involving a number of 
advocates, can be more effective in safeguarding the potential participant’s best interests’. 
 
The issue of ensuring informed consent, and not just acquiescence, has been raised in the literature 
(Stalker 1998). To ensure consent is indeed informed, it is recommended that researchers give due 
consideration to: the quality of information provided; who they provide information to; what format 
they provide the information in; how they will arrange for adequate support for the individual to 
consider the information; ascertaining and adapting the research process to the previous experience 
and familiarity with making choices of that individual (Raghavan and Patel 2010; Nind 2009; 
Keywood and Flynn 2006). For Clinical Trials of Investigational Medicinal Products (CTIMPs), consent 
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is only legal if it is provided in writing, but for other types of research consent may be provided 
verbally, non-verbally or in writing (Health Research Authority 2017b).  Dalton and McVilly (2004) 
recommend that if only verbal consent can be given then it should be witnessed by at least one 
independent individual and formally documented. 
 
When undertaking research involving adults with LD, ascertaining their level of capacity to consent 
and participate will be essential. In addition, ensuring that written information is adapted for people 
with LD and that the process of obtaining consent and data collection is adapted to support the 
individual whilst still adhering to all the principles and requirements laid down by the HRA is also 
essential (NHS Health Research Authority 2017a). 
 
2.10.4 Inclusion in Research 
The need to, and the benefits of, involving people with LD in projects designed to promote health 
and research in their community are well documented (Medical Research Council 2007; Dalton and 
McVilly 2004; Walmsley 2004; Atkinson 2004; Stalker 1998; Ward and Simons 1998). Dalton and 
McVilly (2004 p.59) also state that people with LD, ‘…should not be excluded (discriminated against) 
as potential participants in generic research and every effort should be made to include their 
perspectives, priorities and needs in generic research activities’. However, due consideration must be 
given to the fact that intellectual impairment does limit the extent and means to which people with 
LD can be involved in certain research activities (Walmsley 2004), and that not everyone with LD will 
be able or want to be involved (Ward and Simons 1998). Ward and Simons (1998) also note that 
doing research with people with LD instead of research about them, takes time, thought and energy. 
However, enabling them to be an authority on their own lives (Stalker 1998), and controlling the 
stories of their lives (Atkinson 2004) can bring people with LD enormous benefit. It also strengthens, 
enriches, appropriately focusses and produces more effective outputs within research (Ward 1998). 
Finally, Arscott, Stenfert Kroese and Dagnan (2000) remind us that many people, not just those with 
LD, are content to rely on their doctor’s recommendations and adhere to medication with very little 
knowledge of that medication. All of these issues must be incorporated into any research involving 
adults with LD. 
 
2.10.5 Literacy and Health Literacy  
The definition of the term ‘literacy’ is constantly evolving but is generally understood to refer to an 
individual’s ability to read; sometimes to read and write; and sometimes to read, write, speak and 
listen (Cambridge Assessment 2013). More specifically, the term ‘health literacy’ refers to the 
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degree to which an individual has the cognitive and social skills to obtain, process, and understand 
basic health information and need for services in order to make appropriate health decisions (US 
Department of Health and Human Services 2000; Nutbeam 1998). As a consequence, people with 
limited health literacy often lack knowledge or are misinformed about the body and the nature and 
causes of disease (US Department of Health and Human Services 2000). The diagnosis of LD is only 
given to an individual whose IQ is known to be less than 70 (British Psychological Society 2000). It 
therefore follows that within the LD population, both literacy and health literacy are either 
challenging, limited or impossible. Considering the potential for reduced literacy and health literacy 
in the LD population, amending materials and processes is essential. Another issue that further 
compounds this is the increased incidence of visual impairment within the LD population (Scottish 
Government 2013; Royal College of General Practitioners 2012). 
‘Easy-read’ is one way of making information more accessible to people with milder LD as it limits 
information, simplifies concepts, uses larger font size text, and uses pictures to accompany any text 
(Department of Health 2010). Some of the practical recommendations from the Department of 
Health (2010) are highlighted in Figure 2.2. 
Figure 2.2 Practical recommendations for easy-read (Department of Health 2010) 
  
Main idea should be in 
words and pictures 
Pictures to the left of 
any text
No jargon or 
complicated wording
No acronyms or 
abbreviations
Keep sentences short 
(<15 words)
Make documents as 
short as possible 
(<20 pages)
Use sans serif or arial 
font
Minimum font size =16
Dates should follow 
the format 
31 July 2010
Avoid the 24 hour 
clock
Express all numbers in 
figures
Ask people with LD 
what they think before 
using
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2.10.6 Involvement of Significant Others  
Citing Walmsley 2004, Nind (2009) recommends that those who wish to undertake research in the 
LD population, work closely with those who know the individuals well. These people can then advise 
on the unique ways to maximise communication with each individual and therefore enhance 
participation. Nind (2009) also notes that some people with LD may need the support of a familiar 
person in the interview who can help them communicate their ideas or act as a translator when 
required. Nind (2009) also notes that for many people with profound LD, interviews are just not 
possible.  Involving significant others in the research process is therefore essential.  
 
2.10.7 Capability, Not Disability 
When discussing the transformative paradigm, Mertens (2004) highlights the need for researchers 
who work with populations different to their own to be culturally competent, that is: to be aware of 
their assumptions regarding human behaviour, values, biases; to actively attempt to understand the 
worldview of the group of people they are researching; and to develop and practice appropriate, 
relevant and sensitive strategies and skills for working with that research population. After 
describing the medical, social and biopsychosocial models for ID, Emerson and Hatton (2013) 
highlight the tension between the medical and social models. The medical model views LD as a 
series of functional deficits whereas the social model is concerned with achieving civil rights and 
empowerment. As a result, conducting research that only seeks to highlight deficits within the LD 
community would not be considered culturally competent. Emerson and Hatton (2013) promote 
working within the capabilities framework that was begun by Sen (1999) and Nussbaum (2011) 
which focusses on what individuals are able to do and be, rather than what they cannot do nor be.  
 
2.10.8 Establishing Relational Boundaries 
A survey of 2898 people with LD by Emerson et al (2005) reported that 19% of people with LD never 
saw members of their family; 31% said they did not have any contact with friends; and 5% had no 
friends and did not see anyone from their family. As a result, there is the potential issue of the 
person with LD coming to misinterpret multiple visits from a researcher as a new friendship. In 
addition, there is also the potential for the blurring of lines between the research and current 
medical or pharmaceutical issues when the researcher also a local HCP. This will be both from the 
point of view of the participants who may wish to discuss and action current pharmaceutical issues, 
and from the researcher who may wish to intervene to resolve a current pharmaceutical issue. Both 
issues required to be addressed within the research plans to ensure that, wherever possible, 
appropriate relational boundaries between the researcher and the participants are established and 
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maintained. This would ensure that the focus and integrity of the research would be retained whilst 
not neglecting the wellbeing and safety of the participant.  
 
2.10.9 Adult Support and Protection Legislation (Scotland)  
According to the Adult Support and Protection (Scotland) Act 2007, ‘adults at risk’ are adults who are 
unable to safeguard their own well-being, property, rights or other interests; are at risk of harm; and 
because they are affected by disability, mental disorder, illness or physical or mental infirmity, are 
more vulnerable to being harmed than adults who are not so affected (Adult Support and Protection 
(Scotland) Act 2007). These adults would be considered at risk of harm when either another person’s 
conduct is causing, or is likely to cause, the adult to be harmed; or when the adult is engaging, or is 
likely to engage, in conduct which causes, or is likely to cause, self-harm. Where a public body or 
office-holder knows or believes that a person is an adult at risk, and that action needs to be taken in 
order to protect that person from harm, the public body or office-holder (including all HCPs) must 
always report the facts and circumstances of the case to the LA. The NHS HRA (2017a) clarifies the 
potential clash of clinical and research priorities by stating that, ‘If an unmanageable conflict arises 
between research and patient interests, the duty to the participant as a patient prevails.’ 
 
2.11 DATA PROTECTION 
From 25th May 2018 the European Union General Data Protection Regulation (GDPR) has become 
the governing data protection legislation within the UK (Council of the European Union 2016). 
However, at the time of research, the governing legislation for data storage within the UK was still 
the Data Protection Act 1998 (Data Protection Act 1998).  
 
The eight principles in Schedule 1 of the Data Protection Act (1998) are listed below:  
1. Personal data shall be processed fairly and lawfully and, in particular, shall not be processed 
unless (a) at least one of the conditions in Schedule 2 is met, and (b) in the case of sensitive 
personal data, at least one of the conditions in Schedule 3 is also met; 
2. Personal data shall be obtained only for one or more specified and lawful purposes, and 
shall not be further processed in any manner incompatible with that purpose or those 
purposes; 
3. Personal data shall be adequate, relevant and not excessive in relation to the purpose or 
purposes for which they are processed; 
4. Personal data shall be accurate and, where necessary, kept up to date; 
5. Personal data processed for any purpose or purposes shall not be kept for longer than is 
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necessary for that purpose or those purposes; 
6. Personal data shall be processed in accordance with the rights of data subjects under this 
Act; 
7. Appropriate technical and organisational measures shall be taken against unauthorised or 
unlawful processing of personal data and against accidental loss or destruction of, or 
damage to, personal data; 
8. Personal data shall not be transferred to a country or territory outside the European 
Economic Area unless that country or territory ensures an adequate level of protection for 
the rights and freedoms of data subjects in relation to the processing of personal data. 
 
In addition, the Research Council UK provides an overarching framework to reflect two key principles 
about publicly-funded research data: they are a public good and produced in the public interest; and 
they should be openly available to the maximum extent possible (Research Councils UK 2015). 
Finally, RGU has a guide for students on managing and sharing research data to ensure best practice 
(Robert Gordon University 2016b). 
 
2.12 STUDY DESIGN 
2.12.1 Worldview and Methodological Approach 
From a pragmatic worldview, a predominantly qualitative design, as outlined by Creswell (2013) and 
Denzin and Lincoln (2013), was adopted. This was because the intention of the research was to 
explore, and not quantify, the medication related experiences of adults with LD in order to identify 
ways in which these experiences might be improved by HCPs.  This resonates with Koelsch (2013 p. 
170) who states that the purpose of qualitative research, ‘…is not to achieve representation, but 
rather to change problematic social conditions, institutions, thoughts, behaviours, and so forth.’ 
However, using a framework approach, as detailed by Gale et al (2013), with a priori coding as 
detailed by Miles and Huberman (1994) detracts from a purely constructivist study design.  
 
2.12.2 Qualitative Methodology – Case Studies 
As the purpose of the research was not to build theory, grounded theory was not an appropriate 
choice of methodology. The potential for negatively impacting on the participants when 
withdrawing from their world after the research period ended made ethnography less suitable; the 
potential for limited recall from adults with LD made a narrative approach also less suitable. 
Although phenomenology was considered, case study methodology was chosen in preference for 
this research because it allowed for real-life study of the defined phenomena (medication 
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experience in adults with LD); inclusion of multiple ‘cases’; and inclusion of a variety of data sources 
(Yin 2014; Thomas 2011; Baxter and Jack 2008; and Luck, Jackson and Usher 2006).  
 
Using the case study classification as defined by Thomas (2011) in Table 2.2: the subject (an adult 
with LD) will be selected through the knowledge of local care providers and support charities; the 
purpose will be exploratory; the approach will be illustrative; and the process will be to include 
multiple case studies in a parallel manner. Local care providers and charities will be asked to identify 
potential suitable participants. As recommended by Yin (2014), 6-10 case studies will be included in 
order to allow for an aggregation of evidence.  
 
The boundaries, or inclusion criteria, for each case will be as follows: the adult with LD must be aged 
18 years or more; have taken more than one regularly prescribed medicine for more than 6 months; 
and be living in a community setting. The case will include any aspect of medication experience for 
that adult with LD from any point in their life. Consideration will not be given to any adult with LD 
where: participation would be stressful or inappropriate for the adult with LD and their carers or 
care workers; there are current adult protection issues for that individual or housing unit; adult 
protection issues involving medication were experienced in the past. Whilst the view of associated 
HCPs would add a further dimension to the case study evidence their views will not be sought so 
that the voice of the adult with LD is heard.  
 
As described in Chapter 1, care providers and charities are often involved in supporting adults with 
LD, and are therefore ideal to involve in the recruitment process. The Care and Support Providers 
Aberdeen (CASPA) forum, mentioned in Chapter 1, will be asked to support recruitment and 
identification of suitable cases by disseminating invitations to participate in the research. In order to 
promote the recruitment, the researcher and supervisor will attended a scheduled meeting of 
CASPA.  A presentation will be made to the assembled representatives including relevant study 
information. Subsequently, a request for participants will be emailed to CASPA, including an easy-
read information sheet and consent form. CASPA will be asked to send this information and request 
on to the affiliated care provider companies, charities, and the local LD support group 
 
2.12.3 Data Collection  
The primary data source for each case study will be semi-structured interviews with the adult with 
LD and/or their carers and care workers. However, where possible, information from available 
documents such as medicine administration records and client records, and unstructured indirect 
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observations by the researcher will also be collected. Neither the medical not the pharmaceutical 
records of each individual adult with LD will be accessed so all information pertaining to medication, 
medical conditions, and medical history, must be obtained through interview and through 
observations of the actual medication, repeat prescriptions re-order slips, and other written records.  
 
Interviews 
Wherever possible, interviews will be conducted face-to-face at a time and location 
convenient to the participant. However, a telephone interview will be conducted if 
preferred. With prior consent, all interviews will be audio-recorded. Depending on what the 
participants and their carers or care workers are most comfortable with, interviews may be 
one-to-one, with a carer or care worker present (for an interview with an adult with LD) or 
as a group (for care workers). 
 
Interviews will be semi-structured and the interview schedule will be developed to reflect 
the PLEM conceptual model (see Section 2.12.4). The first part of the interview will be an 
opportunity for the participants to discuss the experiences most important to them; 
following on from this structured questions, based on the PLEM conceptual model, will be 
asked.  
 
Prior to data collection, interview questions in standard and easy-read format will be peer 
reviewed by the researcher’s supervisory team, by senior LD care workers, and by an adult 
with LD, to ensure the wording is as clear and understandable as possible. In addition, a pilot 
interview will be conducted to refine interview technique and process. 
 
A simplified, easy-read version of the interview questions (see Appendix 2.1) will be 
provided to participants at least 48 hours before the interview. The adult with LD (if capacity 
allows), and current care workers and carers will all be invited to participate.  
 
A small financial reimbursement, to cover out-of-pocket expenses, was provided to all 
participants. 
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Observations, Documentation and Field Work Notes 
Direct observation of medication taking practice was not incorporated into the study design 
because of the inherent problem of the participants amending behaviour as a result of being 
observed (commonly known as the ‘Hawthorne effect’ as described by Roethlisberger and 
Dickson 2003, cited by Bowling (2014)). General indirect observations of the setting, the 
actual medication, the medication storage, dynamic between carers and overall impressions 
will be noted in the field work note book. Medication storage, and information in written 
records will be photographed, if anonymity could be preserved, or noted in the field work 
note book.  
 
2.12.4 Theoretical Framework  
Introduction 
Birken et al (2017) cite twelve different ways in which theory is used by researchers within their 
area. This is summarised in Figure 2.3. 
 
Figure 2.3 Use of theory by researchers (Birken et al 2017) 
 
Within the literature these theories are referred to in a variety of terms: theoretical lens; theoretical 
perspective; theoretical framework; conceptual framework; and conceptual model (Grant and 
Osanloo 2016; Creswell 2014; Maxwell 2012). However, within the literature there is not yet 
consensus on the definitions and interchangeability of the various terms, as noted on discussion 
threads on Researchgate (Researchgate 2014a; Researchgate 2014b). To prevent any unnecessary 
confusion by interchanging terminology, ‘theoretical framework’ will be the term used to describe 
identify key constructs 
that may serve as 
barriers and facilitators
inform data collection
guide implementation 
planning
enhance conceptual 
clarity
frame an evaluation
specify the process of 
implementation
inform data analysis
guide the selection of 
implementation 
strategies
specify outcomes clarify terminology
convey the larger 
context of the study
specify hypothesised 
relationships between 
constructs
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the underpinning theory within this research although when referring to other work, the term used 
by those authors will be used.  
 
Choice of Theoretical Framework for this Research  
The challenge of selecting a suitable theoretical framework is highlighted by Birken et al (2017) who 
cite the various criteria used by researchers when selecting theory which is summarised in Figure 
2.4. For this research, ensuring that the theory had a logical consistency and plausibility relating to 
medication experience, and could be used within a qualitative research method, were of primary 
importance.  
 
 
Figure 2.4 Criteria used to select theory (Birken et al 2017) 
 
Existing validated instruments for measuring beliefs about medicines (Horne, Weinman and Hankins 
1999); treatment burden (Tran et al 2014); and experiences with medication (Krska et al 2014), were 
considered. However, all these instruments quantified experience and did not lend themselves to an 
explorative qualitative approach.  
 
Consideration was also given to using the Theoretical Domains Framework (TDF). The TDF was 
developed by Michie et al (2005) to make behavioural change theory more easily understood and 
accessible to non-psychologists. It simplifies and summarises 33 theories and 128 key theoretical 
constructs related to behaviour into 14 domains (knowledge; skills; role and identity; beliefs about 
capabilities; optimism; beliefs about consequences; reinforcement; intentions; goals; memory, 
analytical level
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attention and decision process; environmental context and resources; social influences; emotion; 
and behavioural regulation). Whilst the TDF might have been used as a means of describing the 
behaviours of people with LD or their carers and care workers, the purpose of the study was not 
actually to identify areas of behavioural change and therefore the TDF was limited in its applicability.  
 
In early 2016 (whilst the research proposal was being drafted), Mohammed, Moles and Chen (2016) 
identified and meta-synthesised 34 studies (from an initial 4063) to create a new conceptual model 
describing the Patient’s Lived Experience with Medicine (PLEM) (see Figure 2.5).  
 
Descriptions of Patients’ Lived Experience with Medicines (PLEM) Conceptual Model 
This new PLEM conceptual model incorporated the three major and inter-related themes that 
emerged from the studies: medication related burden; medication related beliefs; and medication 
taking practice. The authors intended medication related burden to be considered an antecedent 
factor and medication taking practice the target behavior or outcome within the model. Under each 
of these three themes, sub-themes were identified. The sub-themes for medication related beliefs 
were developed using the Theory of Planned Behaviour (Ajzen 1991). This theory proposes that an 
individual’s behavioural intentions are a combination of their attitude toward that behaviour, 
subjective norms, and perceived behavioural control (Ajzen 1991). Furthermore, within the PLEM 
model, the combination of medication related burden, medication related beliefs, and medication 
taking practice were shown to influence the patient’s wellbeing or health-related quality of life 
(HRQoL) and negative therapeutic outcomes as well as determining the patient’s lived experience 
with medicine.  Citing Cipolle, Strand and Morley (2004), Mohammed, Moles and Chen (2016 p.1) 
define patients’ medication experience as, ‘the sum of all events involving drug therapy that a 
patient encounters in his/her lifetime’. 
 
Use of PLEM in the Literature 
At the point of research planning and data collection (2016), the PLEM model had only just been 
published so there was no additional literature where the PLEM model had been used, critiqued or 
validated.  In October 2017, eight citations of Mohammed, Moles and Chen (2016) were identified 
through Google Scholar but none of these studies were found to have used, critiqued or validated 
the PLEM model.  
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Figure 2.5 Patient’s lived experience with medicines (Mohammed, Moles and Chen 2016)
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Strengths and Limitations of PLEM Conceptual Model as a Theoretical Framework  
Although the PLEM model may require refinement through validation, it had a high degree of logical 
consistency and plausibility, could be used within a qualitative research method, and had the 
required outcome of interest (experience with medication). Furthermore, it resonated with my 
experience and knowledge as a practising pharmacist. Maxwell (2012 p45) argues against ignoring 
knowledge gained from experience about the settings or issues that are proposed to be studied and 
cites Wright Mills (1959 p.195) as saying ‘The most admirable scholars within the scholarly 
community . . . do not split their work from their lives. They seem to take both too seriously to allow 
such dissociation, and they want to use each for the enrichment of the other.’ Furthermore, no other 
theoretical framework was found that was as specific to medication experience as the PLEM model.  
However, there are some limitations of note: 
 The PLEM conceptual model has not yet been validated and so elements of the model may 
be disputed in the future; 
 Although the burden and negative aspects of medicines are conceptualised, the positive 
aspects of medicines are not as clearly conceptualised and this may result in an imbalance 
within the model; 
 The depth of disease related burden was not accounted for in the model as an issue that 
affecting the extent and impact of any medication related burden; 
 The minor themes of ‘Patients’ wellbeing &HRQoL’ and ‘Negative Therapeutic Outcomes’ 
were not as clearly defined, linked and described as the major themes; 
 Attempting to cover all aspects of the model within an interview would be resource and 
time intensive for both the researcher and the participants; 
 None of the studies included in the metasynthesis included adults with LD; 
 The term, ‘lived experience’ is closely associated with phenomenological enquiry where the 
researcher seeks to describe how an individual experiences a phenomenon in their everyday 
world (Sadala and Adorno 2002). Mohammed, Moles and Chen (2016) have not linked their 
use of the phrase ‘lived experience’ to this phenomenological term and there is therefore 
potential for misunderstanding about the term. 
 
How the PLEM Conceptual Model will be used as a Theoretical Framework in this Research 
The three major and interrelated themes of medication related burden, medication related beliefs 
and medication taking practice, and their individual sub-themes will be used to structure data 
collection and analysis. Furthermore, within their published paper Mohammed, Moles and Chen 
(2016), cite examples of each sub-theme and these examples will also be used to explore 
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participants’ experience with medicines. In addition, these themes, sub-themes, and examples will 
be used as a priori codes for data analysis. The final framework with a priori codes for data collection 
and analysis, adapted from the PLEM conceptual model by Mohammed, Moles and Chen (2016) can 
be found in Appendix 2.2. 
 
The minor themes of Patients’ wellbeing & HRQoL and Negative Therapeutic Outcomes will not be 
used as these were not as clearly defined, linked and described. Furthermore, to accurately assess 
HRQoL would involve the use of validated instruments and quantitative methodology and methods; 
this would detract from the constructivist approach of exploring the experiences of adults with LD in 
relation to medication.  
 
2.12.5 Data Analysis 
Interviews will be transcribed in a denaturalised manner by the researcher as outlined by Oliver, 
Serovich and Mason (2005). Conversational data not relating to the research topic, pauses or 
‘stumblings’, involuntary vocalisations such as sniffing or laughing and movement will therefore be 
excluded, unless to do so would prevent understanding of the verbal data. Audio recordings, 
transcripts, fieldwork notes, photos and information from any formal files will be added to the study 
database in the relevant case file. The transcripts will be checked for accuracy against the audio 
recording by the researcher’s principal supervisor of doctoral studies. 
 
Analysis of all the collected data will therefore be undertaken through a deductive framework 
approach using the PLEM conceptual model a priori codes; these codes can be found in Appendix 
2.2. Any data not fitting the a priori coding system will be assigned a new code. All coding will be 
undertaken by the researcher with regular check by, and discussion with, the researcher’s principal 
supervisor of doctoral studies. 
 
Data analysis will begin at the individual case study level but will then be collated and presented at a 
multiple case study level. A summary of the 7-step process for data analysis, as outlined by Gale et al 
(2013) in Figure 2.1, has been amended for this study to allow the framework to structure data 
collection and accommodate multiple case study methodology. See Figure 2.6 for this amended 
process for data analysis.  
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Figure 2.6 Amended process for data analysis based on the 7-step process by Gale et al (2013)  
 
2.12.6 Maximising the Quality of this Research  
Trustworthiness 
As advised by Shenton (2004), strategies to promote the credibility, transferability, dependability 
and confirmability of the research have been adopted and are outlined in Table 2.7.  
  
1
•Develop PLEM framework and a priori coding list
2
•Transcription of interview but with omission of  dialogue conventions and information not 
relevant to focus of the case; archiving of other data
3
•Familiarisation with all data in each case study
4
•Apply framework coding to data in each case study
5
•Collate all coded data from each case under PLEM a priori headings and review 
appropriateness; recode if necessary
6
•Collate all case study proformas into one multiple case study proforma and review 
appropriateness; recode if necessary
7
•Interpret data
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Table 2.7 Strategies to promote trustworthiness within this research  
Term Strategy within this research 
Credibility  Adoption of best practice methods for arranging and conducting interviews 
 Scrutiny of questions and processes by the academic supervisor and the Aberdeen Provider 
Forum (previously CASPA). The chair of the local LD support group (who has mild LD) helped 
to further refine the questions into easy-read format. This enhanced both academic rigour 
and suitability for the intended participant group.   
 Familiarity with LD services and key people had already been established prior to the research 
being researched  
 Individuals were not selected by the researcher but identified by the services involved 
 Adopting a relaxed attitude in the interview in a time and location of the participant’s choice 
to promote honesty in informants  
 Information from multiple carers or care workers and use of documents to aid triangulation 
of data sources 
 Frequent debriefing with supervisor 
 Written reflective diary kept during research and issues discussed with supervisor 
 Checking of transcription and coding accuracy by supervisor 
 Dissemination focus group-like approach in preference to member checking- described in 
more detail in next section 
 Description of the background, qualifications and experience of researcher within the thesis 
 Rich, thick description of the cases in Chapter 3 and Appendices 3.1 – 3.11  
Transferability  Background data to cases provided in Chapter 3 and Appendices 3.1 – 3.11  
 Context of study established in Chapter 2 
 Quotes and evidence from all cases included in Chapters 4 - 7 and Appendices 3.1 – 3.11 
Dependability  Methodology described to allow study to be repeated in Chapter 2 
Confirmability  Triangulation used to reduce investigator bias 
 Researcher’s beliefs and assumptions described in the introduction to the thesis, Chapter 2 
and Chapter 9 
 Methods described in Chapter 2 
 Limitations of study acknowledged in Chapter 9 
 Audit trail of all aspects of research process kept  
 
Dissemination Check 
Although member checking of the data after transcription is a potential strategy for enhancing 
credibility, concerns of memory and recall for participants with LD and then who holds the ultimate 
responsibility for overall interpretation of group interviews, limited the value of this strategy. 
However, it was important to explore whether the findings resonated with the LD community, 
ascertain if any key issues had been missed, and explore future dissemination strategies. This 
concept has been described as a ‘dissemination focus group’ in the literature and describes a 
situation where new participants explore and clarify research findings together, with a particular 
focus on how the findings could be disseminated (Barbour 2005). Focus groups typically involve 4-10 
participants (Morgan 1996; Kitzinger 1995). However, in order to ensure an interview that could fully 
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explore the views of people experienced in the LD sector it was decided to only invite two people (a 
local LD Service Manager and LD Charity Manager) to formally participate in the research. Although 
this reduced the breadth of views it enhanced the depth of views from two experts in the field. 
However, as there were only two participants, it cannot be termed a focus group. Both participants 
were emailed a copy of the key findings, asked to read through and consider the following before 
meeting together with the researcher: 
Q1 Are the results credible and do they ring true with your experience? 
Q2 From your perspective, what are the most important point(s) about adults with LD's 
experience of medication?  
Q3 Are there any important points about medication experience in adults with LD that you 
think are missing? 
Q4 What issues raised in the research would be most applicable to your current place of 
work? 
Q5 How do you think health care professionals could better support adults with LD with 
respect to their medication?  
Q6 How do you think this information could be best used to improve adults with LD's 
experience of medication?  
The dissemination check was not audio-recorded. Extensive notes of the discussion were taken by 
the researcher. The wording of the key points for each question were agreed by the group during 
the meeting. 
 
Reflexivity 
The research was undertaken in the ‘real world’ so the research was anchored in a pragmatic 
worldview. Approaching the research as both a HCP and researcher and focusing on the impact the 
research might have in the ‘real world’ has significantly shaped and influenced the research process, 
particularly the practical aspects. As highlighted by Maxwell (2012), using knowledge of settings and 
issues gained from prior clinical experience about the settings to optimise the research process and 
maximise the impact from the research can be viewed positively. However, it does have to be 
acknowledged that this may conversely cause bias and negatively impact the quality of the research.  
A more detailed background to the researcher and motivation for the research is provided in the 
introduction to this thesis. Ensuring transparency was a key focus throughout the research process 
and so a reflexive diary was kept throughout; thoughts and experiences were to be discussed 
regularly with the academic supervisor in order to minimise any bias. A final reflexive account is 
given in Chapter 9.  
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2.12.7 Research Governance within this Research   
Review of Research Proposal and Plans 
The Scientific Officer linked to the Adults with Incapacity Research Ethics Committee (AREC) in 
Edinburgh advised that it was not necessary to seek ethical approval from the North of Scotland 
Research Ethics Service or from the AREC because the participants were not being recruited as NHS 
patients; and also because there was no involvement of NHS staff as participants, NHS facilities or 
NHS data. It was, therefore, only the RGU School of Pharmacy and Life Sciences (P&LS) Ethical 
Review Panel that reviewed and approved the proposed research. This review checked that all 
appropriate safeguards for participant and researcher were in place and that the research would be 
in accordance with the RGU Research Governance and Integrity policy (Robert Gordon University 
2016a). At the time of research, the active legislation governing data management was the Data 
Protection Act (1998) and the RGU School of P&LS Ethical Review Panel ensured that processes for 
acquiring, storing and managing data were all in accordance with the Act. 
 
However, in addition to review by RGU School of P&LS Ethical Review Panel, the research proposal 
(aims and objectives; recruitment options; procedures and paperwork; and interview questions) 
were also reviewed for suitability by representatives of CASPA (now the Aberdeen Provider Forum), 
the research team and the Chair of the local LD support group (an individual with LD) who was keen 
to be involved throughout the research process. Questions were worded positively and a capability 
focus was retained in order to maximise acceptance of the research in the LD community. Ensuring 
all information and consent forms were available in easy-read, and adapting processes to ensure 
that adults with LD were included as far as is possible, were integral to the research proposal.  
 
Safeguarding Vulnerable Adults 
If during the course of the fieldwork, a participant raised an issue indicative of abuse (physical, 
emotional, financial, or sexual) the following protocol was agreed: 
 Fieldwork will cease; 
 The researcher will listen to what the individual says and will not ask any more research-
based questions; 
 The relevant LA’s Adult Support and Protection team will be contacted by the researcher 
(the contact number for each LA’s Adult Support and Protection team was added to the 
researcher’s mobile phone); 
 Depending on the allegation and advice from the Adult Support and Protection team, the 
legal welfare guardian or family or carer may need to be notified by the researcher; 
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 The issue, intervention and outcome will all be recorded in fieldwork notes whilst protecting 
identities of participants throughout; 
 A discussion of the event with the supervisory team will take place and agreement reached 
on how to proceed and whether the case should be excluded from the research. If the team 
agrees that it can be included, the researcher will ask for formal consent for the data to be 
included from all relevant participants. 
 
If during the course of the interview or fieldwork, a participant with LD became notably aggressive, 
distressed or distracted the following protocol was agreed: 
 The interview or fieldwork will be suspended and a note made of this in the proforma; 
 If not already present, carers will be contacted and the researcher will step back to allow the 
situation to be addressed and resolved; 
 Advice will be taken from the carers as to whether to recommence, reschedule or terminate 
the interview and fieldwork; 
 If fieldwork is to recommence or be rescheduled, advice will be taken from the carers on 
how to minimise a reoccurrence of the aggression, distress or distraction; 
 The issue, intervention and outcome will all be recorded in fieldwork notes. A discussion of 
the event with the supervisory team will take place and agreement reached on how to 
proceed and whether the case should be excluded from the research. 
 
Consent – Amended Process and Documentation  
All information and consent forms were created in line with Health Research Authority (2017b) 
advice and with the input of LD charity representatives and an individual with LD. Easy-read versions 
of the information and consent forms for participants with LD were also created and used where 
appropriate. A selection of these information and consent forms can be seen in Appendices 2.3 – 
2.8.  
The following protocol for consent was agreed: 
 Consent for the research to be obtained from the person with LD (if they had capacity) or 
from their welfare guardian, family representative, primary carer or care worker; 
 If the person with LD had the capacity to consent: 
o Easy-read information sheets and consent forms were provided to the adult with LD 
and their primary carer or care worker; 
o The person with LD was able to discuss the research with whoever they chose; 
o Written or audio-recorded verbal consent was obtained a minimum of a week later; 
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o Written or audio-recorded verbal consent was taken in the presence of a witness if 
the person with LD was not independently managing their medication; 
 Written, signed consent from the senior manager of any formal Care Provider to access their 
medication-related documentation and to ask their staff to be interviewed was obtained; 
 Written, signed consent from any care worker or carer participating in the research was 
obtained prior to interview and in the standard manner.  
 
Inclusion, Making Choices and Involvement of Significant Others  
Throughout the research process, advice on many aspects of the research was sought from a local 
LD service manager, an LD charity manager and from the chair of the local LD support group (an 
individual with LD). Wherever capacity and capability permitted, the person with LD who was the 
focus of the case study was asked to participate in the research and provide consent. Information 
was provided to participants with LD in easy-read format and more time taken to explain the 
project. In addition, the person with LD was given the option of having a known carer or care worker 
sit in with them during the interview to aid communication and provide support when required. 
Care was taken not to ask questions to which participants with LD would just acquiesce. If the 
person with LD lacked capacity, then their welfare guardian, family representative, main carer or 
care worker provided consent and was invited to participate in the research.  
 
Boundaries 
From the outset of fieldwork, the researcher emphasised to the person with LD and their carer or 
care worker that they were only going to be visiting once or twice to ask them questions about their 
medicines. This was to provide clarity about the reason for the researcher in their life and about the 
temporary nature of the involvement.  
 
If during the course of the fieldwork, a medication issue is identified requiring intervention from the 
researcher as a HCP, the following protocol was agreed: 
 The researcher will make a note during the interview or time of observation to deal with 
afterwards unless there is the potential for immediate harm; 
 If there is the potential for harm, the researcher will intervene immediately to ensure the 
safety of the person; 
 Whether or not fieldwork will continue or be postponed will depend on the situation; 
 The issue, intervention and outcome will all be recorded in fieldwork notes; 
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 A discussion of the event with the supervisory team will take place and agreement reached 
on the effect of this on the data collected and how to highlight this in the formal write up; 
 If required, the researcher will follow the incident up with the individual, relevant HCP, 
social care professional and care provider. 
 
Data Protection  
All data were collected, stored and handled in accordance with the RGU Research Governance and 
Integrity Policy (Robert Gordon University 2016a), the Research Council UK Common Principles on 
Data Policy (Research Councils UK 2015) and the data legislation which was active at the time of 
research, the Data Protection Act (1998).  
 
All case studies were assigned a number and a pseudonym; other participants were assigned an 
identification number linked to the case study. Suitable folders were created on the researcher’s 
secure ‘R’ drive on RGU password protected servers only accessible to the research team. All data 
files were named to include the case identification number, the data source, the participant 
identification number and the date of data collection. 
 
Paper consent forms were scanned into an electronic version and stored in a separate password 
protected file in the researcher’s ‘R’ drive in RGU and the paper versions shredded and disposed of 
in confidential waste. Digital data (audio recordings and photos) were uploaded directly into the 
researcher’s ‘R’ drive in RGU and saved into the appropriate case study folder. Written information 
from care provider records and any written observations were scanned into an electronic version 
and then uploaded into the researcher’s ‘R’ drive in RGU and saved into the appropriate case study 
folder. Typed interview transcripts were uploaded into the appropriate case study folder. The 
researcher’s reflective diary was scanned at the end of the research process and the paper version 
shredded and disposed of in confidential waste. After uploading, photos were then deleted from the 
original device; digital audio recordings were deleted from the recording device after transcription 
was completed. All the data is archived in the researcher’s RGU folders in password protected files 
for 10 years.  
 
Once data were redacted of any person identifiable information, it was held temporarily on the 
researcher’s password protected personal laptop or tablet in a password protected file for data 
analysis; it was deleted from this laptop once analysis was complete.  
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All data within this research will be presented anonymously; only pseudonyms will be used. 
References to named health and social care professionals, places and local services have been 
redacted from the data. In addition, care has been taken to balance the methodological requirement 
for ‘rich, thick description’ with the need to ensure all participants retain their anonymity.  
 
2.13 CHAPTER SUMMARY  
First of all, this chapter provided a brief outline of research worldviews; ontology, epistemology, 
axiology and methodology within these worldviews; and the most common methodological 
approaches. Following on from this, qualitative methodology and then case study methodology 
were outlined. Strategies for qualitative data analysis and for promoting trustworthiness, reflexivity 
and transferability throughout the research process were then evidenced. 
 
Then, this chapter considered both the general research governance requirements and the more 
specific research governance requirements when involving adults with incapacity in research. Issues 
of pertinent legislation, informed consent, inclusion, literacy, health literacy, involvement of 
significant others, capability, safeguarding and establishing relational boundaries were discussed. 
Legislation surrounding the storage of data was also outlined.  
 
Finally, this chapter described the design of this study and outlined how it has been shaped by the 
methodological and research governance requirements and is appropriate for the research focus 
and population.  
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CHAPTER 3: CASE STUDIES SUMMARY  
 
 
 
 
 
 
 
“A conversation where it is the desire for truth itself—on the part of both participants—that is truly 
listening and speaking... So, listen, to yourself and to those with whom you are speaking. Your 
wisdom then consists not of the knowledge you already have, but the continual search for 
knowledge, which is the highest form of wisdom... Assume that the person you are listening to might 
know something you don’t.” 
12 Rules for Life: An Antidote to Chaos - Professor Jordan B. Peterson 
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3.1 CHAPTER INTRODUCTION 
This chapter provides a brief summary of each individual adult with LD who was the focus of each of 
the ten case studies; full summaries are available in Appendices 3.2 - 3.11. The name used for each 
case is a pseudonym. 
 
3.2 CASE STUDIES SUMMARY 
Eleven community-dwelling adults with LD or their care worker or carer volunteered to participate in 
the research; all eleven adults with LD met the pre-determined case study inclusion criteria and 
were recruited as detailed in Section 2.12.2. Consent to participate in the research was obtained 
from all participants as outlined in Section 2.12.7. 
 
Each case study was allocated a unique case identifier which consisted of a number, the letter C or 
N, and a pseudonym for the adult with LD. The C or N was to indicate whether the adult with LD who 
was the focus of each case study had Capacity to consent or Not to the study. With the first case 
study, Case01N, the care workers were not able to participate at the time of the research. As there 
was no opportunity to triangulate the interview data from the parent of Case01N, and because the 
structure of the interview was altered, the interview was considered a pilot and accordingly, data 
from that interview were not included in the full study results. This resulted in ten cases providing 
data for the study: 02N-Anna; 03N-Paul; 04N-Jamie; 05N-Rob; 06C-Mark; 07C-Fiona; 08C-Ruth; 09C-
Donald; 10C-Susan; and 11C-David. As noted in Section 2.12.2, within case study methodology, ten 
cases are accepted as allowing for aggregation of evidence. 
 
For all presented data in the thesis, the type or source of the data follows the case identifier except 
if the source was from the interview with the adult with LD. In this instance the data source will just 
be labelled with the case identifier. Carers and care workers have been differentiated as ‘Carer’ and 
‘CareW’ respectively, and then allocated a number which was appended to the case study identifier. 
 
Data were collected as outlined in Section 2.12.3. All interviews were conducted face-to-face except 
for Case04N-Jamie-CareW02 and Case05N-Rob-CareW03 where the interviewee indicated their 
preference for a telephone interview. With interviewee permission, all interviews were audio-
recorded; interviews ranged in length from 20 - 80 minutes. Although the research was based on the 
PLEM conceptual model, as detailed in Section 2.12.4, and participants were provided with a list of 
proposed interview questions, as detailed in Appendix 2.1, a neutral stance was maintained and 
participants were not pressed to provide answers for all sub-themes covered in the model. 
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Accordingly, there are some areas of PLEM where none of the participants provided data and this 
has been noted in the results. As outlined in Chapter 2, other case study data were gathered either 
before or after interviews, depending on what was most convenient to the participants. Dependent 
on the number of participants being interviewed and the availability of written records, data 
collection times for each case study took between one and four hours. 
 
A summary of all data and identifiers for each case study can be found in Table 3.1. As noted in 
Section 2.12.3, all medical and pharmaceutical information was gathered from interview, 
observation or written record. Only prescribed medication has been noted within the table. Within 
the results and discussion, bought (OTC) medicines are, however, referenced. Written records 
included Care Provider records, MAR charts, and repeat prescription re-order slips. The majority of 
data were from interviews. If inconsistencies with data, e.g. current dose of a medicine, were 
discovered, every attempt to resolve the issue with the relevant participants. If this was not possible, 
the inconsistency was noted.  
 
Appendices 3.1 - 3.11 contain a detailed summary of each adult with LD who has been included as a 
case study in this research. As previously discussed in Section 2.12, every care has been taken to 
balance the methodological requirement for ‘rich, thick description’ with the need to ensure all 
participants retain their anonymity. 
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Table 3.1 Summary of case study identifiers and data sources 
Case and 
pseudonym  
Age 
(years) 
Gender Severity 
of LD 
No. of 
prescribed 
medicines 
(regular)  
Living 
arrangements 
Who is 
responsible for 
ordering 
medication? 
Who is 
responsible 
for 
administering 
medication? 
Interviews Observations/other Data Sources 
Adult 
with LD 
Carers and 
Care 
Workers 
Photos Written 
records 
Fieldwork 
notes 
01N-Pilot  
 
46 M Severe Not 
confirmed 
Small care 
home 
Care workers Care workers  no Carer01-
PILOT 
no no no 
02N 
‘Anna’ 
26 F Severe 8 Shared care: 1 
month in family 
home & 1 
month in 
residential 
accommodation 
 
Parents Parents and 
care workers 
no Carer01 
CareW02 
CareW03 
CareW04 
CareW05 
yes yes yes 
03N 
‘Paul’ 
31 M Severe 6 Small care 
home 
Care workers Care workers no CareW01 
CareW02 
CareW03 
CareW04 
 
yes yes yes 
04N 
‘Jamie’ 
21 
(at 
time 
of 
death) 
 
M Severe 20 Family home Parents Parents and 
care worker 
no 
 
Carer01 
CareW02 
no yes yes 
05N 
‘Rob’ 
20 M Severe 12 Shared care: 
home of formal 
carer (‘adoptive 
parents’) with 
some weekends 
& holidays with 
family 
 
‘Adoptive 
parents’ 
‘Adoptive 
parents’(care 
workers); 
parents; 
additional 
care worker 
no CareW01 
Carer02 
CareW03 
yes yes yes 
06C 
‘Mark’ 
54 M Moderate 5 Room in 
residential 
accommodation 
Care Workers Mark (but 
under 
supervision of 
care worker) 
yes CareW01 
CareW02 
CareW03 
CareW04 
yes yes yes 
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Case and 
pseudonym  
Age 
(years) 
Gender Severity 
of LD 
No. of 
prescribed 
medicines 
(regular)  
Living 
arrangements 
Who is 
responsible for 
ordering 
medication? 
Who is 
responsible 
for 
administering 
medication? 
Interviews Observations/other Data Sources 
Adult 
with LD 
Carers and 
Care 
Workers 
Photos Written 
records 
Fieldwork 
notes 
07C 
‘Fiona’ 
46 F Mild-
moderate 
4 Flat in 
residential 
accommodation 
 
 
Care Workers Fiona (but 
under 
supervision of 
care worker) 
yes CareW01 
CareW02 
yes yes yes 
08C 
‘Ruth’ 
55 F Mild-
moderate 
14 Flat in 
supported 
accommodation 
Care Workers Ruth (care 
workers 
supervise 
administration 
of one drug) 
yes 
 
CareW01 
CareW02 
CareW03 
CareW04 
 
yes yes yes 
09C 
‘Donald’ 
 
29 M Mild 4 Flat Donald Donald yes no yes no no 
10C 
‘Susan’ 
 
59 F Mild-
moderate 
7 Flat in 
supported 
accommodation 
 
Care Worker 
attached to 
supported 
accommodation  
Susan yes no yes no no 
11C 
‘David’ 
68 M Mild 5 Flat in 
supported 
accommodation 
 
David David yes 
 
no yes no no 
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3.4 CHAPTER SUMMARY 
This chapter provided a summary of the process for the identification of case studies, data collection 
and data analysis. Full summaries of the case studies are available in Appendices 3.1 - 3.11.  
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CHAPTER 4 RESULTS – MEDICATION RELATED BURDEN 
 
 
 
 
 
 
 
‘In God we trust, all others must bring data’ 
W. Edwards Deming 
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4.1 CHAPTER INTRODUCTION 
This section will focus on medication related burden - the first section of PLEM as outlined in Figure 
4.1 below: 
 
Figure 4.1 PLEM - medication related burden 
 
As can be seen within the conceptual model, the first section of PLEM (medication related burden) 
contains five themes: medication routines; medication characteristics; medication adverse event; 
medication and social burden; and health care and medication. Within the study by Mohammed, 
Moles and Chen (2016) examples (or sub-themes) of each of these five themes were also listed and 
these are detailed in Table 4.1. These themes and sub-themes were used to structure the results 
that will now be presented within this chapter. 
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Table 4.1 Medication related burden themes and sub-themes 
Theme Sub-theme 
Medication routines 
 
 
General strategies to manage medication routines 
Time required to manage medication 
Adapting life to suit medication routine (intentional) 
Adapting life to suit medication routine (unintentional) 
Adapting medication routine to suit life (intentional) 
Adapting medication routine to suit life (unintentional)  
Medication characteristics Complexity of the number of medicines 
Pill size and shape 
Exchange of medication brands 
Challenges of packaging  
Additional instructions  
Mediation adverse event No experience or not recognised 
Previous negative experience  
Anxiety of future occurrence  
Impact on belief and behaviour  
Medication and social burden Medication impacting social life (positive) 
Medication impacting social life (negative)  
Influence of ‘significant others’ (positive) 
Influence of ‘significant others’ (negative)  
Stigma from medication use 
Health care and medication Time spent dealing with healthcare appointments or services to get medicines 
Practicalities of accessing, obtaining or adhering to medicines 
Inadequate, conflicting or contradicting medication information 
Lack of consideration for patient’s lived experience from health care professionals 
Lack of continuity or co-ordination of prescribing  
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4.2 MEDICATION ROUTINES  
4.2.1 General strategies to manage medication routines 
Carers and care workers cited using visual or audio reminders to remember to give the required 
medication: 
‘We’ve got the medication board with the times. And if there’s a time that’s new – say an 
antibiotic – we’ll set an alarm or something.’ Case02N-Anna-CareW03 
 
‘They [medicines] live in the kitchen cupboard and the boxes that are in use live on the 
window sill [see Figure 4.2] which is perhaps not ideal but if I leave them hiding in the 
cupboard I will forget.’ Case02N-Anna-Carer01 
 
 
Figure 4.2 Case02NPhoto08 Storage of medicines in use at home (kitchen window sill)   
 
Adults with mild LD often highlighted their capability with respect to remembering when and how to 
take their medication: 
‘I think I just must remember. I don’t need to set reminders or nothing.’ Case09C-Donald 
 
‘I get up, answer my front door, they give me a key, I open my cabinet, I take out my box of 
cocodamol, my fluoxetine, my lactulose. ‘Cause I know that’s the three that I take in the 
morning. I fill my glass with water, put my two cocodamols in it. It makes a hissing noise 
which is good. I take my two fluoxetine at the same time ‘cause it’s easier to swallow. Then 
my lactulose.’ Case07C-Fiona 
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One care worker of an adult with moderate LD commented on his capability to remember and 
administer his medicines: 
‘He actually even reminds us about his 1pm meds. He’ll come through… And automatic first 
thing in the morning – he’s out of bed and he knows to himself that’s what he does – he gets 
his tablets before he’ll sort of go for a wash or whatever in the morning.’ Case06C-Mark-
CareW01 
 
Medicine routines were often simplified or amended to maximise the chances of successful 
administration: 
‘Well I eventually got them into a blister pack [pharmacy-filled] so it’s easier for me taking 
them so I know which day I’ve taken them…I’m quite happy with the blister pack ‘cause I can 
handle it better.’ Case10C-Susan 
 
‘The morning routine when he has his first lot of medicine and his gagging with his reflux – I 
don’t like that but that’s just Rob so we’ve learnt to sit him up, don’t rush him.’ Case05N-
Rob-Carer02 
 
Sometimes medication was taken or administered in a specific order: 
‘She takes her tablets the same way every day. It’s the same tablets…just say it’s the blue 
one first, and then the green ones and then the white ones. She does that every day. That’s 
the way she takes her tablets…She has to take them in that certain [way] – she can’t take the 
green one first ‘cause that would be out of sync.’ Case08C-Ruth-CareW04 
 
‘So I went in and I was using the MAR [medicine administration record] sheet. And then I just 
go down, one by one – so I do it one at a time… And then I have my own kind of order for 
putting them in [the PEG tube]…’ Case03N-Paul-CareW04 
 
Two carers stated the way in which the medicine routine is just seen as a normal part of life: 
‘To be truthful, his younger brother can help us – the kids like being involved in Rob’s care. 
And it makes it a normal part of life. There’s no scariness. “Oh, can I do his meds tonight?” – 
of course you can, c’mon then. It’s not a big deal.’ Case05N-Rob-Carer02 
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‘But it’s just part of what she does, it’s just part of routine, it’s part of life…it’s what she does, 
it’s the same as getting your hair brushed and teeth brushed, it’s just what happens.’ 
Case02N-Anna-Carer01 
 
4.2.2 Time required to manage medication 
In general, time required to manage medication was not cited as a burden except by one care 
worker:  
‘So, maybe I took a lot longer because obviously Carer01 and her husband were a lot more 
adept at it and quite confident about what they were doing. I was a bit slower; and Jamie 
was very patient with me!’ Case04N-Jamie-CareW02 
 
One carer commented on the time benefits of administering medicines via a PEG tube, 
demonstrating the positive impact of a change of route of administration:  
‘It’s a five min job, not even five mins – a squirt here and there, ‘cause there’s only four or 
five medications that he has and it’s done in seconds.’ Case05N-Rob-Carer02 
 
4.2.3 Adapting life to suit medication routine (intentional) 
Working the day’s activity around the medicine routine was noted: 
‘… Out and then make sure you’re back at this time for medication.’ Case03N-Paul-CareW04 
 
‘Well, like I was saying, a Monday morning I’ve to take the, the what do you call it, 30 mins 
before I start eating…[then] through to the toilet, manage a shave, come back and well I’ll 
have my cereal then…I have my lamotrigine, aye, just before I start eating and once I’ve had, 
I take my…, that’s it, that’s the order...’ Case11C-David 
 
In addition, the need to ensure the daily routine adhered to the same medicine routine was 
highlighted for one adult with LD:  
‘He doesn’t like change does he?...He likes the normal routine…He’s got a structure he’s to 
follow – like a weekly timetable. If that’s not followed right down to the tee then it’ll knock 
him and it’ll increase his anxieties as well.’ Case06C-Mark-CareW03 
 
4.2.4 Adapting life to suit medication routine (unintentional) 
No data with this theme was provided by any of the cases during the research. 
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4.2.5 Adapting medication routine to suit life (intentional)  
One carer gave two examples of how she adapted the manner of medicine administration to suit: 
‘So yeah, they may go into a spoonful of yogurt or something…if you feed someone yogurt it 
tends to go down as a one-er, as a gulp so if you put the tablets in that it’s not like you’re 
having to get them over so they will go down….’ Case02N-Anna-Carer01 
 
 ‘I got a leaflet [for midazolam]…It’s like, “open the mouth and put it into the cheek”. Well 
the teeth are clamped firmly shut ‘cause she’s in a seizure and “drizzle a little in either side”. 
No, just whack it in and hope for the best. I know that if she swallows it, it doesn’t work as 
well but you have to realise that you are probably wrestling her around the carpet at this 
point so you’re not worried about the niceties really!’ Case02N-Anna-Carer01 
 
Care workers for another adult with severe LD highlighted how they adapted the timing of the 
medicines to suit: 
‘The debate is whether we should actually give him it once he’s up and washed and dressed. I 
know he’s meant to get it at 8 o’clock and it’s sometimes a case of let sleeping dogs lie – 
leave him to sleep and once he’s wakened and if the bathroom’s busy, give him his meds. Or 
whether you should say, right, let’s just leave him and once he’s upright. ‘Cause like this 
morning he had to wait, got his meds and then he spewed them all back up again. And you 
think, well that’s defeating the purpose ‘cause how much is still inside you?!’ Case03N-Paul-
CareW03 
 
‘Because if you’re holding the [PEG] tube and he starts to kick off he can hit it and bang it 
about…you’re kind of in a dilemma…you’ve just got to kind of soothe him at that time – to 
soothe him and calm down…if he’s still kicking off then you have to stop at that moment 
until he’s calmed down. There’s no point in carrying on while he’s in that mood.’ Case03N-
Paul-CareW04 
 
4.2.6 Adapting medication routine to suit life (unintentional) 
No data with this theme was provided by any of the cases during the research. 
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4.3 MEDICATION CHARACTERISTICS  
4.3.1 Complexity of the number of medicines 
None of the carers or care workers in the cases found the complexity of the medicines an issue for 
themselves. One care worker was aware of the impact of additional medicines for one adult with 
mild-moderate LD: 
‘As long as it’s one tablet – he couldn’t do it with heaps – but with one or two I think he 
would cope with knowing what it’s for.’ Case06C-Mark-CareW01 
 
For one adult with LD the complexity of her medicines necessitated a multi-compartment 
compliance aid (MCA), commonly referred to as a blister pack: 
‘If they’re not in a blister pack I can’t manage them – if they’re in boxes.’ Case08C-Ruth 
 
4.3.2 Pill size and shape 
Pill size and shape was only cited an issue for one adult with severe LD; possibly due to the fact that 
the other three cases received their medicines via a PEG tube (so pill size and shape were not an 
issue):  
‘…she doesn’t have any manipulation issues for too small; too big can be an issue particularly 
when people think they are doing us a favour by reducing the number [of tablets] we have to 
take without consultation.’ Case02N-Anna-Carer01 
 
However, for one of the cases with a PEG tube, the need to accurately halve and then administer 
this half tablet (crushed) was cited as a challenge: 
‘He’s got baclofen now which is tablet form and it’s got to be crushed. And because he’s only 
on a half it’s the tiniest – to crush it (to be quite honest) the powder – where is it?!’ Case03N-
Paul-CareW01 
 
Swallowing difficulties with larger tablets were cited as an issue by adults with mild-moderate LD: 
‘I’m not good at swallowing tablets… The fluoxetine are the only size of capsule that I can 
take.’ Case07C-Fiona 
 
[When asked about size of tablets being an issue]: 
‘Yes. Sometimes I can’t get it down so they’ve got to change it to another method.’ Case08C-
Ruth 
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4.3.3 Exchange of medication brands 
In two cases, having the prescription for an epilepsy medicine changed by the prescriber from a 
branded product to a generic product was noted to adversely affect clinical control of the adult with 
LD’s epilepsy in two cases. Of note is the contrasting timescales in resolving the situation. 
‘…we had been on Lamictal for ages, and then we just started getting lamotrigine but it was 
never the same lamotrigine twice... her control went off and she was having a lot more 
seizures. I spoke to the consultant and she…wrote to the GP. So it took a few months to get it 
but we got it back.’ Case02N-Anna-Carer01 
 
‘I was very careful about using the named brand against the generic brand because I did find 
differences with him with the epilepsy medication and immediately had to go back onto the 
named brand.’ Case04N-Jamie-CareW01 
 
Changing the brand or presentation of medicine boxes also caused a degree of confusion: 
‘I think sometimes when you get the own brands people aren’t aware and they think, “Oh! 
That’s not the same!” But then you think no, that is the same, it’s just the own brand…it’s the 
same stuff but just a different company they are using – or a cheaper tablet.’ Case03N-
Jamie-CareW03 
 
[When asked about the boxes of medicines looking different each time]: 
‘I get confused.’ Case08C-Ruth 
 
4.3.4 Challenges of packaging 
Sometimes the packaging was noted to affect the ease of access to the medicines by adults with 
mild LD: 
‘I’ve got my new box of cocodamol but I don’t like the foil paper. It’s too sharp. It’s still the 
same, it’s still the same name – cocodamol – it’s just in foil….The one that I’m using now is 
easier to open [See Figure 4.3] …’ Case07C-Fiona. 
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Figure 4.3 Case07CPhoto08 Two brands of cocodamol 
 
‘I don’t like taking them out of that [compliance aid] packet. They’re fiddly and sometimes 
you lose the tablet.’ Case08C-Ruth 
 
One carer noted the impact of a change of packaging to ease of administration:  
‘I don’t like how they’ve changed the domperidone bottle. It used to be a plastic bottle so you 
could put the syringe in it. And they’ve put it to a glass bottle so the syringe doesn’t go into 
it…So before I would take the bottle and tip it up ‘cause a 20ml syringe would fit into the 
bottle without leaking but now you’ve got to tip it into a container and suck it up [into the 
syringe].’ Case05N-Rob-Carer02 
 
Within one case, packaging was not perceived to be an issue by the adult with LD, but the care 
workers had noticed a potential problem: 
‘The only thing we have to keep an eye on sometimes is the fluoxetine packets. He’ll think it’s 
empty sometimes. You’ve to check it ‘cause he will be quite rushed and think oh it’s finished 
so I’ll put it in the bin. So that’s the only thing you’ve really got to watch for.’ Case06C-Mark-
CareW02 
 
An instance of packaging causing a challenge was observed when Susan (Case 10C), attempted to 
demonstrate how she was able to puncture the back of her MCA pack. Instead of opening an empty 
blister she inadvertently opened a future blister containing medicines.  
 
4.3.5 Additional instructions  
No data with this theme was provided by any of the cases during the research. 
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4.4 MEDICATION ADVERSE EVENTS  
Throughout the cases, carers and care workers of adults with severe LD would mention, 
unprompted, numerous adverse events including adverse drug reactions (ADRs), that is unwanted or 
harmful effects. However, when asked specifically if the adult with LD had experienced ADRs they 
would often respond to say this was not the case. Furthermore, these events did not necessarily 
translate into an associated burden or adversely affect their view of medicines. Specific side-effects, 
withdrawal, allergy or other negative experience with medication were rarely cited by adults with 
mild-moderate LD. 
 
4.4.1 No experience or not recognised  
In three cases (Case 05-Rob; Case 08-Ruth; Case 09-Donald) it was cited that adverse effects had not 
been experienced yet at another point in the interview, adverse effects were highlighted. 
 
4.4.2 Previous negative experience 
For the adults with severe LD, multiple instances of adverse effects from different medicines were 
noted and examples were provided to illustrate the issues encountered: 
 
Case 02N-Anna  
‘…when she was given phenytoin [Anna] became very flushed.’ Case02N-Anna-Letter from 
neurologist 2012 (care workers’ documentation) 
 
‘…mum said to me that she thought she knew what had caused [Anna]’s extreme breakdown 
in behaviour… rapid withdrawal of tramadol and dihydrocodeine.’ Case02N-Anna-Letter 
from neurologist 2011 (care workers’ documentation) 
 
 ‘…but the Epilim [sodium valproate] turned her into a – she was terrified of the world, 
terrified of everything- she just lived in a corner, back to the wall – was just terrified of 
everything.’ Case02N-Anna-Carer01 
 
‘To begin with she was fine but then as the dose [of levetiracetam] increased she got very 
anxious, very agitated, very easily pushed to the point of lashing out and reducing it took 
that away so obviously it was [the problem].’ Case02N-Anna-Carer01 
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‘She has been on topiramate at higher doses in the past (200mg twice daily) but by that dose 
we felt it was affecting her cognition…’ Case02N-Anna-Letter from neurologist 2012 (in 
formal care workers’ file) 
 
Case03N-Paul  
‘…he used to sweat profusely and we’d be changing his clothes constantly and washing him 
down…But that did actually dope him up – that did dope him up and he were really sleepy on 
haloperidol.’ Case03N-Paul-CareW02 
 
‘… just recently we had a bit of a mix up and started to wean him off the risperidone. It were 
[sic] a confusion…and the sweating came back – profuse sweating came back and it 
exacerbated his behaviour as well – the screaming got worse until we got him back on it and 
everything was sorted out.’ Case03N-Paul-CareW02 
 
Case04N-Jamie 
‘I got the midazolam in its infancy...and what I discovered at that point was that his heart 
rate was slowing down when I was using it that method.’ Case04N-Jamie-Carer01 
 
‘…they started him on baclofen for his muscle tone - which at the first was oral baclofen. And 
yes, it helped but it’s also a drowsy - it makes them drowsy. So yes, for a period he was very 
stable but for a period we saw issues with his cognitive abilities – he seemed to slide a bit.’ 
Case04N-Jamie-Carer01 
 
‘They then thought they need to replace the baclofen implant – they thought there must be 
something. And it was withdrawal of baclofen. He was suffering terrible withdrawals from 
the baclofen because he was in distress for the whole five weeks he was in hospital.’ 
Case04N-Jamie-Carer01 
 
‘…he was getting this baclofen implant…but what we didn’t know was that he was 
developing a very rare syndrome through it…arachnoiditis…it’s adhesions up the spinal canal 
and it causes adhesions. And it causes a multitude of symptoms because of course it’s 
affecting all the nerves that come out of the spine.’ Case04N-Jamie-Carer01 
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 ‘Epilim [Sodium Valproate] …It was the one that worked –it was working well for him. But 
obviously we were working on tablets because as I’d spoken to you before, we discovered he 
had a rare allergy to red colouring in medications…’ Case04N-Jamie-Carer01 
 
‘The only thing I used to recognise was that when you used the nebules, salbutamol of 
course, his heart rate would go up.’ Case04N-Jamie-Carer01 
 
Case 05N-Rob 
 ‘Started him on Epilim [Sodium Valproate]. His mood went down…’ Case05N-Rob-Carer02 
 
‘I actually called the paramedics out because I thought I’d OD’d [overdosed] him…because he 
was so drowsy [from the midazolam].’ Case05N-Rob-CareW01 
 
In addition, other negative experiences of medicines were noted for adults with severe LD in relation 
to the route of administration:  
‘The old omeprazole when I had the tablet form of it – which was little tiny balls. And that 
was a flaming nightmare!... I did manage to unblock [the PEG tube] but what I found was, 
that a couple of times it actually damaged the thing.’ Case05N-Rob-CareW01 
 
‘But one carer that we had thought that he got a sexual thrill out of that [insertion of 
suppositories].’ Case03N-Paul-CareW02 
 
‘…somebody thought it would be a good idea to give him a barium meal…I gave him this 
barium drink and then laid him down. Immediate emergency! They had to pump him out and 
he lived with tiny flecks of barium in his lungs all his life.’ Case04N-Jamie-Carer01 
 
‘The nurses were coming in and doing the pen drive [syringe driver] every day. The only thing 
that I was a bit upset about was that he got an ulcer or something where it was in the 
thigh…so they swapped to the other leg.’ Case04N-Jamie-Carer01 
 
For one case (Case 08C-Ruth), an adult with mild LD, several ADRs were highlighted:  
‘I was on a cream for my back. It was called Voltarol [diclofenac]. And they put it all over my 
back twice a day and I had side-effects there. I could hardly breathe. I was feeling sick and 
everything. They had to get the doctor out I think.’ Case08C-Ruth 
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‘Ibuprofen was in it. And she was like [mimics gasping for breath] So we got the paramedics 
in.’ Case08C-Ruth-CareW04 
 
‘She was on that sleeping tablet [zopiclone] and it really made her angry and withdrawn and 
when she didn’t get it [during a trial stop] she was quite aggressive.’ Case08C-Ruth-CareW04 
 
‘She was the same on Sevredol [morphine] with the spike in morphine. If she didn’t get that 
she became quite angry…She was falling asleep on the Sevredol…Initially when she would 
take it she would be zonking out and she was falling asleep at her daughter’s through the 
day and then in the afternoon just falling asleep on the chair.’ Case08C-Ruth-CareW01 
 
 ‘Aye, I stopped it [all painkillers including morphine].  I paid for it because I was sick and 
everything. Cold sweats and I had to go back on it after two days.’ Case08C-Ruth 
 
‘But then it’s kind of ruined the lining of her stomach all these years taking all these 
medications without eating properly. She’s kind of made herself ill with doing it and 
persisting with it.’ Case08C-Ruth-CareW02 
 
Addiction to opiates was also noted to be an issue for another adult with mild LD (Case07C-Fiona): 
[Cocodamol] ‘…you can get addicted to cocodamol. And she was wanting it more and more 
sometimes…She used to always come down before we managed to cut it to twice. She could 
get it four times a day was it? And she kept coming down, “I’m sore, I’m sore”, and we were 
wondering if she was getting addicted to it?’ Case07C-Fiona-CareW02 
 
4.4.4 Anxiety of future occurrence 
Despite the multiple instances of negative experiences of medicines, anxiety about future 
occurrence was not expressed.  
 
4.4.5 Impact on belief and behaviour 
The occurrence of negative experiences with medicines, even those that had impacted more 
severely on the adult’s quality of life, did not appear to significantly affect beliefs and behaviours in 
relation to medication. As noted previously, potential side-effects from medication, affected the 
beliefs of Susan (Case10C), an adult with mild LD:  
‘If you change a tablet, you can get side-effects and I don’t want that.’ Case10C-Susan 
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4.5 MEDICATION AND SOCIAL BURDEN 
Throughout all the cases there was little reference to medicines having a negative impact on the 
adult’s social life. Instead medication had a largely positive effect on the adult’s social life.  
 
4.5.1 Medicines impacting social life (positive) 
The positive impact that medicines have on the social life of adults with LD was stated implicitly in 
one case: 
‘Obviously it [medication] gave him a good quality of life in that he was able to go out and do 
the things he needed to do. He was never in the house. He was always out and about.  It 
gave him strength. It allowed him to overcome some of the difficulties that other people I 
have met have had.’ Case04N-Jamie-CareW02 
 
[In reference to the medicines given during the palliative stage of his life]: 
‘It gave him more time and he was comfortable. We got the impression he didn’t want to go 
anyway. He enjoyed his life. And it allowed him – he was at home for the last while- but it 
allowed him to receive visitors and people would come and say hello for a short time and he 
enjoyed all that social side of things. It just let him do that for him. He had his 21st birthday 
and then after that he kind of went downhill. And the end was fairly peaceful.’ Case04N-
Jamie-CareW02 
 
The supervision of medicine administration for adults with mild-moderate LD by care workers was 
seen not just as a necessary task but as a means of positively impacting the social life of the adult 
with LD: 
‘That’s when she sees staff really…We only see her at medication time. Apart from when 
she’s going out and she’ll come down and sign the book to say she’s going out to her 
activities and stuff. And I suppose it’s probably she’s lonely as well. So I suppose she likes the 
thought that the staff are going up.’ Case07C-Fiona-CareW02 
 
4.5.2 Medication impacting social life (negative) 
The negative impact of a medicine on a social outing was cited:  
 [In reference to midazolam administration]: 
‘And I was with a couple of friends and I said, I’m going to have to take him home – he’s gone 
really drowsy and I’m not sure what’s going on.’ Case05N-Rob-CareW01 
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In one case, it was actually not having a suitable medication to help moderate behaviour that was 
impacting negatively on one adult with LD’s social life: 
‘I think that if he was on something that made him calmer. …We try and keep it all about him 
but our staff team too are getting very stressed by it so you find that the behaviour escalates 
for him and people are withdrawing in a way ‘cause they just can’t cope. I mean some of us 
can cope and others really can’t cope… I think people are frightened too because when he 
does go into a huge paddy [tantrum] it’s like his blood vessels bulge, his heart races.’ 
Case03N-Paul-CareW01 
 
‘It’s quite hard because our whole ethos of here is to be part of the community, be out there, 
doing normal things and it’s harder and harder to take him now…we are vulnerable to the 
perception of the public.’ Case03N-Paul-CareW02 
 
4.5.3 Influence of ‘significant others’ (positive) 
For adults with severe LD, their ‘significant others’ are their only advocates and examples of how 
that was a positive influence were apparent in the cases studied: 
‘I thought it was worth going and seeing my GP and going and having a chat about his 
regime... I don’t worry about speaking to my GP. And the neurologist I’ve known for years – I 
wouldn’t hesitate to get advice from her either. I’m lucky in that way.’ Case05N-Rob-
CareW01 
 
‘They [doctors] tried to reduce it [fluoxetine] a few years ago and I was at the GP 
appointment and I kind of disagreed and said it wouldn’t have a very good effect if we were 
to reduce it. So we kept it as it is and it seems to be working.’ Case06C-Mark-CareW02 
 
4.5.4 Influence of ‘significant others’ (negative) 
However, the influence of ‘significant others’ also has the potential to be negative for adults with LD: 
‘But I know when he stayed in the family home, his sister – they weren’t giving him his 
medication. So per chance he remembers the hard times he went through because of that. 
And that’s the reason he was moved out. I think they were drinking quite a lot and he wasn’t 
getting his medication. And they had to get him somewhere where they could be better 
organised.’ Case06C-Mark-CareW04 
 
 91 
One adult with mild LD (Case 10C-David) described the influence of friends with regards to buying 
OTC products which could be considered potentially positive or negative depending on the 
knowledge and intention of those friends: 
‘Well, I’ve a few friends that recommended something for me…I would have gone in and 
bought the Strepsils on the strength of just doing what I’ve heard.’ Case11C-David 
 
4.5.5 Stigma from medication use  
No data with this theme was provided by any of the cases during the research.  
 
4.6 HEALTH CARE AND MEDICATION 
Carers and care workers of adults with LD cited numerous examples of health care burden in relation 
to the medication of the adult with LD. However, none of the adults with mild LD (who were all self-
administering) made any reference to medication being a burden to them with regards to time, 
practicalities, accompanying information, consideration of their experience or lack of prescribing 
continuity. 
 
4.6.1 Time spent dealing with health care appointments or services to obtain medicines 
Although there was no reference made to the time spent dealing with health care appointments or 
services to obtain medicines, reference was made to the time required to obtain an answer to 
medication queries: 
‘Sometimes it’s quite a while before the GP actually manages to get back to us.’ Case07C-
Fiona-CareW02 
 
[In reference to contacting the pharmacist]: 
‘And at least that’s a faster response than having to wait for phoning the doctor, get the 
doctor to phone back - or somebody to phone back. At least if we can phone the pharmacist, 
we’ve got an answer more or less right away.’ Case07C-Fiona-CareW02 
 
4.6.2 Practicalities of accessing, obtaining and adhering to medicines 
Although the practicalities of accessing and obtaining medicines were rarely mentioned by carers 
and care workers, the practicalities of adhering to medicines were frequently cited. General 
administration practicalities, practicalities associated with administering medicines via a PEG tube, 
practicalities faced by care workers in particular, and other issues were noted within all the cases: 
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General administration practicalities  
The adult with LD not being well was cited as an issue for adhering to medication: 
‘…if she’s had a prolonged seizure – she then obviously feels nauseous and then she won’t 
take anything – she refuses everything so we have to get it down her…, someway or other.’ 
Case02N-Anna-Carer01 
 
Paul’s reflux and vomiting were so severe that a PEG tube had to be inserted for feeding. 
Despite the PEG tube, Paul still vomits. Staff had kept a record of the number of instances of 
vomiting in the last 8 months up to October 2017: March (n=11); April (n=13); May (n=16); 
June (n=15); July (n=20); August (n=8); September (n=17); October (n=9). There were four 
recorded instances of medicines being visible in the vomit in the last eight months. Case03N-
Paul-Fieldnotes 
  
The issue of the adult with LD not being able to swallow medication safely was noted by one 
carer: 
 ‘It was very hit and miss in those early stages of getting his drugs down [orally, pre-PEG 
tube] and then obviously what we didn’t know was how much was going into his tummy and 
how much he was aspirating.’ Case04N-Jamie-Carer01 
  
For one adult with mild LD, the size and visibility of the measuring cup graduations was an 
issue: 
‘I keep the same glass and the little medicine cup with the bigger letters, no numbers, so I 
can see how much I am putting in [for lactulose]. ‘Cause I’ve got that little caps that you get 
on fluoxetine [sic – meant lactulose] bottles and I can hardly see the numbers on that. So the 
bigger [cup] I can read ‘cause their numbers are better.’ Case07C-Fiona 
 
Administration practicalities of adhering to medicines administered via a PEG tube 
Administering medicines via a PEG tube requires additional skills and can cause problems 
unique to that route of administration: 
‘The crushable tablets [Epilim] were a problem. They used to get stuck in the tube and it was 
sometimes a bit of an effort to try without distressing Jamie.’ Case04N-Jamie-CareW02 
 
[In reference to the PEG tube coming out of the stoma]: ‘…one of the times it happened I had 
to give him all his medication orally which was hugely difficult and stressful for me. I 
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managed to get the medication down him very slowly, very carefully… But it was stressful 
because I just knew I didn’t want his stomach upset, I didn’t want the epilepsy medication 
upset too much.’ Case05N-Rob-CareW01 
 
However, the PEG tube also aided adherence in one situation: 
‘…the only thing I can say with the gastrostomy more would be fluids - so if he’s had a tummy 
bug at least I can get Dioralyte into him instead of having to stress over his mouth. Or if he’s 
not wanting to swallow, at least I’ve got that.’ Case05N-Rob-Carer02 
 
Practicalities of adhering to medicines faced by care workers in particular 
Care workers cited their issue of having to maintain skills for administering emergency 
medication for epilepsy seizures: 
‘If we haven’t been the one that’s been administering buccal [midazolam] for a while, it can 
be quite nerve-wracking you know. It’s something that if you’re not often doing, you start 
getting apprehensive…’ Case02N-Anna-CareW03 
 
Ensuring clarity of prescribed instructions was another practical issue they had to deal with: 
‘…if it says take Epilim 100mg twice a day, we have to put times for staff to follow  ‘cause 
obviously there’s different shifts. So, we’ll say 8am, 8pm. If staff miss giving it at 8am, and 
then we do a med count and we find at med count time that she hasn’t had the morning 
meds, we have to get medical advice. And some of the GPs, well I’ve had them say, “As far as 
I’m concerned it’s prescribed twice a day, I’m not caring what time – that’s your company 
policy and procedures”, and they won’t give advice. And some of them are really good at 
giving advice.’ Case02N-Anna-CareW03 
 
Care workers also found themselves having to balance the needs of several service users all 
working to fixed timetables:  
‘Because if the residents and service users go to day centres. Our policy is two staff to 
administer meds whenever possible. Staff start at 7:30 and the service users will be picked up 
at 8:30/8:45. So we have a very short window to get four service users up, dressed, washed, 
breakfasted and medication.’ Case02N-Anna-CareW03 
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Care workers also noted that only being able to follow the prescriber’s instructions with 
regards to the administration of medicines sometimes caused problems between them and 
carers: 
‘We’ve had families go to the Care Inspectorate because we’re following best possible 
practice (as in social care medication) and they’ve went to the Care Inspectorate ‘cause they 
think we’re being difficult.’ Case02N-Anna-CareW03 
 
Other practicalities 
Care workers noted that having the responsibility to judge whether a ‘when required’ 
medicine should be administered is a practical issue for them: 
‘There’s a conflict all the time…Yeah, you doubt yourself…It’s your own judgement.’ 
Case03N-Paul-CareWs01+02 
 
4.6.3 Inadequate, conflicting or contradicting medicine information 
Through experience, carers and care workers build their knowledge and understanding of 
medication. However, carers were able to recollect when this was not the case: 
[In reference to the first prescription of rectal diazepam]: 
‘…and one of the GPs…said, “Oh well, we’ll need to give you some of that to have at 
home…You stuff it up her arse and squeeze”, I believe were the instructions I was given…I 
later discovered she should have been on her side with her knees folded up and I could have 
punctured her bowl. I didn’t know.’ Case02N-Anna-Carer01 
 
[In reference to learning about medicines]: 
‘I mean it was a learning curve for us. As you say – very much a learning curve for parents.’ 
Case04N-Jamie-Carer01 
 
The problem of ambiguous dosage instructions was cited:  
‘You can have various difficulties in ensuring that it’s easy for staff to follow and that there’s 
no grey areas. Like, are we doing half or one and a half? It has to be clear. Staff, if they’ve 
been involved in med errors, they can end up having disciplinaries. So, we need to have it as 
clear as possible for staff to follow… It’s just about ensuring everybody’s clear and making 
sure that it reads clear on the labels.’ Case02N-Anna-CareW03 
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Contradicting information was also noted: 
‘But there’s some tablets if you read the instructions it says don’t crush and yet we’re being 
asked to crush them.’ Case03N-Paul-CareW02 
 
‘The only thing I remember was getting ear drops once and reading the leaflet and it said not 
to be given in a burst ear drum and of course he did have a burst ear drum.’ Case05N-Rob-
Carer02 
 
4.6.4 Lack of consideration for patient’s lived experience from health care professionals  
Carers cited instances of when their knowledge and lived experience was ignored: 
‘And also, sometimes having to stand up to professionals which I did have to. On a number of 
occasions, I had to be quite brave and stand up knowing that I was doing right by him… Ok 
you’re the one with the qualifications but I know how his body works and I know him and I 
need to say this…I got the midazolam in its infancy...and what I discovered at that point was 
that his heart rate was slowing down when I was using it that method. I stood my ground in 
the hospital because they wanted to give him another dose and I said no. And I said his heart 
rate’s reducing.’ Case04N-Jamie-Carer01 
 
[In reference to pain control during a hospital admission]: 
‘…and the nurses were doing their own thing with the medication… They couldn’t get him, 
they could not get him – terrible!’ Case04N-Jamie-Carer01 
 
‘…ask any family carers and they’ll tell you, there’s a link between increased seizure activity 
and severe constipation. Doctors will say but there’s no reason for that. And you say, but 
you’re not living it. You speak to family carers and they’ll tell you we see it; we absolutely live 
it.’ Case05N-Rob-CareW01 
 
In addition, a response for a request for help was dealt with in a way which failed to appreciate the 
impact this might have on the care workers: 
‘So, he’s got about six pages of proactive strategies and six pages of reactive strategies…and 
when we said we really do need help again, the psychiatrist got back to us and said do you 
want the psychology involved again? And it was like oh I don’t know. That felt like they 
condemned us a wee bit – are you all working to this 100%?’ Case03N-Paul-CareW01 
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4.6.5 Lack of continuity and co-ordination of prescribing 
The complexity of prescribing when both the GP and Specialist(s) were involved resulted in a lack of 
co-ordination with prescribing:  
‘I think sometimes too with medication we think we’d really like to try something else… but 
because we’re going through psychiatrists and learning disability nurses and doctors, no 
change takes place really quickly…so you have your appointment with the psychiatrist and he 
might say, “Ok, we’re going to introduce baclofen or pain relief or something…” Then we’ve 
got three or four weeks ‘til it gets communicated down to start. So, he goes to a 
psychiatrist’s appointment, and then two weeks later and like I say, everything’s on 
computer so our doctor’s looking at it – the letters are not physically coming to them now 
they’re all [electronic].’ Case03N-Paul-CareW01 
 
‘But it’s quite a delay now between a psychiatry appointment … and actually a change taking 
place. It’s three or four months each time.’ Case03N-Paul-CareW01 
 
‘That’s another thing that’s changed you see. We used to get whatever letter was sent to the 
doctor [from the Specialist], we’d get a copy of but we don’t get that now, it just goes to the 
doctor [GP].’ Case03N-Paul-CareW02 
 
Within one case, the lack of a consistent approach to the prescribing of a hypnotic was noted: 
‘…the doctor that she has presently - another doctor had said this shouldn’t happen – we had 
to do a sleep chart on her to not have the zopiclone but to get it reduced. But the doctor that 
said this isn’t right, Ruth got angry with that doctor and they then also gave her it. And this 
was the doctor that said she shouldn’t get this, this is outrageous – but then gave her it. It 
just seems strange – like she was the one saying no, why has she ever been allowed this? And 
then when it became her dealing with her, she gave her it as well in the end!’ Case08C-Ruth-
CareW01 
 
However, a positive example of communication regarding prescribing changes from health care 
professionals was also noted: 
‘We used to go to the doctor with her, but now she does it herself. If she got a prescription 
from the GP it would get kept at the GP practice and the pharmacy would come and pick it 
up… and we would get the information back from them and it would go into her dossette. 
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But just recently, because we’re not going down, she came with a letter telling us that her 
medication had been reduced so that we knew about it.’ Case08C-Ruth-CareW02 
 
4.7 CHAPTER SUMMARY 
This chapter explored the medication related burden experienced by adults with LD in relation to the 
first section of PLEM (medication related burden) under the five themes of: medication routines; 
medication characteristics; medication adverse event; medication and social burden; and health care 
and medication. 
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CHAPTER 5 RESULTS – MEDICATION RELATED BELIEFS 
 
 
 
 
 
 
 
‘Life is choices, and they are relentless. No sooner have you made one choice than another is upon 
you’ 
Being Mortal: Medicine and What Matters in the End - Dr Atul Gawande 
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5.1 CHAPTER INTRODUCTION 
This section will focus on medication related beliefs - the second section of PLEM as outlined in 
Figure 5.1 below. Due to the often limited ability to articulate belief, and the involvement of carers 
and care workers in many aspects of their life, beliefs of carers and care workers involved in 
supporting adults with LD with their medication have been included instead of, or alongside, the 
beliefs of adults with LD.  
 
 
Figure 5.1 PLEM - medication related beliefs 
 
As can be seen within the conceptual model, the second section of PLEM (medication related 
beliefs) contains three themes: family peers and health care providers; medication related burden 
magnitude and coping skills; and general attitude. Within the study by Mohammed, Moles and Chen 
(2016) examples (or sub-themes) of each of these three themes were also listed and these are 
detailed in Table 5.1. These themes and sub-themes were used to structure the results that will now 
be presented within this chapter. 
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Table 5.1 Medication related burden themes and sub-themes 
Theme Sub-theme 
Family, peers, health care 
providers (normative beliefs) 
n/a 
Magnitude and intensity of 
medication related burden and 
coping skills (control beliefs)  
 
Intensity of medication related burden 
Self-awareness of coping skills  
Ability to develop problem solving strategies 
Lack of medication information  
Lack of comprehension  
Unmet need or expectation  
Response to negative aspects of medication 
General Attitude  Weighing up the burden and benefits 
Controls illness or disease 
Hope 
Prevents consequences of illness or disease 
Allows them to fulfil social roles  
Negative past experience 
Lack of perceived desired outcomes 
Preconceived negative attitudes  
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5.2 NORMATIVE BELIEFS OF FAMILY, PEERS AND HEALTH CARE PROVIDERS 
5.2.1 Cases 02N-05N (adults with severe LD) 
The belief that medication was needed by, and of benefit to, adults with severe LD was expressed by 
their carers and care workers: 
‘…as I added another drug on it sort of reinforced the fact that, oh gosh, you know this is how 
it’s going to be and you think you’re coming to terms with the fact that you’re dealing with 
an individual who’s got a lot of medical needs and it’s about coming to terms with that.’ 
Case04N-Jamie-Carer01 
 
 ‘…it’s medication and it’s not something you’re having for fun. It’s something you have to 
have to make you better.’ Case02N-Anna-Carer01 
 
‘I enjoy doing the medication, I like doing the medication. You feel and hope that the 
medication is quite important to them. It’s helping them, it’s keeping them healthy. So, I 
think it’s quite an important task throughout the day to do the medication. I think it’s one of 
those things that you feel are really important, that it’s got to be done. It’s the one thing you 
always remember - medication time, medication time.’ Case03N-Paul-CareW04 
 
‘I think it [medication] is giving him a good quality of life.’ Case05N-Rob-CareW03 
 
However, some care workers did express some doubts about medication: 
‘And whether he needs them all is debateable. If we could get one that did the job it would 
be easier but no that’s about it. For me, too many for the same thing and I think they’re 
counteracting each other.’ Case03N-Paul-CareW02 
 
‘’Cause I’m finding as I’m doing this kind of job that doctors are reluctant to remove a 
medication but they just keep adding to them. Yeah – that has worked in the past – we’ll not 
touch that. But we’ll give you this on top just to see how that works!’ Case04N-Jamie-
CareW02 
 
Carers and care workers also expressed views on the extent to which they believed the adult with 
severe LD was aware of their need for, and benefit of, their medicines: 
‘I don’t know if he really knows he’s getting medicines.’ Case03N-Paul-CareW03 
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‘He had the ability to think through I need this to feel, you know – I think he realised that 
medication was something he needed.’ Case04N-Jamie-Carer01 
 
‘I’m sure he knows what it is because if he doesn’t want to open his mouth to a yoghurt and 
you take over the Gaviscon because you think he’s gulpy, he’ll open his mouth for that. So, he 
definitely knows he gets relief from it.’ Case05N-Rob-Carer02 
 
‘He doesn’t know he’s taking them [medicines] does he – with the gastrostomy? He’s happy 
with it.’ Case05N-Rob-Carer02 
 
Care workers also expressed their views on the limitations to their knowledge on medicines and 
deference to HCPs: 
‘We’re not pharmacists, we’re not nurses, we know nothing, we’re being guided by them.’ 
Case03N-Paul-CareW03 
 
 ‘…but I’m not a doctor, I don’t know – but that’s just my thought.’ Case07C-CareW02 
 
In addition, the belief that the way medicines may work for the general population may not extend 
to those adults with severe LD was stated: 
‘It’s about looking at how things work on people whose bodies are working full tilt may not 
be how a drug will work on people’s bodies who are not working full tilt.’ Case04N-Jamie-
Carer01 
 
5.2.2 Cases 06C-11C (adults with mild – moderate LD) 
Care workers of adults with mild-moderate LD expressed views on the extent to which they believed 
the adult knew and understood what their medicines were for and the extent of the adult’s 
capability to manage and organise their medicines: 
‘He knows what medication he’s on too!’ Case06C-Mark-CareW03 
 
‘She was down at the doctor one day and the doctor was offering her a 2.5 and she says, 
“No, that doesn’t work. And you discontinued the 6.3 so can I have the 7.5?” And I’m like 
[mimes jaw open]. How do you know these things?!’ Case08C-Ruth-CareW04 
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[In response to whether Case07C would make good decisions about her medicines if the 
care workers were not there]:  
‘Yeah, I don’t think she would really.’ Case07C-Fiona-CareW01 
 
‘I think he would recognise if you gave him something different – he would know a different 
colour.’ Case06C-Mark-CareW02 
 
‘At the beginning we did her tablets in the dossette. And as time’s progressed we’ve realised 
that Ruth’s capable of doing more. So we’ve carried on with that over time.’ Case08C-Ruth-
CareW01 
 
‘I don’t think she’d be able to do it herself would she, and order [her medicines]. No, she’s a 
very reliant person. She relies on us for a lot more than we actually think she should – 
emotional support and things... She likes people to do things for her rather than do it herself.’ 
Case08C-Ruth-CareW04 
 
For Case08C-Ruth, the relationship that the adult with mild-moderate LD had with their medicines 
was of concern to the care workers: 
‘She just relies on the tablets. That’s her sole way of coping with life I think.’ Case08C-Ruth-
CareW02 
 
‘It’s a shame – she thinks a pill will cure everything for her.’ Case08C-Ruth-CareW04 
 
‘It’s an obsession is it? She’s got to have them… She’s always got creams for her back pain as 
well. She’s had so many different creams and it’s an obsession. She even went and bought 
one over the counter which went against her tablets one time. So, it’s an obsession really is it 
– the cream for the back.’ Case08C-Ruth-CareW02 
  
 105 
5.3 MAGNITUDE AND INTENSITY OF MEDICATION RELATED BURDEN AND COPING SKILLS 
(CONTROL BELIEFS) 
In all cases, the extent (or perceived extent) of the medication related burden in combination with 
coping and problem solving abilities of the individuals involved in managing the medication, was 
cited. 
 
5.3.1 Intensity of medication related burden 
Getting the medication ‘right’ was cited as a concern for care workers: 
‘I suppose because it was polypharmacy it was a concern about getting the doses right.’ 
Case04N-Jamie-CareW02 
 
For Case08C-Ruth, the problem and intensity of medication related burden was of concern to her 
care workers: 
‘Because it domineers her life. If they’re going to reduce her medication in any way she gets 
in a panic. I think she thinks that pills fix everything: I’ll get a pill and that’ll fix this and that.’ 
Case08C-Ruth-CareW02 
 
‘She does get annoyed I would say slightly because if the doctor didn’t give her what she 
wants. If the doctor tries to encourage her to change or decrease, then she gets very 
annoyed with that. She just wants to go to the doctor and say, “I need this, give it to me”.’ 
Case08C-Ruth-CareW02 
 
However, medication was also just accepted as a normal part of life for Case09C-Donald: 
[In response to how he thought his life would be without medicines]: 
‘Em, I’m not sure because it’s something that I’ve known most of my childhood life and most 
of my adult life. I don’t really know how life would be without them.’ Case09C-Donald 
 
5.3.2 Self-awareness of coping skills 
An awareness of their coping skills was expressed by carers of adults with severe LD: 
‘It was just something you got because from when he was tiny then he was only on one or 
two meds. But it was a gradual process. So, by the time he was 20, 21 [years old] the fact 
that he had half a pharmacy morning, noon and night – you just took in your stride.’ 
Case04N-Jamie-Carer01 
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‘I’m quite organised – I think you’ve got to be. I’ve never had an issue where I’ve forgotten.’ 
Case05N-Rob-Carer02 
 
A self-awareness of coping skills was also expressed by adults with mild LD: 
‘I would say I find it all pretty easy. You know, it’s just a case of popping them out of the pack 
when you can and just sticking them down your throat.’ Case09C-Donald 
 
‘I know what I’m taking, I watch what I’m taking…No. I’m used to taking them myself ‘cause I 
know what I’m taking.’ Case10C-Susan 
 
‘Ah well, it’s fairly easy now. I’ve been in a daily routine for years now so it’s fairly easy to fit 
in the other ones [medicines]...I’ve been doing this routine so long it’s second nature... Aye, 
I’ve a pretty good idea about what’s effective.’ Case11C-David 
 
‘When I’m at my mum’s I remember the stuff, right down what I take with me but I know 
what I take at what time in the morning and what I take at night. I’m pretty good… Say I’m 
at my mum’s tomorrow, I’d take my own medication with me. And I’d look out what I need to 
take at night. I’d organise myself!’ Case07C-Fiona 
 
5.3.3 Ability to develop problem solving strategies 
Adults with mild-moderate LD, and the carers and care workers of adults with LD, demonstrated a 
wide variety of problem-solving strategies in relation to medicine including: shared and informed 
decision making; how to solve practical administration issues; gaining and sharing medication 
knowledge; knowing how and where to seek advice and support. 
 
 Shared and informed decision making 
Shared and informed decision making was apparent as a problem solving strategy for adults 
with LD and their carers and care workers: 
‘…she [his care worker] was also his citizen advocate…My husband and I felt we had this 
balance – somebody who knew him well but who could look on…on his behalf as an outsider 
and say yes or no. And on a couple of occasions she said, ‘Do you think he would really want 
that?’ and I’d go no, you’re right. It was really good to have her there alongside us.’ 
Case04N-Jamie-Carer01 
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‘We always take her meds sheet up to the hospital so they know exactly what she’s on – 
what she can get, what she can’t get.’ Case02N-Anna-CareW04 
 
See Figure 5.2 and Figure 5.3 below for written permission for care workers (from GP) to 
administer bought medicines: 
 
 
Figure 5.2 Case02NPhoto04 GP authorisation to administer bought paracetamol 
suspension  
 
 
Figure 5.3 Case02NPhoto05 GP authorisation to administer bought simple linctus 
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A topical product aide memoire, see Figure 5.4, was used by care workers to communicate 
the site of application for a cream to all care workers.  
 
Figure 5.4 Case02NPhoto03 Topical product aide memoire 
 
Solving administration issues (practicalities) 
Strategies from carers and care workers to solve practical administration issues were noted: 
‘So yeah, they [the tablets] may go into a spoonful of yogurt or something…Suprax [cefixime] 
liquid…it’s foul, it’s like sand in milk, it’s gritty, it’s disgusting – serious bribery required here 
but I would recommend you have a glass of something that they love to bits that they don’t 
get very often (for example coca cola or chocolate buttons) ready.’ Case02N-Anna-Carer01 
 
‘If there’s a tendency to get [medicines] stuck [in the PEG tube] I usually leave that until last 
which possibly should go down first – I’m not quite sure. But because of the difficulty getting 
it down I always leave that until last so that I know that he’s got his other medication.’ 
Case03N-Paul-CareW02 
 
Adults with mild-moderate LD also shared how they solved practical administration issues: 
‘I keep the same glass and the little medicine cup with the bigger letters… Sometimes I’ve 
missed! But if I [put on] my kitchen light, put the cup there and put my finger on the actual 
number. So I know how much I’m putting in – it’s a good tip.’ Case07C-Fiona 
 
[In response to finding tablets hard to swallow]: 
‘I hide them in breakfast or I just bite the bullet and take them…Sometimes it can be cereal. 
But it seems to be the one that gets it over at the moment.’ Case09C-Donald 
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‘… you see I did consider putting all the daily tabs in the one box but then I says, no, no, at 
least if I have them separately I’ll be able to keep track better.’ Case11C-David 
 
Gaining and sharing knowledge 
Carers and care workers also shared strategies on gaining knowledge about the medication: 
‘I think because we’re pretty involved in taking him to the doctor’s and speaking to the 
doctor’s we know what they’re [medicines] for.’ Case03N-Paul-CareW04 
 
‘…we used to read through the side-effects and be aware of them – if he was given anything 
new. So, we were always on top of that.’ Case04N-Jamie-CareW02 
 
‘In front of their medication sheets we’ve got our own sheet that the Care Inspector advised 
us to have a wee bit of guidance [see Figure 5.5] as to what ‘as required’ means.’ Case03N-
Paul-Carer01.  
 
Figure 5.5 Case03NPhoto02 ‘When required’ medicine protocols 
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Adults with mild LD also noted how they relied on their care workers to support them in solving 
problems: 
‘‘Cause when they do the medication [check] on a Sunday, I do sometimes ask [the care 
workers], sometimes I forget. I don’t know whether to keep my Daktacort or throw it out.’ 
Case07C-Fiona 
 
[In response to what she would do if she forgot to take any of her medicines]:  
‘I’d tell the staff and then I’d have to miss that dose out.’ Case08C-Ruth 
 
Adults with mild LD also demonstrated their own ability to problem solve: 
[In response to what he would do if he realised he had forgotten to take his medicines]: 
‘I would probably just wait until the next dose.’ Case09C-Donald 
 
‘Depending on what time of day it is. Say in the morning if I didn’t take it first thing, I would 
just take it when I remembered. Much the same in the evening. If I didn’t take it along with 
my tea, I would make sure I took it before I went to bed.’ Case11C-David 
 
5.3.4 Lack of medication information  
In one case, the care workers noted concerns about the source(s) of information for the adult with 
LD:  
‘I think she talks to people because she’ll come back and say, “Betty’s on such-and-such; I 
want that”… So she must talk to other people about it because I’m not sure how she comes 
up with these.. She’ll come back and say, “I’ve got a friend and she took this in 1986…”.’ 
Case08C-Ruth-CareW01 
 
5.3.5 Lack of comprehension 
A logical, but incorrect, belief in respect to multiple medicines being used to treat the same 
indication was expressed by one care worker: 
‘That’s debateable – ‘cause it’s all for reflux – Gaviscon, domperidone, omeprazole - all for 
reflux…For me, too many for the same thing and I think they’re counteracting each other.’ 
Case03N-Paul-CareW02 
 
Care workers for one adult with mild LD knew the names of the medicines but not the indications for 
the medicines: 
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[In response to the question about what health problems Case07C has]:  
‘Well she takes omeprazole… I’m not really sure.’ Case07C-Fiona-Carer02 
 
[In response to the question about what health problems Case07C has]:  
‘I’m not 100% sure. She is on fluoxetine.’ Case07C-Fiona-Carer01 
 
For one adult with mild LD, a care worker noted her concern about the extent and depth of 
knowledge that she was perceived to have regarding her medicines:  
‘And she doesn’t always understand what would coincide [interact] with the medication she 
already takes. So, she has an idea in her head: I could get this and this will give me pain 
relief, I know someone who gets it. But it might not necessarily work with what she already 
has, or the dosage or the strength of it. So, she doesn’t always link that part together. She 
has an idea and she’s going in with that idea.’ Case08C-Ruth-CareW01 
 
During an interview with Susan (Case10C), sometimes she provided information in a muddled way 
that made it difficult to know if there was underlying lack of comprehension or just a struggle with 
the articulation of information: 
[In response to being asked if she took medicines or called the doctor out when she was 
unwell the previous night]: 
‘No, no, no. I took my laparozone [sic] – the ones over there that you were looking at.’ 
 
[In response to being asked if it was the loperamide]: ‘That’s it. loperamide is for my 
stomach.’ Case10C-Susan 
 
[In reference to when a change in medication was going to happen]: 
‘I don’t know yet; I won’t know until I get them [compliance aid] on Friday. No, no, they’ve 
already done it, I think they’ve already done it. No, no, I’ve to finish that ones that’s there.’ 
Case10C-Susan 
 
[When asked to explain what a side effect was]: 
‘Is this yours and I’d be going – no, that’s not mine.’ Case10C-Susan 
 
A lack of understanding regarding indications for medication was expressed by some of the adults 
with mild LD, which may have been due to limited recall and/or understanding: 
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[When asked if she knew what her mirabegron and solifenacin were for]: 
‘No. It’ll tell you on there – on the packet…They give me tablets for it [urinary incontinence]. 
They give me a brown tablet. Can you tell me what it’s for?’ Case10C-Susan 
 
[When asked what his OTC medicines were for]: 
‘Tyrozets, ah no, I couldn’t say… [Strepsils and other lozenges] I can’t remember having 
bought any of these…[Ibuprofen] I couldn’t say…[Senna] Is that a painkiller?...Bonjela? On 
my face – somewhere round my mouth, nose?’ Case11C-David 
 
5.3.6 Unmet need or expectation 
Care workers of Paul (Case03N) highlighted the frustration of medication not meeting Paul’s needs:  
‘…we are trying everything…I think ultimately people think there must be a magic pill...’ 
Case03N-Paul-CareW01 
 
‘It needs something a bit more extreme because in my opinion it’s gone on too long and I 
think there needs to be some kind of [medication] detox and strip back and start again and 
really test what it is. I don’t think it’s good for him to have to deal with this day in, day out 
either.’ Case03N-Paul-CareW04 
 
Unmet expectation was also raised in Case08C-Ruth: 
‘She would just like the ultimate tablet to cure how she feels, day in, day out. If she’s 
unhappy she wants that tablet to make her be happy. If she’s over-happy she wants that 
tablet not to be over-happy.’ Case08C-Ruth-CareW04 
 
Recognition that the medication was not controlling a particular condition was highlighted by Susan 
(Case10C): 
‘Well how’s it [incontinence] not under control? ‘Cause I’ve been on that tablet a long time 
now.’ Case10C-Susan 
 
5.3.7 Response to negative aspects of medication 
Unwanted or intolerable side-effects resulted in medicines being altered or never prescribed in the 
first place to adults with severe LD: 
‘Keppra [levetiracetam] rage is what they call it because they just become angry and short 
fuse…I eventually said to the neurologist that I’m prepared to put up with more seizures if 
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she goes back to being a happy bunny because this is no life for anybody, it’s just not right.’ 
Case02NCarer01  
 
[In response to why haloperidol treatment was stopped]: 
‘We didn’t want him to be sedated.’ Case03N-Paul-CareW02 
 
However, in other instances the negative aspects of the medicines were accepted and rationalised: 
‘What they said was it [arachnoiditis – side-effect of intrathecal baclofen] isn’t in itself fatal, 
but …because of the powerful drugs that are needed to control it, it can actually shorten the 
life - which is exactly what happened to him. What comfort I got was that they’d been using 
the right medication.’ Case04NCarer01 
 
[In reference to Epilim (sodium valproate) causing a lowering of mood]: 
‘But that was maybe about the time as well of the bad winter so it’s all tying in together.’ 
Case05N-Rob-Carer02 
 
The care workers of Ruth (Case08C) articulated Ruth’s confused response to the negative side-
effects of one of her medicines:  
 ‘But she did know about what those tablets [zopiclone] were doing to her in the morning 
‘cause she said she didn’t like speaking the way she was speaking to staff – so she knew. She 
still wanted them but I think by that time she was addicted to them. She knew things were 
changing inside her because she would often snap at you and then say, “I’m really sorry, I 
can’t help it.” So, she knew things were changing inside her, but she still wanted it.’ Case08C-
Ruth-CareW02 
 
5.4 GENERAL ATTITUDE  
The general attitude of carers and care workers of adults with LD towards medication is affected by 
a mixture of their experience and then the specific circumstances and history of the adult with LD. 
For adults with mild-moderate LD, their circumstances and history affected their attitude.  
 
5.4.1 Weighing up the burden and benefits of medication 
Compliant medication taking practice masked a variety of underlying views on the burden and 
benefits of medication for that individual. Sometimes positive views were expressed about the 
notable benefits of medication to the adult’s life: 
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‘[Without medication] She wouldn’t have a life I don’t think…She needs her medication.’ 
Case02N-Anna-CareW04 
 
‘As they get older you’re seeing it as this is maintaining a quality of life or this is improving 
their quality of life so you just accept it – that’s another one [medicine] in, you know!... It 
really was acceptance… ‘cause you’re then coming to terms with it and looking at what’s in 
their best interest really.’ Case04N-Jamie-Carer01 
 
‘And I would rather have that [hyoscine for excess salivation] than him with a sore chin or 
looking a bit awkward for people to look at him – personal dignity I think would be the 
word…’ Case05N-Rob-Carer02 
 
A considered understanding and acceptance of risk was also articulated: 
‘Now the domperidone – they’ve for a long time known that that can cause heart issues for 
long term use. And again, he’s on a reasonable dose morning and night as well… On the 
domperidone she [mum] said she knew (being a nurse) about the heart and they had tried to 
bring him off - no luck. It caused a huge amount of issues with him. So, she thought it wasn’t 
worth it for the slight risk of maybe some heart issues. And knowing he has such massive 
problems with his reflux. So, we’ve decided leave well alone with that.’ Case05N-Rob-
CareW01 
 
‘And my cocodamol – I take two in the morning and two at night. It was 9[am], 1[pm], 5[pm] 
and 10[pm]. But they cut it down as there’s only so much you can have. It’s not good for your 
liver and kidneys and that. So, it’s the morning and at night – two in the morning and two at 
night… ‘Cause I’m not like putting too much, I’m keeping my liver and kidneys healthier. I’m 
glad. ‘Cause you get some druggies that take too much and they destroy, their liver’s 
destroyed - like damaged. I’m glad I cut down mine…’ Case07C-Fiona 
 
However, conflicted views were also expressed: 
‘I don’t like taking the water ones [solifenacin and mirabegron] because I feel they’re not 
helping… If I didn’t take them, that would be worse. I’m dry at the moment.’ Case10C-Susan 
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‘As I say, the impact of too many for the same thing - we’re wondering what it’s doing to 
him. You know – is it actually helping him or is it making him worse… He makes himself sick 
so I mean in a sense us putting that down – is that upsetting things?’ Case03N-Paul-CareW02 
 
Interestingly, the weighing up of the benefits and burden of medication often resulted in care 
workers expressing informed concerns over the efficacy and safety of medication: 
‘One of them – omeprazole – that’s supposed to dissolve in the gut but he has it all day in his 
PEG tube so it goes into his stomach and we have to crush the tablet so it’s being digested by 
the stomach – so is it doing any good?’ Case03N-Paul-CareW02 
 
‘But the psych, the ones, the magic one we want, that helps his behaviour. Because we really 
don’t know, because we don’t know other people that have it - I don’t know what affect it 
really should be having to be honest. Should it be – what’s it doing to him? I don’t know what 
it’s doing to him…’ Case03N-Paul-CareW02 
 
‘I used to think that if he didn’t have them, what would happen to him – did he really need as 
many?’ Case04N-Jamie-CareW02: 
 
5.4.2 Medication controls illness or disease 
The purpose of medication being to control illness or disease was generally taken for granted but 
was sometimes expressed explicitly by care workers: 
‘They [medication] do the job they’re supposed to do. They must do because I’ve not seen 
him without them and I wouldn’t want to. So, they obviously do the job they’re supposed to.’ 
Case05N-Rob-CareW01 
 
 [In response to a question about the benefits of fluoxetine]: 
‘Outbursts – he had a lot of them before. And although he’ll still have them, they’re more 
controlled now and there’s a lot of things in place with other health professionals that have 
been involved to make things better for him…I think he’d just be as high as a kite if he wasn’t 
taking his tablets to be honest with you…’ Case06C-Mark-CareW02 
 
The control of illness or disease was articulated clearly by adults with mild-moderate LD too: 
‘It took a while but the fluoxetine – I’m more relaxed. Having two fluoxetine helps me more 
than having just 20[mg] fluoxetine… I wouldn’t want to stop that. That really helps me be 
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more relaxed and everything ‘cause I’m not so anxious like I used to be. I’m not so, ‘C’mon!’ 
I’m just more laid back and it helps a lot.’ Case07C-Fiona 
 
‘…they [duloxetine] take the pain away. They keep me ok… They keep me on an even keel 
and everything. I don’t get depressed so often…At least I don’t end up in hospital…I would 
never be out of my bed. I wouldn’t care about myself or nothing.’ Case08C-Ruth 
 
‘I suppose to keep my mood up, keep me healthy. You know, I’m able to do stuff. So, it’s 
pretty good actually.’ Case09C-Donald 
 
5.4.3 Hope 
For Case03N (Paul), the hope that there was a medicine that might help reduce or resolve the 
escalating behavioural problems was expressed several times: 
‘I don’t know – I still feel there must be something that would really help, that would cause 
him less distress than he’s experiencing ‘cause I think that sometimes the focus always come 
away from him and it’s how it’s affecting others and we’re not forgetting but he must be in 
chaos and we just want to try and help him and it’s very difficult ‘cause I don’t know what is 
out there that could help him.’ Case03N-Paul-CareW01 
 
‘So, it just seems to be a cycle of trying things over and over and over. Seems to be that new 
people coming in bring up the same ideas to try and they do get tried and I think we’re 
always hopeful that it will work this time, it will work this time.’ Case03N-Paul-CareW04 
 
The fact that the adult with mild-moderate LD expressed hope that the medicine will make them 
better was cited by care workers: 
‘And he’ll just keep saying, “That’ll make me better now, that’ll make me better”.’ Case06C-
Mark-CareW02 
 
‘I think she believes it though. She believes these things will make her better.’ Case08C-Ruth-
CareW01 
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5.4.4 Medication prevents consequences of illness or disease 
The role of medication in preventing the consequences of illness or disease was noted: 
‘The seizures – we’d be concerned that there’d be an increase and the length of time she was 
actually having in an actual seizure.’ Case02N-Anna-CareW03 
 
‘I think it’s the fact that when you’re caring for someone like Jamie that this was keeping him 
safe, keeping him well, keeping him alive.’ Case04N-Jamie-Carer01 
 
‘It’d be really hard for him just for daily life I think without his medications.’ Case06C-Mark-
CareW02 
 
‘I think without them [painkillers] it would be a lot, lot worse. Even though she’s still in pain 
at times, without them I think the pain would be a lot worse for her.’ Case08C-Ruth-CareW03 
 
[In response to why she chose to take her medicines]: 
‘Well it’s to keep you better. If I didn’t take them I would be ill.’ Case10C-Susan 
 
5.4.5 Medication allows them to fulfil social roles 
The independence that medication conferred was important to one adult with mild LD: 
‘Well it stops me from having the fits when I’m out, and still my own boss as I like to think!’ 
Case11C-David 
 
5.4.6 Negative past experience 
No data with this theme was provided by any of the cases during the research. 
 
5.4.7 Lack of perceived desired outcomes 
Failing to achieve the perceived desired outcome has had a significant impact on the beliefs of the 
care workers of one adult with severe LD (Case03N-Paul) in relation to the efficacy of medication: 
‘He was getting diazepam, fluoxetine, risperidone and none of them seemed to do whatever 
it was meant to do. And we’ve been giving him the paracetamol regularly since the weekend 
and that’s not even calming him…And I don’t know if there’s any medical tablet. We’ve tried 
medicine, he’s been on medicines, we’ve reduced medicines…’ Case03N-Paul-CareW03 
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‘And then it was decided to wean him off fluoxetine because he’s on risperidone and 
fluoxetine. It’s not made – in fact it’s exacerbated his issues – it’s not made it any better at 
all.’ Case03N-Paul-CareW01 
 
5.4.8 Preconceived negative attitudes 
Preconceived negative attitudes to medication were related to efficacy and the negative impact of 
change: 
‘Medication is a waste of time for me – for him.’ Case03N-Paul-CareW02 
 
‘If you change a tablet, you can get side effects and I don’t want that.’ Case10C-Susan 
 
5.5 CHAPTER SUMMARY 
This chapter explored the medication related beliefs of adults with LD, or of their carers and care 
workers, in relation to the second section of PLEM (medication related beliefs) under the three 
themes of: family peers and health care providers; medication related burden magnitude and coping 
skills; and general attitude. 
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CHAPTER 6 RESULTS – MEDICATION TAKING PRACTICE 
 
 
 
 
 
 
 
“You can only find out what you actually believe (rather than what you think you believe) by 
watching how you act.”  
12 Rules for Life: An Antidote to Chaos - Professor Jordan B. Peterson, 
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6.1 CHAPTER INTRODUCTION  
This section will focus on medication taking practice - the third section of PLEM as outlined in Figure 
6.1 below: 
 
 
Figure 6.1 PLEM - medication taking practice 
 
As can be seen within the conceptual model, the third section of PLEM (medication taking practice) 
contains two themes: accepting medicine; and modifying or altering medicine. Within the study by 
Mohammed, Moles and Chen (2016) examples (or sub-themes) of each of these three themes were 
also listed and these are detailed in Table 6.1. These themes and sub-themes were used to structure 
the results that will now be presented within this chapter. 
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Table 6.1 Medication taking practice themes and sub-themes 
Theme Sub-theme 
Accepting medicine  
 
Unconditional acceptance 
Forced into it by underlying illness 
Aiming to please family 
After experiments or consequences non-adherence 
Modifying or altering medicine  Intolerable medication related burden 
To evaluate effect of own medication or to discover optimal doses 
Lack of perceived outcome 
Fear of potential side effects  
Peer pressure  
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6.2 ACCEPTING MEDICINE 
Adults with LD or their carers and care workers cited a few examples of unconditional acceptance of 
medication and acceptance of the regimen after experiments with the medication. 
 
6.2.1 Unconditional acceptance 
Truly unconditional acceptance was rarely verbalised as acceptance was generally linked to efficacy 
and the absence of side-effects. However, unconditional acceptance of the medication routine by 
the adult with LD was noted by care workers: 
‘I’ve seen her when she’s really tired actually come through for the tablet…and I thought 
you’re tired - you’re wanting your tablets – that’s at 7 o’clock instead of 8. So, she does let us 
know!’ Case02N-Anna-CareW05 
 
‘He actually even reminds us about his 1pm meds. He’ll come through… And automatic first 
thing in the morning – he’s out of bed and he knows to himself that’s what he does – he gets 
his tablets before he’ll sort of go for a wash or whatever in the morning.’ Case06C-Mark-
CareW01 
 
‘And come dinner time, she’s asking if we’ll go up maybe half past seven/quarter to eight to 
give her her last tablet. She’s always asking.’ Case08C-Ruth-CareW04 
 
Unconditional administration of medication by care workers was actually seen as a potential 
problem by one carer: 
‘Come hellfire or high water…people won’t necessarily use their discretion because if they’re 
in a care home situation, what it says on the label is what happens– even if it’s wrong, that is 
what happens…’ Carer02N-Anna-Carer01 
 
6.2.2 Forced into it by underlying illness 
One adult with LD (Case 08C-Ruth) did express the view that she only took her medicines out of a 
need to control her illnesses. This was in contradiction to the views of her care workers who noted 
an obsession and reliance on medication. 
 
6.2.3 Aiming to please family  
No data with this theme was provided by any of the cases during the research. 
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6.2.4 After experiments or consequences of non-adherence 
The worsening of a condition upon cessation of the medicine resulted in an acceptance of the 
medicine: 
‘Domperidone – we tried him off it, it didn’t work. He had to be put back on it - his symptoms 
got worse. So, we did try it, but it didn’t work.”’ Case05N-Rob-Carer02 
 
‘Aye. I stopped it [all painkillers including morphine]. I paid for it because I was sick and 
everything. Cold sweats and I had to go back on it after two days.’ Case08C-Ruth 
 
6.3 MODIFYING OR ALTERING MEDICINES 
Adults with LD or their carers or care workers cited examples of how they modified or altered 
medicines. 
 
6.3.1 Intolerable medicine related burden 
A key factor in medicines becoming intolerable was if they had a detrimental effect on already 
reduced cognitive abilities or on the behaviour of adults with severe LD, previously detailed in 
Section 4.4 for Case02N-Anna, Case03N-Paul, Case04N-Jamie and Case05N-Rob. In addition, oral 
administration of medicines if swallowing difficulties were an issue also caused a degree of burden: 
[In reference to giving medicines orally as a child]: 
‘Obviously it was a nightmare when he was little, before he got the PEG. That was a 
nightmare!’ Case04N-Jamie-Carer01 
 
6.3.2 To evaluate the effect of their own medicines or discover optimal doses 
Although the medicine itself was accepted, several instances of dose optimisation were recounted. 
However, it was not always stated whether these changes were authorised by the prescriber 
beforehand: 
‘Epilim – we got him down on to the minimum dose that he needed…He had to be kept on a 
tiny amount of that [clonazepam]. We tried to take him off it but it’s such a powerful 
medication. I weaned it down to the absolute minimum but when I tried to take him [off it] -  
we had some really bad effects.’ Case04-Jamie-Carer01 
 
‘And one of the things that she’d looked at and asked about was about the once a day of the 
omeprazole…I’m giving a large dose but once a day. So, I thought, okay- I’ll have a look at 
…splitting the dose to work with his overnight feed and with the food that he takes during 
the day.’ Case05N-Rob-CareW01 
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‘She used to get it three times a day. Then it got reduced to two and all of a sudden she 
started feeling sick again and it got back up to three. I’m not saying she wasn’t sick but it’s 
like every time they take something away she finds another replacement of some other make 
or name or whatever. So, we’ve got to the stage when we just stop trying. Because it was like 
up and down, up and down.’ Case08C-Ruth-CareW01 
 
6.3.3 Lack of perceived outcome 
Carers and care workers could cite instances of when medication did not achieve their desired 
outcome for that adult with LD: 
[In reference to epilepsy treatment]: 
‘We gradually had everything up as far as it would go to try and prevent all these seizures 
but it just wasn’t working…Carbamazepine didn’t seem to do very much…’ Case02N-Anna-
Carer01 
 
‘He still suffers really badly from reflux. We’re thinking that the new medication omeprazole 
to lansoprazole swap is not working very well. He is getting more – he was retching two days 
ago. So, we’re not absolutely sure if it’s that that’s causing the problem.’ Case05N-Rob-
CareW03 
 
6.3.4 Fear of potential side effects 
Only in two cases was an aversion to potential side-effects noted: 
‘It’s like this. Everything is conflicting with each other. If she takes the iron tablet then she’s 
constipated. And if she’s constipated she’s unhappy about that. But then the lack of iron 
makes her sleepy. So, it’s this whole mismatch.’ Case08C-Ruth-CareW01 
 
‘I don’t want to change them [blood pressure tablets] because you can get side effects.’ 
Case10C-Susan 
 
6.3.5 Peer pressure 
Within the cases, two instances of care workers being pressured to administer medicines (in an 
acute situation) were cited: 
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‘He had a massive paddy [tantrum] while they were here … and my colleague got a phone 
call the next day saying, “You must be able to sedate him – you have to sedate him”...’ 
Case03N-Paul-CareW01 
 
‘…when he took the turn in the daycentre, it was very difficult to decide whether I should give 
him his midazolam. Basically because it would have conflicted with the medication that he’d 
had in the morning. So, what I did was, I waited with a lot of stress around me saying, 
“You’ve got to give him it! You’ve got to give him it!”’ Case04N-Jamie-CareW02 
 
6.4 CHAPTER SUMMARY 
This chapter explored the medication taking practice of adults with LD, or of their carers and care 
workers, in relation to the third section of PLEM (medication taking practice) under the two themes 
of: accepting medicine; and modifying or altering medicine. 
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CHAPTER 7 RESULTS – SUB-THEME EXAMPLES NEW TO PLEM 
 
 
 
 
 
 
‘To see what is in front of one’s nose requires a constant struggle’ 
George Orwell 
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7.1 CHAPTER INTRODUCTION 
This chapter highlights the new sub-theme examples from the case study data that were not 
identified within the PLEM conceptual model paper by Mohammed, Moles and Chen (2016) which 
are summarised in Table 7.1. 
 
Table 7.1 New sub-theme examples for PLEM 
Theme New Sub-Theme Examples Identified 
Medication 
related burden 
Medication Routines  
 Specialist administration issues related to PEG tube 
Medication Characteristics 
 Formulation  
 Palatability 
Adverse Events 
 Recognised but not considered negative 
Health Care and Medication  
 Carer and care worker responsibility  
 NHS policy 
Medication 
related beliefs 
Magnitude and intensity of medication related burden and coping skills (control beliefs) 
 Magnitude and intensity of medication related burden and coping skills unique to care 
workers  
 Challenge of communication between adult with LD and their carer or care worker 
General Attitude  
 Informed questioning of safety  
 Querying the benefit of medication 
Medication 
taking practice 
Accepting Medicines 
 Proven efficacy and clear benefits  
 Lack of side effects  
 Deferring to health care professionals  
 Perceived norm or reliance 
Modifying or Altering Medicines 
 Non-compliance (reason unknown)  
 Lack of side effects 
 
 
7.2 NEW SUB-THEMES - MEDICATION RELATED BURDEN 
7.2.1 Medication Characteristics: specialist administration issues related to PEG tube  
The administration of medicines via a PEG tube can affect the medication related burden – both 
positively and negatively. The formulation of the medicines was a key issue:   
‘If there’s a tendency to get [medicines] stuck [in the PEG tube] I usually leave that until last 
which possibly should go down first – I’m not quite sure. But because of the difficulty getting 
it down I always leave that until last so that I know that he’s got his other medication.’ 
Case03N-Paul-CareW02 
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‘The omeprazole – that dissolves in water and you’ve got to make sure that it is totally 
dissolved. Of course it’s little balls as I call them – they can get stuck and that’s the one thing 
that I find very difficult getting down his tube. If you don’t leave it to dissolve enough…’ 
Case03N-Paul-CareW02 
 
‘Because it’s easy because of the gastrostomy you’re not stressing anybody.’ Case05N-Rob-
Carer02 
 
7.2.2 Medication Characteristics: formulation 
The prescribed formulation of the medicine was noted by care workers of adults with severe LD as 
another medication characteristic that impacted on the ease of administration and, as a result, the 
associated burden: 
‘I much prefer the dissolvable ones.’ Case03N-Paul-CareW02 
 
‘Omeprazole – yes. And we’d gone on to the solution ‘cause we’d started off on the tablets 
which kept clogging up the gastrostomy.’ Case05N-Rob-CareW01 
 
‘Now that it’s buccal [midazolam] we find that it’s much easier to administer. We haven’t got 
the same concerns …when it was rectal [diazepam].’ Case02N-Anna-CareW03 
 
7.2.3 Medication Characteristics: palatability 
Carers and care workers also cited the taste, and associated palatability, as another medication 
characteristic that impacted on ease of administration and, as a result, the associated burden: 
‘I’ve seen her with the lacosamide and the Topamax [topiramate] lately - I think she’s taken 
it out of her mouth…I think it’s the taste.’ Case02N-Anna-CareW05 
 
‘Midazolam. It’s vile, absolutely vile. So if she’s only half out she won’t let you give it to her 
which is difficult ‘cause it’s disgusting…it’s very sweet.’ Case02N-Anna-Carer01 
 
‘She wouldn’t take the medicine – she didn’t like the taste of it…’ Case08C-Ruth-CareW01 
 
7.2.4 Adverse Effects: recognised but not considered negative 
For one adult with mild LD (Case07C-Fiona), the side-effect from a medicine was noted but not 
considered to be negative: 
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‘They [hyoscine travel sickness tablets] make me nod off…I have a sleep…it doesn’t bother 
me…If I didn’t have my travel pill I probably would be sick. I just nod off.’ Case07C-Fiona 
 
7.2.5 Health Care and Medication: carer and care worker responsibility 
The responsibility associated with making ongoing decisions on behalf of the adult with LD was 
consistently noted as an area of burden for carers and care workers: 
‘If we forget [to give medication], she’s oblivious but mum and dad panic!’ Case02N-Anna-
CareW01 
 
‘And the other thing which I think I need to say which is extremely hard is that I had to make 
decisions on behalf of somebody who would normally make decisions for themselves…I was 
always conscious of that as a young man of that age what would he want, what would his 
choice be? And acting in his best interest…’ Case04N-Jamie-Carer01 
 
‘Also, when you get her medication box, it’s checked twice here. We do two checks, two 
different people to make sure that her medication’s correct because sometimes mistakes can 
be made.’ Case08C-Ruth-CareW02 
 
7.2.6 Health Care and Medication: NHS policy 
The UK’s health care system removes financial pressure for medicines from the patient or their 
carer. However, the system’s policies on cost-effective medicine choices mean that sometimes 
certain drugs, or formulations of drugs, are less easy to obtain: 
‘I’d gone online to see if there was anything else and I couldn’t find anything else but mum 
said, “Yes there is – there’s a medicine… but it’s not broadcast about because it’s very 
expensive…”. I went to the GP and I said I know it’s expensive but it keeps clogging up his 
gastrostomy – that’s a hundred odd pounds a time. I said okay, you’ve got an expensive med 
but it would save £100 a time every time that clogs up. And also, a great deal of problems 
‘cause I have to take him to the hospital now – I’m not allowed to change it myself.’ 
Case05N-Rob-CareW01 
 
[In reference to why they couldn’t get clonazepam liquid]: 
‘We did – it was all down to financial [sic] wasn’t it?’ Case06N-Mark-CareW02 
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‘Even just a smaller tablet. ‘Cause that’s what the GP said, “No, it’s too expensive”.’ 
Case06N-Mark-CareW04 
 
7.3 NEW SUB-THEMES - MEDICATION RELATED BELIEFS 
7.3.1 Magnitude and intensity of medication related burden and coping skills: burden unique to 
care workers  
The standards of care set by their employer and their regulatory body generates additional 
medication related burden for care workers: 
‘…What’s on the pharmacist’s label is what we have to follow. So, if mum comes in and says, 
“Oh we’re at such-and-such [a dose]”, but that’s not what’s on the pharmacist’s label I have 
had to get in touch with GP surgeries. And I can’t accept verbal instructions over the phone 
so we have to get a fax stating what stage we’re at ‘cause sometimes if somebody comes in 
and there’s changes with meds we have to have that really clear in writing as to what staff 
are following. Sometimes we can get labels that come in and mum or dad have scored out 
bits which is unacceptable for us as well. So, again sometimes we’ve had to speak to mum 
and say would you be able to get the pharmacist to issue a current label.’ Case02N-Anna-
CareW03 
 
‘We can only give the set dose within the times.’ Case03N-Paul-CareW02 
 
‘So we’re trying baclofen at the moment – but a very small dose. And then they mentioned 
pain relief as well because of the ...but they never said to start one with the other. And 
because of the Care Inspectorate you’ve got to be so careful…’ Case03N-Paul-CareW01 
 
7.3.2 Magnitude and intensity of medication related burden and coping skills: challenge of 
communication between adult with LD and their carer or care worker 
Being able to determine how an adult with severe LD and no verbal communication is responding to 
a medicine and/or if they require a particular medicine is challenging for carers and care workers: 
‘Because he can’t tell you I’m not feeling great or…you read the side effects and you think is 
he experiencing the side effect, is he not?’ Case03N-Paul-CareW01 
 
‘Rocking. Which obviously is a sign in a non-verbal person that they’re getting discomfort. 
He… gets a look on his face of, “Uugghh - there’s a nasty taste in my mouth”, so immediately 
I’ll give him Gaviscon.’ Case05N-Rob-CareW01 
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7.3.3 General Attitude: informed questioning of safety 
The negative impact of medication on a condition was raised by one care worker: 
‘Maybe she’s got the hiatus hernia- could that be to do with the amount of tablets she takes 
maybe?’ Case08C-Ruth-CareW01 
 
7.3.4 General Attitude: querying the benefit of medication 
The actual benefit of one particular medicine was queried by Ruth (Case08C): 
‘I don’t know if that [paracetamol] helps really. I’ve got a sore head and it still doesn’t put that 
away.’ Case08C-Ruth 
 
7.4 NEW SUB-THEMES - MEDICATION TAKING PRACTICE 
7.4.1 Accepting Medication: proven efficacy and clear benefits 
Acceptance of medication was strongly linked to whether the drug was perceived as necessary and 
whether the benefits were apparent: 
 ‘As they get older you’re seeing it as this[medication] is maintaining a quality of life or this is 
improving their quality of life, so you just accept it – that’s another one in, you know!’ 
Case04NCarer01 
 
‘Oh no, they’re all there for my benefit. Like I say, years ago, I was a bit unsure on the effects 
they were having…So, like I say, I’ve just accepted it and well, that accounts for the routine.’ 
Case11C-David 
 
‘I suppose because it keeps me a bit, you know, it keeps me well, it keeps me happy.’ 
Case09C-Donald 
 
One carer also demonstrated an acceptance of ‘higher risk’ medicines because of the benefit: 
‘She had been under Dr X and he had started her on lamotrigine even though she was too 
young, she shouldn’t have been on it and it was off-licence but, by god, did it work – we were 
pretty much seizure free.’ Case02N-Anna-Carer01 
 
7.4.2 Accepting Medication: lack of side effects 
Acceptance of a medicine was also linked to a lack of side-effects: 
‘And what’s great is that he’s not got drowsy [on lamotrigine] – which you don’t want.’ 
Case05N-Rob-Carer01 
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‘The [morphine] MST’s better ‘cause that doesn’t knock me out. I mean, ‘cause the other 
ones did. I was falling asleep on buses and everything. My worker was worried about it – so I 
got taken off it.’ Case08C-Ruth 
 
7.4.3 Accepting Medication: deferring to health care professionals 
Care workers outlined their doubts but deferred to the expertise of health care professionals:  
‘I would maybe be trying to cut back that cocodamol and instead of having two a day, one a 
day. Just to actually see if...‘cause I think maybe psychologically, the fact that she’s taking 
them – that’s just my opinion, I don’t know… If she was taking one instead of two, would she 
still think I’m getting my tablets? You know? Because it is addictive, then if we cut…but I’m 
not a doctor, I don’t know – but that’s just my thought.’ Case07C-Fiona-CareW02 
 
‘Like I don’t personally think she needs all that but I’m not a professional doctor. So, when I 
take her down and the doctor says, “Ok we’ll easily increase your pregabalin.” I’m like, ok. 
But because I’m not medically trained, I think well, I can’t say anything.’ Case08C-Ruth-
CareW01 
 
7.4.4 Accepting Medication: perceived norm and reliance 
One care worker expressed the view that the adult with LD relies heavily on her medicines to cope 
with life and perceives them as the norm: 
‘She probably doesn’t remember what it was like to not have as many meds. So that worries 
her if the slightest tablet is reduced. It worries her and she gets angry. But it’s a good thing. 
And you tell her it’s a good thing. I think she’s had it for so long it’s now a norm. This is the 
norm having all these. That’s normal, that’s what she’s used to so that’s what she wants to 
stick to ‘cause she knows it.’ Case08C-Ruth-CareW03 
 
7.4.5 Modifying or Altering Medication: non-compliance (reason unknown) 
For adults with profound LD, the decision surrounding whether to accept, amend or reject a 
medication rests with the carers or care workers. However, an instance of the adult with LD 
choosing to refuse a medicine for a period of time was cited: 
‘‘Cause he gets Gaviscon as well – the Gaviscon is by mouth. Now he takes it quite well. 
There was a period last month where he was just letting it drool out – he just wasn’t taking 
it.’ Case03N-Anna-CareW04 
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Unknown compliance with salbutamol in Case08C (Ruth) was raised by one of her care workers: 
‘But she won’t use her puffer [inhaler].’ Case08C-Ruth-CareW04 
 
7.4.6 Modifying or Altering Medication: lack of side effects 
In one instance of increased dosage it was the absence of side-effects that ensured acceptability: 
‘So, we upped it a wee bit – just one tablet for the day for lamotrigine and definitely it hasn’t 
changed his mood. He’s still the same ….’ Case05N-Rob-CareW02 
 
7.5 CHAPTER SUMMARY 
This chapter highlighted the sub-theme examples from the case study data that were not identified 
within the original PLEM conceptual model paper by Mohammed, Moles and Chen (2016). 
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CHAPTER 8 DISSEMINATION CHECK 
 
 
 
 
 
 
 
‘However beautiful the strategy, you should occasionally look at the results’  
Sir Winston Churchill  
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8.1 CHAPTER INTRODUCTION  
This chapter is a summary of the collated key responses from the participants of the dissemination 
check to a first draft of the discussion in Chapter 9; these responses have also been incorporated 
into Chapter 9. 
 
8.2 BACKGROUND 
As noted in Chapter 2, enhancing the credibility of data through member checking would have been 
problematic in this study because of: the potential problems for participants with LD recalling the 
information they provided; the changing nature of interpretations of phenomena over time by 
participants; potential ethical issues of returning collated data to participants; the dilemma of 
anticipating and assimilating the disconfirming voices; and deciding who has ultimate responsibility 
for the overall interpretation.However, there remained a need to maximise the credibility of the 
findings of the study and potential for impact through a dissemination focus group approach, as 
outlined by Barbour (2005). The process for this dissemination check was outlined in Section 2.12.6. 
The two participants were selected as independent advisors with extensive practical experience of 
adults with LD who had been involved with the research project from the outset. It should be noted 
that the answers to each question are not quotes from one individual, but a mutually agreed 
summary of the discussion. 
 
8.3 RESULTS FROM THE DISSEMINATION CHECK 
1. Are the results credible and do they ring true with your experience? 
Yes, and yes (both participants). 
 
2. From your perspective, what are the most important points about adults with LD's experience of 
medication? 
 Care workers and carers are the experts about the adult with LD: 
o Inclusion of carers and care workers in decisions about medication for the adult 
with LD are so important; 
o Too often there is an issue of ‘professional power’; 
o Asking for and listening to the views of carers or care workers would be so 
helpful and diffuse feelings of exclusion. 
 Significance of medication routine for an adult with LD: 
o It has a direct impact on the adult’s everyday life; 
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o It has the potential to dictate routine and delay social activities (especially in 
group settings); 
o There is then a ripple effect on the family and other residents; 
o Some adults with LD have a tendency to obsess about medication; 
o Some adults with mild-moderate LD will obstruct medication changes just 
because it is change.  
 The responsibility and demands placed on care workers in the formal care setting in 
relation to medication: 
o Time and resource is required to ensure medication is administered, recorded 
and stored in accordance with regulatory body’s standards; 
o Day centre staff and travel escorts also impacted; 
o Care workers are really fearful of making medication errors; disciplinary action 
and suspension are real concerns; 
o Care workers in day centres have had to turn service users away because carers 
or care workers have not supplied them with all the required medication 
(including rescue medication for epileptic seizures). 
 Medication can be a flashpoint between family carers and care workers:  
o Care workers can only follow the prescriber’s instructions; carers often amend 
the dose or timing and then request that this change is followed by care workers; 
o Views of the family often outweigh views of care workers even when the family 
are not involved in the day-to-day care of the adult with LD. 
 
3. Are there any important points about medication experience in adults with LD that you think are 
missing? 
 The impact of prescribers deciding unilaterally to reduce antipsychotic medication. Dose 
reductions have caused an increase in behavioural problems in some adults with LD which 
then impacted negatively on social activity. The loss of social activity then impacted 
negatively on behaviour, and a vicious circle was created. 
 Medication refusals by adults lacking capacity: 
o Spitting out of tablets – should this be seen as the adult with LD communicating that 
they don’t want their medication and should that decision be respected? 
o Administration via PEG– is that technically covert administration as the person has 
no idea you are administering medication?  
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o Using food to make it easier for adult with LD to swallow – is that technically covert 
medication even when you show the adult you are putting the medication in the 
food? 
 
 Hospital: 
o Care workers not allowed to administer medication to the adult with LD in hospital 
even though the HCPs are busy and some wards have prevented carers or care 
workers from even being present; 
o Support for adults with moderate-severe LD is so individualised and HCPs are often 
out of their depth trying to work out the adult’s needs during a hospital stay; 
o The adult with LD often can’t communicate their medication needs to strangers and 
behaviour can worsen as a result; 
o Medication being administered late often causes problems because of the 
importance of routine to the adult with LD. 
 
4. What issues raised in the research would be most applicable to your current place of work? 
 The power relationship between HCPs and carers or care workers - HCPs have more status; 
 Impact of medication on social activity and the wider family and service such as delaying a 
group outing because of the need to medicate one person at a particular time; 
 Lack of flexibility with medication administration causing problems. 
 
5. & 6. How do you think health care professionals could better support adults with LD with respect 
to their medication? How do you think this information could be best used to improve adults with 
LD's experience of medication?  
 General education of HCPs about some of the common challenges faced by adults with LD 
and their carers or care workers in relation to medication; 
 Ask HCPs to work in partnership more with carers or care workers in all aspects of care but 
also in relation to prescribing decisions; 
 HCPS to listen to the lived experience of adults with LD and/or their carers or care workers; 
 Proactively ask care workers and carers about medication issues, procedures or routines so 
these are known and understood by everyone; 
 More holistic care from prescribing professionals for adults with LD so that polypharmacy is 
minimised; often specialists in different areas don’t speak to each other and it’s the carer or 
care worker who has to link them up. 
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8.4 CHAPTER SUMMARY 
This chapter detailed the results of the dissemination check that was undertaken after all data had 
been gathered, collated and analysed.  
 140 
  
 141 
CHAPTER 9 DISCUSSION OF RESULTS 
 
 
 
 
 
 
 
‘Discussion and argument are essential parts of science; the greatest talent is the ability to strip a 
theory until the simple basic idea emerges with clarity’  
Albert Einstein  
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9.1 CHAPTER INTRODUCTION  
This chapter will first of all discuss the collated case study findings for the three research objectives, 
as set out in Chapter 1, which were: 
1. To explore and describe the medication related burden experienced by adults with LD; 
2. To explore and describe the medication related beliefs of adults with LD; 
3. To explore and describe the medication taking practice of adults with LD. 
Then this chapter will discuss the use of the PLEM conceptual model as a theoretical framework 
within the research before discussing the reflexivity, transferability, and strengths and weaknesses 
of the research. 
 
9.2 MEDICATION RELATED BURDEN EXPERIENCED BY ADULTS WITH LD 
The following key themes emerged from the data: desensitisation to the burden of medication; the 
impact of drugs affecting cognitive ability and mental wellbeing; burden from the medication routine 
and any change to routine; reduction of burden through optimisation of the routine; the social 
benefit of medication; the transfer of burden to carers or care workers. Each of these themes will 
now be discussed, relating the case study findings to existing literature, and noting comments from 
the dissemination check. 
 
9.2.1 Desensitisation to the burden of medication 
All of the cases, to varying degrees, contained examples of burden that medication had placed on 
the adult with LD or their carers and care workers. However, the burden that was attached to the 
medication was often downplayed or not perceived to be a burden; medication, and by default 
medication related burden, was just the norm and perceived to be part of everyday life. This 
correlates with Bhaumik et al (2015) who suggest that people with LD experience altered 
sensitivities to drugs, different effects from drugs, different optimum doses, and more adverse drug 
reactions.  Furthermore, desensitisation to the burden of medication was also notable through the 
absence of expressed anxiety of future problems or burden from medication. A possible explanation 
for this desensitised view of medication related burden is that carers and care workers of adults with 
moderate-severe LD have developed a higher threshold of what constitutes a burden. This is 
because there is a general, everyday burden that exists in caring for a person with multiple medical 
and social needs and the burden or risk of not controlling certain medical conditions is greater than 
any medication-associated burden or risk.  
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Whilst it is not possible to comment on whether the case studies had similar or different experiences 
with medication to the general population, there was evidence of numerous adverse drug reactions 
and potentially increased sensitivity to medication, as evidenced in Chapter 4.  
 
Davis et al (2016); Van Schrojenstein Lantman De Valk and Walsh (2008), and Straetmans et al 
(2007), note the challenges that adults with LD have relating illness to dysfunction in their body, 
recognising relevant signs and symptoms, and then being able to communicate these to a HCP. It 
could then be argued that adults with LD would also have problems in recognising side effects, 
relating them to their medication and then communicating these to an HCP, or indeed recognising 
when they might benefit from a medicine. Furthermore, Bhaumik et al (2015), and Stenfert-Kroese, 
Dewhurst and Holmes (2001) also note that adults with LD who have communication difficulties may 
not volunteer information on side effects or only be able to express the information in idiosyncratic 
ways. This was noted in Case05N-Rob when his care worker noted how he rocked when he was in 
discomfort from heartburn and within the dissemination check when they noted that worsening 
behaviour of an adult with LD in hospital may be related to their inability to communicate their 
needs to strangers. In the cases within this research which focused on people with mild-moderate 
LD, none of the adults with mild LD were able to provide an answer about experience of general side 
effects. However, when asked about specific side effects, they were better able to answer. 
 
General issues with memory and perception of time were highlighted as having the potential to 
adversely affect ability to independently manage medication for people with mild-moderate LD 
(Bond and Hurst 2010; Arscott, Stenfert Kroese and Daganan 2000). Several case studies within this 
research (Case09C-Donald; Case10C-Susan; Case11C-David) demonstrated how impairment of 
memory and recall adversely affected the adult’s ability to provide a complete medication related 
history with description of medication related burden.    
 
9.2.2 Burden of medication adversely affecting cognitive ability and mental wellbeing 
Although medication in totality was not cited as an area of burden, adverse effects on cognitive 
ability or mental wellbeing from medication, or indeed from cessation of medication, were 
highlighted by carers and care workers as an intolerable burden. Within the case studies, 
psychoactive medicines were most frequently referred to as the cause of impaired cognitive ability 
or mental wellbeing (Case02N-Anna; Case03N-Paul; Case04N-Jamie; Case05N-Rob). 
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In recent years, there have been moves to address the over-use of psychoactive medication in 
people with LD (Public Health England 2015; Department of Health 2012) and published studies have 
often sought to identify the prevalence in various LD populations (Murray et al 2014; Doan et al 
2014; Paton et al 2011; Lott et al 2004). Whilst carers and care workers cited instances of how side 
effects from psychoactive medication had impacted negatively on learning potential, social 
opportunities, daily living and quality of life for both the adult with LD and their carers or care 
workers, many of the case studies highlighted the positive impact of psychoactive medication 
(Case02C-Anna; Case06C-Mark; Case07C-Fiona; Case08C-Ruth; Case09c-Donald). Furthermore, for 
one case (Case03N-Paul), the hope for a psychoactive drug that would help with behavioural 
challenges, and by default the quality of life, was cited several times by different care workers. This 
issue resonated in the dissemination check where one participant cited recent experiences of 
antipsychotic dose reductions causing an increase in behavioural problems and adversely affecting 
mental wellbeing. 
 
9.2.3 Burden from medication routine and change to routine 
All the cases highlighted that for the adult with LD, medication and the associated routine was just a 
normal part of daily life. In most of the cases studied, medication administration was strongly 
associated with particular times of day and adhering to the set routine was important to the adult 
with LD and their carers or care workers. Interestingly, it was the disruption of, or change to, a 
routine which had the potential to cause anxiety for the adult with LD and thereby increase the 
anxiety for the carers or care workers (Case06C-Mark; Case08C-Ruth). There was also the potential 
for medication routines to dictate, or limit, social activities, and as a result cause a degree of burden 
(Case02N-Anna; Case03N-Paul). This view was echoed within the dissemination check and the 
potential for obsessive behaviour in relation to medication routine from some adults with LD 
resonated with them. 
 
Self-management of the daily medication routine was important to adults with mild LD (Case 07C-
Susan; Case09C-Donald; Case10C-Susan). For one adult with moderate LD (Case06C-Mark), enabling 
him to self-administer under supervision had been viewed positively by his care workers. This 
reflects the view of Williams and Evans (2013) that personal development, self-esteem and 
community participation are achieved when adults with LD are not over-protected and are given 
opportunities, where appropriate, to be involved in activities where there is a degree of risk.  
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However, for formal care workers, ensuring that medication was routinely given in accordance with 
the prescriber’s instructions generated its own burden. Belief in the importance of medication for 
the wellbeing of the adult with LD was cited (Case02N-Anna; Case03N-Paul) but also the fear of 
making medication ‘errors’ by deviating from the established routine (Case02N-Anna; Case03N-
Paul). The literature reviewed in this research did not identify this particular issue. 
 
9.2.4 Reducing burden by optimisation of medication 
Within all the cases it was apparent that carers, care workers, or the adult with LD had optimised the 
routine to maximise the chance of successful administration. Examples of this optimisation included: 
refining the timing of administration in the wider morning routine (Case03N-Paul); requesting 
formulation changes (Case02N-Anna; Case 05N-Rob); refining the order of medicine administration 
(Case 03N-Paul); enhancing palatability of medication (Case02N-Anna); refining administration 
technique during illness or in an acute behavioural situation (Case02N-Anna; Case03N-Paul; 
Case05N-Rob); using multi-compartment compliance aids (Case10C-Susan; Case11C-David); refining 
level of carer support (Case05C-Mark). 
 
As medication had been tailored to optimise successful administration and provide assurance of 
necessity, it follows that even seemingly insignificant changes by prescribers or pharmacists have the 
potential to significantly affect the related burden of medication – both positively and negatively. 
The instance of changing from multiple lower strength tablets to fewer higher strength tablets was 
cited in Case02N-Anna as a potential problem, due to their larger size. Carers and care workers were 
not automatically averse to changes, but expressed the need for their involvement in any decision to 
ensure practicalities were considered and concerns allayed. Within the dissemination check, the 
view that the carer or care worker was the expert on the adult with LD and that asking for, and 
listening to, the views of carers or care workers would help diffuse feelings of exclusion in decisions. 
The literature reviewed in this research did not identify this particular issue in relation to 
medication. 
 
For three of the cases where the adult had severe LD, medicines were administered via a PEG tube 
(Case03N-Paul; Case04N-Jamie; Case05N-Rob). Whilst there is some associated burden for carers 
and care workers with PEG tubes, such as having to ensure that medicines are crushed adequately 
and knowing what to do if the tube blocks, this is less of a burden than having to take responsibility 
for administering medicines orally when aspiration and choking is likely. It was also noted in 
Case05N-Rob that administration of medicines via a PEG tube was less disruptive to the adult with 
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LD and that the time required to administer medicines was reduced as a result of the PEG tube. The 
level of expertise in administering medicines via a PEG tube was not a focus of this study so data 
were not specifically gathered to ascertain competency – as was done by Joos et al (2016) and Joos 
et al (2015).  However, of interest was the fact that carers and care workers did not make reference 
to any formal written guidance when discussing medicine administration via PEG tubes. The 
dissemination check also queried whether administration of medication by PEG tube and the use of 
food to make swallowing easier should be considered covert administration in those adults with LD 
who lack capacity.  
 
9.2.5 Medication has the potential to be either a benefit or a burden socially 
Medication which improved mental wellbeing resulted in the adult with LD being able to better 
engage in social activity which then improved their quality of life.  These medicines were viewed 
positively and defended as both essential and beneficial within the case studies (Case04N-Jamie; 
Case05N-Rob; Case06C-Mark; Case07C-Fiona; Case09C-Donald). In addition, medicines which 
addressed physical conditions that limited mobility or wellbeing such as medicines for epilepsy or 
heartburn, were viewed as allowing the adult with LD to have more social opportunities within the 
case studies (Case02N-Anna; Case04N-Jamie; Case05N-Rob). 
 
Within supported housing, it was interesting to note that medication administration times were 
viewed as an opportunity for social contact between the carers and the adults with LD (Case06C-
Mark; Case07C-Fiona). Care workers noted that the arrangement of them supervising self-
administration provided the adult with LD with an acceptable level of independence but also served 
as daily social contact to check how they were doing in general, and that this was of mutual benefit. 
The literature reviewed in this research did not identify this benefit to medication. 
 
In the majority of cases, medication was not collected from the pharmacy by the adult with LD but 
was instead collected by carers or care workers or delivered by the pharmacy. This lack of contact 
with pharmacy services may be the reason for Flood and Henman (2015 p.235) commenting that 
people with LD are invisible to pharmacists and that, ‘…Pharmacists may have little knowledge or 
experience of the challenges faced by this group...’. 
 
Conversely, any medication or change to medication that reduced the ability of the adult with LD to 
engage in social activities was viewed as a burden. For one case (Case03N-Paul) the limited effect of 
any psychoactive medication in helping manage his challenging behaviour to enable increased social 
activity was a notable disappointment. Maximising the quality and quantity of social engagement 
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was viewed, by case study and dissemination check participants, as an essential outcome of therapy 
for adults with LD. 
 
9.2.6 Burden of medication decisions being transferred to carers and care workers 
Adults with moderate-severe LD are dependent on their carers and care workers to make the vast 
majority of their health decisions, including medication related decisions (Davis et al 2016; Flood and 
Henman 2015). Within the case studies focusing on an adult with moderate-severe LD, carers and 
care workers often highlighted the burden of having to make decisions on behalf of another adult. 
Aspects of that burden included: making decisions that the adult would want (Case05N-Rob); living 
with decisions that had resulted in an adverse event (Case04N-Jamie); weighing up the benefits and 
problems associated with medication (Case03N-Paul); ascertaining if medication was actually having 
a benefit (Case03N-Paul); the ‘panic’ when a dose was missed (Case02N-Anna); and having to 
‘battle’ with HCPs to have their views heard (Case04N-Jamie). This last issue linked to the issues 
raised in the literature of exclusion from decision-making and an ignoring of raised concerns (Redley 
et al 2013; Buelow et al 2006; and Keywood and Flynn 2006). 
 
Whilst there was a lesser transfer of burden to care workers in Case07C-Fiona and Case08C-Ruth 
because the adult with LD had sufficient capacity and capability with respect to medication 
management, concern about the adult’s ability to make informed decisions about medication and 
retain relevant information was expressed. For Case09C-Donald, Case10C-Susan, and Case11C-
David, who were all managing their medicines independently, little medication burden was 
expressed. It was not possible to determine if this was due to a lack of awareness or if it was an 
informed view. However, having no support with medication from care workers and little contact 
with their community pharmacy potentially makes these adults with LD more vulnerable than those 
adults with LD who have support from carers or care workers. The literature reviewed in this 
research did not identify this as an issue for community dwelling adults with LD. 
 
9.3 MEDICATION RELATED BELIEFS OF ADULTS WITH LD 
The following key themes emerged from the data about medication related beliefs: beliefs and 
influence of significant others; medication being viewed as both beneficial and necessary; carers and 
care workers of adults with severe LD being the experts on the person being prescribed for; 
maximising the coping skills of adults with mild-moderate LD; and recognition of the coping skills of 
carers and care workers. Each of these themes will now be discussed, relating the case study 
findings to existing literature, where available, and noting comments from the dissemination check.   
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9.3.1 Beliefs and influence of significant others  
Within the case studies of adults with moderate-severe LD, both positive and negative beliefs about 
medication were expressed by the carers and care workers. Some of these beliefs were medicine 
specific and related to the efficacy or tolerability of the medicine. However, sometimes conflicting 
beliefs were expressed, such as in Case03N-Paul where there was a desire for a ‘magic pill’ to resolve 
the current behavioural challenges, despite past drugs being ineffective.  
 
For adults with mild LD (Case07C-Fiona; Case08C-Ruth; Case09C-Donald; Case10C-Susan; Case11C-
David) there was variation in their level of capacity and capability, their living arrangements, the 
number of significant others in their life, who their significant others were, and the involvement or 
influence of significant others with medication. The influence of significant others, both current and 
past, was rarely mentioned by the adult. If care workers were involved it was they who articulated 
their current level of influence in relation to medication. Whether the lack of reference to the 
influence of others in relation to their medication was due to there being an absence of any 
influence, a lack of recall, or lack of insight into this influence is debateable. This situation may in 
part relate to the results of a survey of 2898 people with LD by Emerson et al (2005) where it was 
found that 19% participants never saw members of their family, 31% said they did not have any 
contact with friends and 5% had no friends and did not see anyone from their family.  
 
Care workers sometimes expressed a view and then downplayed the importance of that view by 
highlighting that they were only a care worker and not a HCP (Case03N-Paul; Case07C-Fiona; 
Case08C-Ruth). This latter issue was noted by the participants in the dissemination check who 
commented that there is often a perceived ‘power relationship’ between HCPs and carers or care 
workers. The literature reviewed in this research did not identify this as an issue for carers and care 
workers of adults with LD although reference was made to carers and care workers having to 
become ‘battle weary health advocates’ (Keywood and Flynn 2006).  
 
9.3.2 Belief that medication is both beneficial and necessary  
Whilst some burden was attached to medication, this burden was most commonly perceived to be 
less than the burden that would have been experienced without it. Therefore, the belief that 
medication reduced morbidity or mortality was expressed within all the cases. For adults with 
moderate-severe LD, any benefit that the medication was able to confer was believed worthwhile by 
their carers and care workers. However, two situations caused belief in the benefit and necessity of 
medication to be questioned by the carers: intolerable side-effects, in particular side-effects relating 
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to cognitive ability or mental wellbeing (see Section 4.2.2); and failure to control, manage or reduce 
symptoms of a condition (Case03N-Paul). Within the case studies focusing on adults with mild LD it 
was more difficult to explore the reasons for believing their medication to be beneficial and 
necessary.  A factor to consider in the acceptance of medication is an issue highlighted by Stalker 
(1998): some adults with LD tend to acquiesce, not because of their LD, but because they are so 
used to having other areas of their life controlled by others.  
 
9.3.3 Belief that carers and care workers of adults with severe LD are the experts on the person  
All the cases of an adult with severe LD highlighted the conflict and tension that arises when HCPs 
did not involve the carers and care workers in key decisions, including prescribing. The stress and 
frustration of medicines being prescribed in inappropriate formulations, excessive doses and with 
little accompanying communication about any changes was a recurring theme. Carers and care 
workers did not describe themselves as experts in prescribing or medication – although their 
knowledge of past medication, and particularly medicines that had caused adverse events, would be 
invaluable to prescribers.  They did, however, consider themselves an expert on the adult they were 
caring for, and this was evident in the detail they provided during the interviews. Their belief was 
very much that their expertise and views were often not consistently taken into consideration, to 
the detriment to the adult with LD. In the dissemination check, the participants highlighted this as a 
key issue and reiterated the importance of involvement of the carers and care workers in prescribing 
decisions and using their enhanced knowledge of the adult with LD in the decision making process. 
The literature reviewed in this research did not identify this particular issue. 
 
9.3.4 Beliefs in maximising the coping skills of adults with mild-moderate LD 
Care workers of adults with mild-moderate LD often expressed a degree of concern regarding the 
extent of the adult with LD’s capability to make informed medication related decisions or their 
capability to manage their medication. Beliefs of care workers about the adult with LD’s capability 
affected the level of support provided (Case06C-Mark; Case07C-Fiona), and seeing the adult with LD 
making poorer decisions in relation to their medicines was a source of stress (Case08C-Ruth). 
Ascertaining capacity, capability, level of health literacy and then ensuring ongoing understanding in 
people with mild to moderate LD, has been noted as a challenge for all clinicians and prescribers 
(Ferguson and Murphy 2014; Stenfert Kroese, Ngoh 2009; Schwartzberg et al 2007; Davis et al 2006; 
Arscott et al 2003; and Dewhurst and Holmes 2001). 
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Managing their medication with minimal support from carers or care workers was a source of pride 
to adults with milder LD as it evidenced their capability (Cases07C-11C). This confidence in their own 
capability contrasts to the study by Crossley and Withers (2009) where people with milder LD 
expressed the belief that because their carers knew more about their medicines than they do, then 
their carers should make all the decisions on their behalf. The care workers in Case06C-Mark and 
Case07C-Fiona also expressed their belief in the benefits of increased self-esteem through an 
enablement approach to medication. There were, however, some concerns about removing all 
support, and the importance of routine for the individuals was stressed. 
 
Donald (Case 09C), Susan (Case 10C), and David (Case 11C) had no care worker supporting them with 
their medicine administration and expressed no concerns about their ability to manage their 
medication. However, during the interview there was sometimes evidence to the contrary. For 
example, Donald (Case 09C) could not explain why he received his medication on a weekly basis; 
Susan (Case 10C) did not correctly identify an empty blister in her MCA and was confused about 
when a medication change was occurring; and David (Case 11C) was not able to recall the indication 
for bought medicines. Accepting some degree of risk in relation to self-management of medication is 
challenging for carers, care workers and HCPs. However, Williams and Evans (2013) raised the 
interesting point that it is important for people with LD to be exposed to some level of hazard so 
they learn how to be safe and this in turn aids their development, self-esteem and community 
participation. 
 
9.3.5 Carers and care workers’ beliefs of their own coping skills   
Supporting adults with LD to take their medication was seen by carers and care workers as part of 
their role. Care workers received some formal training from their employer on administration and 
record keeping. However, family carers developed these skills through trial and error over the years. 
Both carers and care workers demonstrated a person-centred approach to administration as they 
adapted the medication routine (Case03N-Paul; Case06C-Mark; Case07C-Fiona), formulation 
(Case04N- Jamie; Case05N-Rob; Case06C-Mark) or route (Case04N- Jamie; Case05N-Rob) to best suit 
the adult with LD and optimise the chances of successful administration.  
 
Administering medication was not the only skill noted in the case studies. For carers and care 
workers of adults with moderate - severe LD, recognising how the adult with LD would communicate 
medication related issues such as the need for a ‘when required’ medication, was important. This 
was particularly important when the adult with LD was non-verbal. Bhaumik et al (2015), and 
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Stenfert-Kroese, Dewhurst and Holmes (2001), highlighted the challenges associated with 
monitoring side effects in patients with LD because of their limited or idiosyncratic ways of 
communication. The dissemination check noted that these challenges are heightened in the hospital 
setting where the surroundings and HCPs are all unknown to the adult with LD.  
 
Also highlighted in the case studies was the unique burden faced by care workers because of their 
employer’s and regulatory body’s policies. Care workers highlighted that family carers can adopt a 
more flexible approach to medication whereas care workers must always administer medication in 
exact accordance with the prescriber’s instructions and any deviation would be considered a 
reportable error. As highlighted in one case (Case02N-Anna), where both carers and care workers 
care for an adult with LD, tension over medication can arise and become a flashpoint. The 
participants of the dissemination check echoed this issue as being one they encountered frequently 
yet there was no evidence of this issue in the literature identified for this research.  
 
9.4 MEDICATION TAKING PRACTICE OF ADULTS WITH LD 
The following two key themes emerged from the data: conditional acceptance of medication; and 
compliant medication taking or administration. Each of these themes will now be discussed, relating 
the case study findings to existing literature where available, and noting comments from the 
dissemination check. 
 
9.4.1 Conditional acceptance of medication 
Whilst there was evidence to suggest that some adults with moderate-severe LD accepted the 
medication unconditionally, several case studies suggested that it may have been the routine itself 
that was accepted unconditionally (Case02N-Anna; Case06C-Mark). This unconditional acceptance of 
medication as a routine may explain why changes to medication can be so problematic; not only do 
the clinical implications need to be understood and consented to, but the impact on routine and 
change to the familiar need to be considered. For adults with milder LD, understanding of their 
medication was perhaps more simplistic. However, it was still conditional on it making them feel 
better, not making them feel worse, being acceptable in terms of palatability and also being easy to 
take.  
 
Within the majority of cases, carers and care workers of adults with moderate-severe LD 
demonstrated an acceptance of medication that was conditional on tangible benefits or the absence 
of significant side effects.  Acceptance of a medication regimen, particularly from carers, was also 
generally only after experimentation with doses and timings or alternative medicines to find the 
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optimal regimen. However, some care workers accepted medication for the adult with LD that they 
were caring for with fewer conditions and a lesser desire for experimentation. This was not due to 
them being less concerned about the adult with LD’s welfare, but because they saw the doctor or 
prescriber as the expert and did not feel it appropriate for them to question or influence decisions 
made by a HCP. This was even more acute for care workers of people with mild LD because of the 
greater ability of the adult with LD to deal directly with their clinicians and make independent 
decisions about their medication. The result was often that care workers were left in a position of 
accepting the medication and supporting the adult with LD to take their medication as prescribed 
despite having unvoiced or unanswered concerns. This issue of perceived ‘power’ was again echoed 
by the dissemination check participants but not noted within the literature identified within this 
research. 
 
9.4.2 Compliant medication taking or administration 
Acceptance of medication, whether conditional or unconditional, in the lives of people with LD is not 
actually synonymous with medication taking or administering practice. Within the case studies, 
despite any doubts, medication was taken or administered in accordance with the prescriber’s 
instructions. Any non-adherence was either unintentional or for a legitimate reason, such as 
challenging behaviour. Whilst unintentional non-adherence generated anxiety for both carers and 
care workers, there were additional employment consequences for care workers.  The Human 
Medicines Regulations (2012) state that prescription only medicines (POMs) can only be given in 
accordance with the directions of an appropriate practitioner. Having to ensure that medication was 
administered only as per the prescriber’s instructions meant that care workers would not consider 
any change to the medication regimen without written instruction from the prescriber. In most 
instances this restriction will safeguard the adult with LD from potentially dangerous decisions. 
However, as demonstrated in one of the cases (Case02N-Anna), this lack of permitted flexibility for 
care workers can generate a flashpoint between themselves and family carers. In another case 
(Case03N-Paul) it prevented the timely trial of potentially helpful changes of dose to assist in 
managing challenging behaviour. A desire for more flexibility with medication for care workers in 
similar situations was also expressed within the dissemination check. The literature reviewed in this 
research did not identify this particular issue. 
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9.5 THEORETICAL FRAMEWORK 
The Patient’s Lived Experience with Medicine (PLEM) conceptual model by Mohammed, Moles and 
Chen (2016) was adopted as a theoretical framework for this study. A description of this model and 
an initial discussion of the strengths and limitations of the model was provided in Chapter 2. As the 
purpose of this research was not to formally validate or critique this model, only a brief discussion 
on the experience of using this model will now be undertaken with some recommendations for 
improvement. In addition, it is recognised that this study only included a small number of 
participants, and from a very particular population, and so a comprehensive critique of the model is 
therefore limited.  
 
As noted by Birken et al (2017) the ultimate purpose of a theoretical framework is to act as a 
‘synthesizing architecture’. PLEM was chosen because it had a high degree of logical consistency and 
plausibility, could be used within a qualitative research method, and had the required focus of 
interest – experience with medication. However, a key limitation was the lack of validation or 
critique of the model within the literature. To date, no work has been published critiquing the PLEM 
model. 
 
In general, the PLEM conceptual model facilitated systematic data collection and analysis. However, 
as advised by Maxwell (2012), the researcher was mindful not to confine interview questioning to 
the framework, or to force insights into the framework, or to overlook data which did not fit into the 
framework. Participants were provided with the interview questions before the interview but in the 
interview were encouraged, through an open question, to tell their story. Often this yielded 
information that direct questioning from the framework might not have done. It also allowed the 
participants to talk about what mattered most to them as opposed to what the researcher thought 
might matter most. 
 
The framework approach to analysis, as detailed by Gale et al (2013), promotes systematic and 
consistent handling of qualitative data. The PLEM conceptual model was easily used to create a 
deductive list of themes, sub-themes, and sub-theme examples, but care was taken to allow other 
sub-theme examples to emerge from the data. Table 7.1 lists the new sub-theme examples 
identified within the data that had not been identified within the PLEM framework. 
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From the outset of the research, the absence of a section with the PLEM model that accounted for 
the benefit of medicines due to the reduction of disease burden was noted as a potential limitation.  
Within this study there were several instances where the medicines, despite any burden that they 
brought, were accepted because the disease burden was in comparison much greater: 
 
[In response to a question about the benefits of fluoxetine]: 
‘Outbursts – he had a lot of them before. And although he’ll still have them, they’re more 
controlled now…I think he’d just be as high as a kite if he wasn’t taking his tablets to be 
honest with you…’ Case06C-Mark-CareW02 
 
‘[without medication] She wouldn’t have a life I don’t think…She needs her medication.’ 
Case02N-Anna-CareW04 
 
Imbalance towards the negative aspects of medicines can also be seen in that there was only a 
Negative Therapeutic Outcomes element within the model; to truly describe lived experience, a 
positive therapeutic outcomes element should be included. Whilst it could be argued that the 
Patients’ wellbeing & HRQoL element within the model addresses this, I would argue it does not 
provide the required balance or neutrality within the model. An element on medication related 
benefits needs to be included alongside medication related burden. In addition, wellbeing and 
health related quality of life is linked to more than just medication, and the relationship between the 
two is more complex than that indicated within the model. In fact, it could be argued that your 
wellbeing and quality of life will influence your lived experience with medicine as much as medicine 
will influence your wellbeing and quality of life.  
 
As both a researcher and clinician I was unclear as to whether a side-effect or adverse event from a 
medicine (a ‘drug related problem (DRP)’) was to be classed as a Medication Related Burden or a 
Negative Therapeutic Outcome or both.  Double weighting should not be given to DRPs within the 
PLEM model so clarification or refinement of this particular aspect of the model is recommended.  
 
Finally, the relationships between all the themes require review and refinement. Relationships are 
often only annotated as one way and feedback loops missing. For example, medication taking 
practice is not linked back to medication related burden yet, it is clear that how and when a person 
actually takes a medicine will affect the potential burden. It would also appear from the model that 
the Patient’s wellbeing and HRQoL and Negative Therapeutic outcomes do not influence the three 
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major themes of medication related burden, medication related beliefs, and medication taking 
practice. Further research to specifically review and refine this model would be recommended.  
 
9.6 REFLEXIVITY 
‘Are the researcher’s motives, background, perspectives and preliminary hypotheses presented, and 
is the effect of these issues sufficiently dealt with?’ Malterud (2001 p.485) 
 
Motives for the research and the researcher’s background were outlined in the introduction to this 
thesis and the impact of being both a local HCP and researcher acknowledged. As detailed in 
Chapter 2, the methodology and methods employed have been outlined and made as transparent as 
possible to the reader. It is acknowledged that a more experienced researcher, with more honed 
skills, may have yielded a different data set. It is also possible that my being a practicing clinician 
inadvertently affected participants’ responses – potentially both negatively and positively. Data from 
the study has been presented in Chapters 3-8, before discussions in Chapter 9 to allow the reader to 
decide if the findings reached are reflective of the data gathered. During the entire research process 
an open dialogue with my primary supervisor occurred to ensure that my actions and decisions were 
checked regularly. However, whilst every attempt has been made to acknowledge the impact of the 
researcher on the research, it is possible that, as outlined in the Johari Model of self-awareness, I 
have unknowingly influenced the research and not accounted for that influence (Luft and Ingham 
1961). Undertaking this research has enhanced my ability to project manage and my attention to 
detail, extended and improved my listening and questioning skills, and also developed my writing 
skills.  
 
9.7 TRANSFERABILITY OF RESEARCH FINDINGS 
As detailed in Table 2.3, the transferability of a study, is the level to which the findings of a 
qualitative research study can be applied to another group by the reader. This can only be achieved 
when the researcher provides background data, establishes the context of study and provides 
detailed descriptions of phenomenon in order to allow for comparison. The context of the study was 
established in Chapter 1 and included a background to: LD; health and social care service in the UK; 
medicines, medication and polypharmacy; and a summary of the literature relating to adults with LD 
and medication. Full descriptions of all the cases and background data are included in Appendices 
3.1 – 3.11. As will be discussed in Section 9.8.2, the lack of geographical diversity in the cases may 
limit the degree of transferability. Another issue is that health care in Scotland, including provision of 
medication, is free at the point of delivery. This is different to so many other countries and will affect 
the degree of transferability of data relating to financial burden from medication.   
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9.8 STRENGTHS AND LIMITATIONS OF THIS RESEARCH  
As with all research studies, this study has both strengths and limitations which will now be 
considered: 
 
9.8.1 Strengths 
First and foremost, this study was designed to involve and include both adults with LD, and those 
who are actively involved in their care. As detailed in Chapter 2, methodology and methods which 
were sensitive to the needs and challenges of the LD population were chosen and an adult with mild 
LD was involved in ensuring materials and questions were appropriate for the LD community. In 
addition, appropriate professional and academic governance and safeguarding were established and 
adhered to throughout the study thus prioritising the wellbeing of any participant.  
 
Situated in a pragmatic ‘real life’ worldview, methodology and methods best suited to answering the 
research questions were chosen. The use of a new conceptual model could be considered a strength 
but, as it was not validated, it could also be considered a potential limitation. Contact was made 
with the corresponding author of PLEM before data collection to ensure as full an understanding of 
the model as was possible. The PLEM model was discussed in more detail in Section 9.5. 
 
As detailed in Table 2.7, as far as was possible, the study was designed to be transparent and to 
maximise the credibility, transferability, dependability and confirmability of the data gathered and 
analysed. Reflexive practice was employed throughout the study.  
 
Finally, local care providers and charities were involved from the outset to help shape and influence 
the research. This improved the quality of the research methodology and methods, maximised 
acceptability of the research in the LD community, helped in recruitment, checked the credibility of 
the results and aided in the local dissemination of the study outcomes.  
 
9.8.2 Limitations 
Firstly, the study was limited to a local geographical area in the north of Scotland. All the cases 
studied were born and lived their lives in north east Scotland and this may therefore limit the 
transferability of results to other populations.  
 
As noted by Meyer (2001), non-random selection of cases may give rise to a possible accusation of 
lack of rigour or indeed bias. The cases were not chosen by the researcher, and all cases who 
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volunteered were included. There is always the possibility that these volunteers were those who 
were most interested in and engaged with medication, and that participants with less interest in 
medication were not included. However, the purpose of the study was to allow a small number of 
participants to share their unique experiences with medication and not to reflect all ‘types’ of 
people in respect to their engagement with medication.  
 
Engagement and communication with those participants who had mild LD and no carer or care 
worker involved in medication management was a challenge for the researcher. Without the 
guidance of carers or care workers it was more challenging to gain rapport and to ensure that 
information and questions were provided in a manner which maximised the understanding of the 
participant. Of note was Donald (Case09C) who provided little information in response to the 
interview questions. Furthermore, it was difficult to verify and triangulate data in cases focused on 
an adult with mild LD where no carer or care worker was involved (Case 09C-Donald; Case10C-
Susan; Case11C-David). However, this in and of itself highlighted the opportunity for HCPs, including 
community pharmacists, to develop and maintain the coping skills of adults with LD in relation to 
medication. 
 
As with all studies, the degree of participant biases, as outlined in Table 2.4, cannot be verified. 
However, throughout the research process, every attempt was made to minimise participant bias by 
encouraging honesty and reassuring anonymity.  
 
Another potential limitation was the lack of data from other sources, notably interviews of 
significant others, in the cases focusing on adults with mild LD, as was recommended by Yin (2014), 
Thomas (2011), Stake (1995) and Eisenhardt (1989). Inclusion of data from health care records 
(medical or pharmacy) and the inclusion of views of significant HCPs would have enhanced 
triangulation of data. Furthermore, the noted issue of recall and memory has meant that there are 
potentially significant events relating to medication that the participants, particularly those with LD, 
were unable to recall and so the data in these cases are potentially incomplete. Whilst inclusion of 
HCP views and records would have provided additional data and perspective, it also had the 
potential to detract from the key focus of the research – to understand the lived experience of 
adults with LD in relation to medication and to give them, their carers and care workers a voice.  
 
Finally, the data used in analysis was heavily weighted to the interview(s) undertaken in each case. 
Additional observational data from the researcher may have yielded greater insight into current 
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situations that were not properly understood or articulated by the participants, as noted by Bowling 
(2014). However, due consideration would have had to be given to the time commitment required 
to make this successful, the potential for the Hawthorne effect (as detailed in Chapter 2), and the 
impact on participants with LD of having the researcher becoming part of their life and then leaving. 
 
 
9.9 CHAPTER SUMMARY  
This chapter discussed the collated case study findings for the three research objectives, as set out in 
Chapter 1, which were: 
1. To explore and describe the medication related burden experienced by adults with LD; 
2. To explore and describe the medication related beliefs of adults with LD; 
3. To explore and describe the medication taking practice of adults with LD. 
Then this chapter discussed the use of the PLEM conceptual model as a theoretical framework 
within the research before discussing the reflexivity, transferability, and strengths and weaknesses 
of the research. 
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CHAPTER 10 IMPACT AND CONCLUSION 
 
 
 
 
 
 
 
‘We must go on and take the adventure that comes to us’  
The Last Battle - C.S.Lewis 
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10.1 CHAPTER INTRODUCTION 
Before providing a conclusion to this thesis, this chapter will discuss the potential impact of the 
research, and possible future work identified within this research. 
 
10.2 POTENTIAL IMPACT OF THE RESEARCH  
Impact from research has to be defined as more than just academic knowledge creation; it has to 
also include the influence or effect out with of academia (Denicolo 2014). The Research Councils UK 
(RCUK) defines impact as academic or as being economic and societal (Research Councils UK 2018). 
RCUK also notes the importance of engaging the public with research in order to improve both the 
quality and impact (Research Councils UK 2018). Rivera et al (2017), identified the current 
frameworks used to demonstrate impact from health research and recognising the common 
concepts and themes. The collective summary of pathways to health research impact from Rivera et 
al (2017) is detailed below in Figure 10.1: 
 
Figure 10.1 Pathways to research impact (Rivera et al 2017) 
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10.2.1 Primary Research Related Impact 
Using the pathways to research impact framework by Rivera et al (2017), the following is a 
description of the potential key categories of impact for this research: 
 
Research and Innovations Outcomes 
It is the intention to publish aspects of this research in both a pharmacy and an LD peer-reviewed 
journal so that the learning can be shared and accessed by all researchers and clinicians interested in 
this area. 
 
Dissemination and Knowledge Transfer 
 A workshop entitled, ‘Tackling inequalities in access to clinical pharmacist led healthcare: 
recognising and overcoming ethical issues of inclusion in research’, was delivered at the 
European Society of Clinical Pharmacy conference in Oslo (5th-7th October 2016). 
 A further workshop entitled, ‘Medication related experiences of adults with learning 
disabilities’, was delivered at the European Society of Clinical Pharmacy conference in 
Belfast (24th-26th October 2018). 
 Poster abstracts have been presented at: 
o NHS Grampian’s Quality and Safety in Healthcare event, Aberdeen (1st May 2018); 
o RGU’s Pharmacy and Life Sciences Research Day, Aberdeen (28th May 2018); 
o European Society of Clinical Pharmacy conference, Belfast (24th-26th October 2018); 
o NHS Scotland’s Research conference, Perth (30th October 2018). 
 Local participation in Scotland’s national Learning Disability Week (14th – 20th May 2018). 
 Feedback to the Aberdeen Provider’s Forum, formerly CASPA (27th June 2018). 
 Meeting with NHS Grampian’s newly appointed Nurse Consultant for LD to discuss how to 
disseminate and apply research locally (31st July 2018). 
 A summary of the research will be sent to the Scottish Commission for Learning Disabilities 
(SCLD) in Glasgow. 
 Planned participation (poster and/or oral abstract) for the International Association for the 
Scientific Study of Intellectual and Developmental Disabilities (IASSIDD) conference in 
Glasgow (6th – 9th August 2019). 
 
Capacity Building, Training and Leadership 
This research study has been part of the doctoral training for the researcher. As a result of this 
training, project work for NES was undertaken January-June 2018.   
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10.2.2 Influence on Policy-Making 
Level of Policy Making; Type and Nature of Policy Impact; Policy Networks 
This research will influence local medication management policies, procedures and training 
which can then be shared nationally. However, as Rivera et al (2017 p.18) noted, ‘The 
outcomes of research may emerge slowly and be absorbed gradually. Consequently, it is 
difficult to determine the influence of research in the development of a new policy, practice, 
or guidelines.’ 
 
10.2.3 Health-related and Societal Impact 
Health Knowledge, Attitudes and Behaviours  
It is hoped that this research involving adults with LD will encourage other researchers to include 
adults with LD in research design and also encourage other adults with LD to participate.  
 
10.3 POSSIBLE PRACTICAL KEY LEARNING POINTS FOR HEALTH CARE PROFESSIONALS  
 
A key element of the Doctorate of Professional Practice is to focus on the impact of the research. The 
following section was created by the researcher to demonstrate how the emerging themes from 
medication related burden; medication related beliefs; and medication taking practice might be 
summarised into practical key learning points for HCPs. It is important to stress that these learning 
points have not been validated and would require such a process before they could be disseminated 
within the academic sphere. The possible practical key learning points for HCPs are first of all 
summarised in Table 10.1 before being expanded upon. Evidence from the case studies and, if 
applicable, relevant UK Government health polices as outlined in Chapter 1, illustrate or evidence the 
issue. 
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Table 10.1 Summary of proposed practical key learning points for health care professionals 
Proposed 
Learning 
Point 
Description 
#1 
 
For adults with LD, medication is generally viewed to be both beneficial and 
essential in respect to morbidity and mortality; a perceived lack of efficacy or 
intolerable side-effects challenges this belief. 
 
#2 
 
Maximising cognitive ability and mental wellbeing is essential for adults with LD so 
adverse effects on cognitive ability or mental wellbeing from medication or 
medication withdrawal are often unacceptable. 
 
#3 
 
Carers and care workers of adults with LD, particularly those of adults with severe 
LD, are the expert on the person; they want to work with HCPs but are often 
excluded from discussions and decision making. 
 
#4 
 
Medication has the potential to both enhance and hinder the quality of life for 
adults with LD; enhanced social ability or experiences and quality of life is an 
important outcome and small gains are valued. 
 
#5 
 
Medication routine is an important aspect of life for adults with LD and altering it 
can have unexpected impact on their life. 
 
#6 
 
HCPs need to be mindful of the practical issues surrounding medication 
administration for carers, care workers of adults with LD, and of self-medicating 
adults with LD. 
 
#7 
 
The coping skills of adults with mild-moderate LD in relation to medication should 
be developed and maintained by carers, care workers and HCPs; but their potential 
limitations of capability and responsibility remembered. 
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Proposed 
learning 
point #1 
 
For adults with LD, medication is generally viewed to be both beneficial and 
essential in respect to morbidity and mortality; a perceived lack of efficacy or 
intolerable side-effects challenges this belief. 
 
 
HCPs might improve the medication related experiences of adults with LD by: 
 being aware that medication for adults with LD is viewed as beneficial and essential in respect 
to both morbidity and mortality; 
 considering that even seemingly small benefits from medicines may be of value to the adult 
with LD and their carers or care workers; 
 being aware that sensitivity to the effects and side-effects of medication may be increased in 
adults with LD; 
 considering the possible side-effects and the impact on the adult with LD, particularly before 
prescribing new medicines; 
 counselling adults with LD or their carers and care workers about potential side effects of new 
medicines; 
 reviewing all medication on a regular basis and amending doses or discontinuing medication 
where efficacy is lacking or side-effects are considered intolerable. 
 
‘She wouldn’t have a life [without medication] I don’t think…She needs her medication.’ 
Case02N-Anna-CareW04 
 
 ‘It’d be really hard for him just for daily life I think without his medications.’ Case06C-Mark-
CareW02 
 
‘Epilim – we got him down on to the minimum dose that he needed…He had to be kept on a 
tiny amount of that [clonazepam]. We tried to take him off it but it’s such a powerful 
medication. I weaned it down to the absolute minimum but when I tried to take him [off it] - 
we had some really bad effects.’ Case04-Jamie-Carer01 
 
‘You should expect the doctor (or other health professional) to explore and understand what 
matters to you personally and what your goals are, to explain to you the possible treatments 
or interventions available with a realistic explanation of their potential benefits and risks for 
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you as an individual, and to discuss the option and implications of doing nothing.’ (Scottish 
Government 2017b p. 4) 
 
Proposed 
learning 
point #2 
 
Maximising cognitive ability and mental wellbeing is essential for adults with LD so 
adverse effects on cognitive ability or mental wellbeing from medication or 
medication withdrawal are often unacceptable. 
 
 
HCPs might improve the medication related experiences of adults with LD by: 
 ensuring that optimal cognitive ability and mental wellbeing is a primary focus of care; 
 being aware that any adverse effect on cognitive ability or mental wellbeing from medication, 
or medication withdrawal, is likely to be considered intolerable; 
 prescribing drugs with the least potential negative impact on cognitive ability or mental well 
being; 
 involving the adult with LD, their carers, or care workers before initiating any change to 
medication which may impact negatively on cognitive ability or mental wellbeing; 
 considering the impact on the adult’s quality of life from adverse effects on cognitive ability 
or mental wellbeing when reviewing medication or changes to doses of medication. 
 
‘I suppose to keep my mood up, keep me healthy. You know, I’m able to do stuff. So it’s 
pretty good actually.’ Case09C-Donald 
 
‘It took a while but the fluoxetine – I’m more relaxed. Having two fluoxetine helps me more 
than having just 20[mg] fluoxetine… I wouldn’t want to stop that. That really helps me be 
more relaxed and everything ‘cause I’m not so anxious like I used to be. I’m not so, ‘C’mon!’ 
I’m just more laid back and it helps a lot.’ Case07C-Fiona 
 
 ‘…some of them are fairly sedative and obviously that has a knock-on effect to people’s 
development… the impact on their cognitive abilities…’ Case04N-Jamie-Carer01 
‘… we’ve been trained in a reductionist environment where people don’t trust measures that 
aren’t highly objective and generalisable, when most things that contribute to value at the 
level of the individual are highly subjective and context specific, including their preferences…’ 
(Scottish Government 2017b p. 11).  
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Proposed 
learning 
point #3 
 
Carers and care workers of adults with LD, particularly those of adults with severe 
LD, are the expert on the person; they want to work with HCPs but are often 
excluded from discussions and decision making. 
 
 
HCPs might improve the medication related experiences of adults, particularly those with severe LD 
by: 
 viewing the carers and care workers as the experts on the adult with LD whilst remaining the 
experts on clinical care and medication; 
 being aware that it is the carers and care workers of adults with LD, particularly adults with 
moderate-severe LD, who carry the responsibility and any associated burden related to 
medication; 
 always involving the carers and care workers of adults with severe LD in any medication 
related decision or change; 
 respecting the lived experience of carers and care workers and valuing the expertise they can 
bring; 
 listening to the wishes and concerns of carers and care workers about the medication or the 
administration practicalities; 
 reaching a mutually acceptable decision for medication provided this would promote the 
wellbeing of the adult with LD; 
 retaining awareness of the potential for medication to become a flash point between carers 
and care workers, so encourage proactive and ongoing communication between them. 
 
‘…[tablets that are] too big can be an issue particularly when people think they are doing us 
a favour by reducing the number [of tablets] we have to take without consultation.’ 
Case02N-Anna-Carer01 
 
‘And the other thing which I think I need to say which is extremely hard is that I had to make 
decisions on behalf of somebody who would normally make decisions for themselves…I was 
always conscious of that as a young man of that age what would he want, what would his 
choice be? And acting in his best interest…’ Case04N-Jamie-Carer01 
 
 167 
‘And also sometimes having to stand up to professionals which I did have to. On a number of 
occasions, I had to be quite brave and stand up knowing that I was doing right by him… Ok 
you’re the one with the qualifications but I know how his body works and I know him and I 
need to say this.’ Case04N-Jamie-Carer01 
 
‘Health professionals caring for people with learning disabilities should assess and keep 
under review the medicines requirements for each individual patient to determine the best 
course of action for that patient, taking into account the views of the person if possible and 
their family and/or carer.’ (Department of Health 2012 page 45) 
 
Proposed 
learning 
point #4 
 
Medication has the potential to both enhance and hinder the quality of life for 
adults with LD; enhanced social ability or experiences and quality of life is an 
important outcome and small gains are valued. 
 
 
HCPs might improve the medication related experiences of adults with LD by: 
 being aware that seemingly small improvements to quality of life are valued; 
 enabling increased social activity and enhancing quality of life through medication; 
 using enhanced social activity or experiences as an outcome measure for certain medicines;  
 involving carers and care workers of adults with LD in discussions and decisions as outlined in 
learning point #3. 
 
‘Well it stops me from having the fits when I’m out, and still my own boss as I like to think!’ 
Case11C-David 
 
‘Keppra [levetiracetam] rage is what they call it because they just become angry and short 
fuse…I eventually said to the neurologist that I’m prepared to put up with more seizures if 
she goes back to being a happy bunny because this is no life for anybody, it’s just not right.’ 
Case02N-Anna-Carer01  
 
‘As they get older you’re seeing it as this is maintaining a quality of life or this is improving 
their quality of life so you just accept it – that’s another one [medicine] in, you know!... It 
really was acceptance… ‘cause you’re then coming to terms with it and looking at what’s in 
their best interest really.’ Case04N-Jamie-Carer01 
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Proposed 
learning 
point #5 
 
Medication routine is an important aspect of life for adults with LD and altering it 
can have unexpected impact on their life. 
 
 
HCPs might improve the medication related experiences of adults with LD by: 
 working with the adult with LD and their carers or care workers to optimise their regimen so 
it maximises quality of life (see learning point #4) but also minimises disruption to everyday 
life; 
 supporting carers and care workers to alter the routine appropriately to minimise disruption; 
 being aware of the practical issues surrounding medication administration (see Key Finding 
#6); 
 involving adults with LD and their carers or care workers when making any change to 
medication – no matter how small; 
 recognising the importance of medication routine for many adults with LD and maintaining 
that routine in other settings such as a hospital; 
 being aware of the possibility for medication and medication routine to become an obsession 
for some adults with mild-moderate LD. 
 
‘He doesn’t like change does he?...He likes the normal routine…He’s got a structure he’s to 
follow – like a weekly timetable. If that’s not followed right down to the tee then it’ll knock 
him and it’ll increase his anxieties as well.’ Case06C-Mark-CareW03 
 
‘Yeah, the day’s built... I mean even the social activities that go on – like going out. You have 
to be out and then back for meds. Out and then make sure you’re back at this time for 
medication.’ Case03N-Paul-CareW04 
 
‘Because it domineers her life. If they’re going to reduce her medication in any way she gets 
in a panic. I think she thinks that pills fix everything: I’ll get a pill and that’ll fix this and that.’ 
Case08C-Ruth-CareW02 
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Proposed 
learning 
point #6 
 
HCPs need to be mindful of the practical issues surrounding medication 
administration for carers, care workers of adults with LD, and of self-medicating 
adults with LD. 
 
 
HCPs might improve the medication related experiences of adults with LD by: 
 giving due consideration to the formulation and practicalities of administration when 
prescribing new medicines; 
 seeking the views of carers and care workers regarding the practicalities and timings of 
administration for the adult with LD; 
 ensuring all ‘when required’ medication prescriptions have details of the dose, maximum daily 
dose, minimum time interval between doses and a description of the indication; 
 specifying the timing of doses to breakfast, lunch, teatime or bedtime, where possible; 
 enabling carers and care workers of adults with moderate-severe LD a degree of 
‘experimentation’ with doses and timings to ascertain optimal regimen; for care workers 
these instructions must be given in writing; 
 remembering that for care workers all changes to medication must be provided in writing; 
verbal direction is insufficient; 
 encouraging regular and timely communication between carers and care workers about any 
changes to medication or administration. 
 
‘She wouldn’t take the medicine – she didn’t like the taste of it…’ Case08C-Ruth-CareW01 
 
‘…What’s on the pharmacist’s label is what we have to follow... And I can’t accept verbal 
instructions over the phone…Sometimes we can get labels that come in and mum or dad 
have scored out bits which is unacceptable for us as well…You can have various difficulties in 
ensuring that it’s easy for staff to follow and that there’s no grey areas...It’s just about 
ensuring everybody’s clear and making sure that it reads clear on the labels.’ Case02N-Anna-
CareW03 
 
‘The debate is whether we should actually give him it once he’s up and washed and dressed. I 
know he’s meant to get it at 8 o’clock and it’s sometimes a case of…leave him to sleep and 
once he’s wakened and if the bathroom’s busy, give him his meds. Or whether you should 
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say, right – let’s just leave him and once he’s upright. ‘Cause like this morning he had to wait, 
got his meds and then he spewed them all back up again. And you think, well that’s 
defeating the purpose ‘cause how much is still inside you?!’ Case03N-Paul-CareW03 
 
Proposed 
learning 
point #7 
 
The coping skills of adults with mild-moderate LD in relation to medication should 
be developed and maintained by carers, care workers and HCPs; but their potential 
limitations of capability and responsibility remembered. 
 
 
HCPs might improve the medication related experiences of adults with LD by: 
 encouraging the collection of medication from the pharmacy and establishing a relationship 
with the pharmacy staff so that they are another support for the adult with LD and their carers 
or care workers; 
 encouraging carers and care workers to consider enabling an adult with mild-moderate LD to 
self-administer medication under supervision and then, if safe and appropriate, unsupervised; 
 involving adults with mild-moderate LD in medication related decisions, where appropriate; 
 providing medication information in easy-read format, where possible; the University of 
Birmingham has easy-read medication leaflets and accompanying audio recordings for the 
majority of medicines used in behavioural problems (University of Birmingham 2018); 
 retaining awareness that adults with LD may have reduced or variable levels of memory and 
recall and/or limited ability to articulate information, worries and problems and in these 
situations, the involvement of carers or care workers should be encouraged; 
 allowing more time for counselling, using simple terminology, reinforcing key information and 
providing regular review of their medication; 
 checking what prescribed and OTC medication the adult with LD has in their home and what 
they understand it to be for. 
 
‘Ah well, it’s fairly easy now. I’ve been in a daily routine for years now so it’s fairly easy to fit 
in the other ones [medicines]...I’ve been doing this routine so long it’s second nature... Aye, 
I’ve a pretty good idea about what’s effective.’ Case11C-David 
 
‘I keep the same glass and the little medicine cup with the bigger letters, no numbers, so I 
can see how much I am putting in [for lactulose]. ‘Cause I’ve got that little caps that you get 
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on fluoxetine [sic – meant lactulose] bottles and I can hardly see the numbers on that. So the 
bigger [cup] I can read ‘cause their numbers are better.’ Case07C-Fiona 
 
‘At the beginning we did her tablets in the dossette. And as time’s progressed we’ve realised 
that Ruth’s capable of doing more. So we’ve carried on with that over time.’ Case08C-Ruth-
CareW01 
 
10.4 FURTHER WORK 
As noted in Chapter 1, a greater understanding of the experiences of medication of people with LD is 
required (Bell, Kirkpatrick and Alderman 2015; Flood and Henman 2015; Hollins and Tuffrey-Wijne 
2013). This study has begun that conversation and further research will continue to inform HCPs 
how they can provide optimal person-centred care in relation to medication to this group of 
patients. Future research, identified within this research study, might include the validation of the 
proposed learning points suggested in Section 9.5 and then investigating the medication related 
experiences of: children with LD and their carers or care workers; children and adults with LD within 
an acute care setting; and children and adults with LD and their carers or care workers in relation to 
the dose reduction of antipsychotic medication. Such research would continue to build the 
knowledge base of the experiences of medication of people with LD. 
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10.5 CONCLUSION 
Anchored in a pragmatic worldview and using qualitative case study methodology, this programme 
of research has explored the medication related experiences of ten adults with LD living in a 
community setting. Using the PLEM conceptual model, their medication related burden, medication 
related beliefs, and medication taking practice were investigated, documented, collated, and 
analysed. The data were presented in Chapters 3 through to 8 and discussed in Chapter 9. The key 
medication related experiences of community dwelling adults with LD within this study were found 
to be: 
 a  general desensitisation to the burden of medication due to it being perceived as a normal, 
beneficial and necessary part of life; 
 the impact on cognitive ability and mental wellbeing being as an important consideration for 
acceptance of long term medication; 
 the burden from the medication routine itself, and also any change to an established 
routine; 
 adapting the medication regimen and routine to optimise therapy;  
 the social benefits provided by medication;  
 the impact of the medication related beliefs and influence of their significant others, 
including family and carers;  
 a general acceptance of their medication on the condition that there were tangible benefits 
or an absence of significant side effects.   
 
In addition, the carers and care workers of adults with moderate- severe LD noted the transfer of 
medication related burden to themselves. However, they often felt excluded from medication 
related decisions related to the adult with LD that they were caring for. 
 
All these experiences were further considered in this chapter and proposed learning points for HCPs 
were outlined in Table 10.1. Whilst not without its’ limitations, this study it will contribute to the 
evidence base and aid HCPs’ engagement in understanding and improving the medication related 
experiences of community dwelling adults with LD. 
 
10.6 CHAPTER SUMMARY 
This chapter discussed the potential impact of the research, and possible future work identified 
within this research. The chapter also provided a conclusion for the research undertaken and 
presented within this thesis. 
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APPENDICES 
Appendix 2.1 Interview Questions Provided to Participants Before the Interview 
 
 
 
 
 
 
 
You and your medicines 
 
What medicines do you take just now? 
[Take your medicines with you to the interview] 
 
 
 
What is the reason for taking them? 
 
 
 
Have you had to take any other medicines? 
 
 
 
Do you have any other health problems that you don’t take medicines for? 
 
 
Do you have to see the doctor or nurse regularly? Tell me more about this. 
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Organising your medicines 
 
How do you organise your medicines in your home? 
 
 
 
Do you look after your medicines or does someone help you? 
 
 
 
What part(s) of organising and taking your medicines do you find easy? 
 
 
 
What part(s) of organising and taking your medicines do you find hard? 
 
 
Where do you store your medicines? 
 
 
How do you manage your medicines if you are going out on a day trip or on 
holiday?  
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Remembering to take your medicines 
 
How do you remember to take your medicines? 
 
 
What do you do if you forget? 
 
 
 
 
 
 
 
 
How medicines affect your life 
 
How do you think your medicines(s) affect your life in good ways?  
 
 
 
How do you think your medicines(s) affect your life in bad ways?  
 
 
 
Have you ever had a row or got cross about having to take your medicines 
with your carers or family? 
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How do you manage your medicines if you are going out on a day trip or on 
holiday?  
 
 Side Effects 
Every medicine is given for a particular reason (e.g. to stop your knee from 
hurting). However, medicines can also end up doing things we don’t always 
want them to do. So they might stop your knee from hurting but then they 
cause your stomach to hurt or your skin to itch. These are called side effects. 
 
Do you think any of your medicines have ever caused you side effects? 
 
 
 
 
 
 
Taking your medicines 
 
How do you feel about having to take regular medicines?  
 
 
Why do you choose to take your medicine? 
 
 
 
Why do you choose not to take any medicine? 
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Do you ever change when or how you take your medicines? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Have you ever experienced any of the following problems with medicines? 
 
Complicated instructions on your medicines  
 
Example:   “Five tablets in the morning reducing by one tablet every other 
week until taking one tablet in the morning then take one tablet alternate 
days for two weeks” 
 
 
 
Too many medicines to manage 
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Size of tablet  
– too big?  
– too small? 
 
 
Shape of tablet  
- Hard to swallow? 
 
 
Colour of tablet 
- Hard to see? 
- Keeps changing? 
 
 
Taste of medicine 
 
 
 
The box my medicine comes in looks different each time 
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I have different medicines that come in similar looking boxes 
 
 
 
It is hard to get the medicine out of the packaging  
 
 
 
Other? 
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Pharmacists and pharmacies 
 
Do you collect your medicine from the pharmacy?  
 
 
 
Do you speak to anyone working in the pharmacy? 
 
 
 
Have you ever discussed your medicine(s) with your pharmacist?  
 
 
 
Is it easy to go into a pharmacy and ask the pharmacist about your 
medicines? 
 
 
 
Who gives you advice on your medicine? 
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Appendix 2.2 A Priori Coding from PLEM Conceptual Model  
MEDICATION RELATED BURDEN 
Code Description Sub-
Code 
Description  
MRB-
ROUT 
Medicine ROUTINES A General strategies to manage med routines 
B Time required to manage meds 
C Adapting life to suit med routine (intentional) 
D Adapting life to suit med routine (unintentional) 
E Adapting med routine to suit life (intentional) 
F Adapting med routine to suit life (unintentional)  
X Other 
 
MRB-
CHAR 
Medicine 
CHARACTERISTICS  
A Complexity of the number of medicines 
B Pill size and shape 
C Exchange of medication brands 
D Challenges of packaging  
E Additional instructions  
X Other 
 
MRB-
ADVE 
ADVERSE EVENTS  A No experience/not recognised 
B Previous negative experience  
C Anxiety of future occurrence  
D Impact on belief & behaviour  
X Other 
 
MRB-
SBURD 
SOCIAL BURDEN from 
medicines 
A Meds impacting social life (positive) 
B Meds impacting social life (negative)  
C Influence of ‘significant others’ re: meds (positive) 
D Influence of ‘significant others’ re: meds (negative)  
E Stigma from meds use 
X Other 
 
MRB-
HBURD 
HEALTHCARE BURDEN 
from medicines 
A Time spent dealing with healthcare 
appts/services/issues to get medicines 
B Practicalities of accessing/obtaining/adhering to 
medicines 
C Inadequate/conflicting/contradicting meds 
information 
D Lack of consideration for patient’s lived experience 
from health care professionals 
E Lack of continuity/co-ordination of prescribing  
X Other 
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MEDICATION RELATED BELIEFS  
 
Code Description Sub-
Code 
Description  
BEL-
PEER 
FAMILY, PEERS, HEALTHCARE PROVIDERS (Normative beliefs) 
 
BEL-
SKILL 
MAGNITUDE/INTENSITY 
of medication related 
burden & COPING 
SKILLS 
(Control beliefs) 
A Intensity of medication related burden 
B Self-awareness of coping skills  
C Ability to develop problem solving strategies 
D Lack of meds information  
E Lack of comprehension  
F Unmet need/expectation  
G Response to negative aspects of medicines 
X Other 
 
BEL-
ATTIT 
GENERAL ATTITUDE   A Weighing up the burden and benefits 
B Controls illness/disease 
C Hope 
D Prevents consequences of illness/disease 
E Allows them to fulfil social roles  
F Negative past experience 
G Lack of perceived desired outcomes 
H Preconceived negative attitudes  
X Other  
 
PRA: MEDICATION TAKING PRACTICE  
 
Code Description Sub-
Code 
Description  
PRA-
ACCEPT 
ACCEPTING medicines A Unconditional  
B Forced into it by underlying illness 
C Aiming to please family 
D After experiments/consequences non-adherence 
X Other 
 
PRA-
ALTER 
MODIFYING/ALTERING 
medicines  
A Intolerable medicine related burden 
B To evaluate effect of own meds/discover optimal 
doses 
C Lack of perceived outcome 
D Fear of potential side effects  
E Peer pressure  
X Other 
 
 197 
Appendix 2.3 Participant Information Sheet (LD)  
 
 
Exploring the medication related experiences 
of adults with learning disabilities. 
 
  
 
 
 
 
 
 
 
 
PARTICIPANT 
INFORMATION 
SHEET 
 
 
 
Dear  
You are invited to take part in a research study to find out about 
your experience of taking regular medication.  
Please read this letter so you understand why the research is being 
done and what it will involve.  
If anything is unclear, or if you would like more information, please 
just ask. 
 
 
 
Who is the researcher? 
My name is Joan and I am a pharmacist who 
works in Aberdeen.  
I am also studying at the Robert Gordon 
University. 
 
 
 
What is the purpose of the study? 
To find out more about people with learning 
disabilities’ experience of taking regular 
medication. 
 
 
Researcher:   Joan MacLeod  
  
 email: j.m.macleod1@rgu.ac.uk  
 phone: xxxxxx 
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Why have I been chosen? 
I asked local Care Providers to think of people 
with learning disabilities who take regular 
medication and who might want to take part.  
 
 
Do I have to take part? 
You only have to take part if you want to. 
You can pull out at any time without giving a 
reason. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What will happen if I take part? 
 
   With your permission I will: 
 
 come to your home 
 
 look at your medicines and take a photo 
of them 
 
 ask you some questions about your 
medicines 
 
 use a tape recorder to record your 
answers 
 
 write some notes 
 
 arrange to speak to any family members 
and carers who help you with your 
medicines 
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If you have formal (paid) carers I will also look 
at the records they keep in relation to your 
medicines and make some notes. 
 
 
When will this happen? 
The day and time will be agreed with you and 
any carer(s) or family. 
 
 
 
 
Is this an exam? 
No – this is not an exam. 
I just want to hear your views on your 
medicines. 
There are no right or wrong answers. 
 
 
No change to your 
medicines 
 
You are a pharmacist - will you change my 
medicines?   
No - but if I see a problem with your 
medicines I will help arrange for you (or your 
carer) to speak with your doctor. 
 
 
 
What are the possible benefits of taking 
part? 
There is no direct benefit to you but 
hopefully you will enjoy speaking with me. 
It is possible that the findings will allow 
pharmacists, doctors and carers to help other 
people with learning disabilities in the future 
 
 
 
Will my contribution to this study be kept 
confidential?  
Yes - but it is okay for you to talk about it. 
Your name (or any information that would 
identify you) will not be used in any report. 
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Only if you tell me about something bad that 
is happening to you will I tell someone. This is 
so that they can help you. 
 
 
 
 
What will happen to the results of the 
research study? 
I will send you a short report of the findings. 
The full findings of the study will be written 
up as a report for the Robert Gordon 
University.  
The findings may also be published in a 
health care journal and presented at a 
conference.  
 
 
 
 
 
Who is organising and funding the research? 
I am organising this research as part of my 
Doctorate of Professional Practice at the 
Robert Gordon University. 
It is funded by NHS Education for Scotland 
(NES) and Pharmacy Research UK (PRUK). 
 
 
 
 
Who has reviewed the study? 
The wording of this information sheet and 
the consent form have been reviewed by 
CASPA, the Chair of Aberdeen and 
Aberdeenshire’s Learning Disability Group,  
and the Robert Gordon University’s ethical 
review panel. 
 
The aims and intentions of the study have 
been reviewed by academic experts and 
approved by the Robert Gordon University’s 
ethical review panel. 
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What do I do now? 
 Talk to your friends or family or carers 
about this and show them the 
information.  
 Let them know if you would like to take 
part or not. 
 I will then get back in touch and get a 
consent form completed. 
 
 
Thank you for your time and consideration in reading this 
information sheet.  If you have further questions about this study 
please contact me on: 
 xxxxxx        j.m.macleod1@rgu.ac.uk   
 
Joan MacLeod, Pharmacist and Research Student, RGU 
 
Supervisors: Dr Katie MacLure k.m.maclure@rgu.ac.uk  
        Prof Derek Stewart d.stewart@rgu.ac.uk  
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Appendix 2.4 Consent Form (LD)  
 
 
Exploring the medication related experiences 
of adults with learning disabilities. 
 
  
 
 
 
 
 
 
 
 
CONSENT 
FORM 
 
 
 
 
Area of Consent 
 
Participant 
tick/initials 
Carer 
(advocate) 
initials  
 
 
 
 
 
 
 
 
The researcher has: 
 described the study to me  
 left me written information 
v1.3 dated 15thJuly2016 
 asked me if I had any 
questions 
 answered any questions I 
had 
 
 
 
 
  
 
Researcher:   Joan MacLeod  
  
 email: j.m.macleod1@rgu.ac.uk  
 phone:  xxxxxx 
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I understand that I only need to 
take part if I want to and I can 
change my mind at any time. 
 
 
 
  
 
 
 
 
 
 
 
 
 
I am happy for the researcher to 
 see my medicines and take a 
photo of them 
 ask me questions about my 
experience taking medicines 
 record my answers  
 take notes  
  [If applicable] read the 
notes my carers keep about 
my medicines 
 speak to my carers and/or 
family about their 
experience of my medicines 
  
 
 
I understand that my name (or any 
information that would identify 
me) will not be used in any report, 
journal article or conference. 
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The researcher has confirmed that 
everything I say is confidential 
UNLESS the researcher knows that 
she has to tell someone to keep me 
safe and well. 
 
  
 
I understand that there may be a 
need for information collected by 
the researcher to be seen by a 
regulatory authority (e.g. Local 
Authority; RGU exam board)  
 
 
  
AGREEMENT TO PARTICIPATE IN RESEARCH  
 
 Name Signature Date  
Participant   
 
  
Witness  
 
  
Researcher  
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Appendix 2.5 Guardian Information Sheet 
 
Exploring the medication related experiences 
of adults with learning disabilities. 
 
  
 
 
 
 
 
 
 
RELATIVE/ WELFARE 
GUARDIAN INFORMATION 
SHEET 
 
 
 
Dear [relative/ welfare Guardian] 
 
You are being invited to consider giving your permission for your relative to take part in a 
research study. The study explores the impact of medication on the lives of people with 
learning disabilities and their carers (formal and unpaid).  Please read this information 
sheet so you understand why the research is being done and what involvement would be 
required. If anything is unclear, or if you would like more information, please just ask. 
 
 
What is the purpose of the study? 
I [Joan] am a pharmacist and am interested in finding out about the experiences of 
people with learning disabilities with their regular medication. I am doing this by 
generating case studies of 6 -10 individuals with learning disabilities. In each case study I 
plan to detail the medication related experiences of that individual.  
 
 
Why has your relative been chosen? 
Care and Support Providers Aberdeen (CASPA) were approached by myself to identify 
people with learning disabilities on regular medication who may be suitable for 
inclusion in the study. Your relative was one of the clients identified but they lack the 
capacity to make an informed decision about whether they can take place in a research 
study.  I am therefore asking you as their nearest relative/welfare Guardian if you will 
give consent on their behalf to join this study. This is permissible under the Adults with 
Incapacity (Scotland) Act 2000. 
 
 
 
 
Researcher:    
Joan MacLeod  
 
Email: 
j.m.macleod1@rgu.ac.uk
  
Phone: XXXXXX 
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Does my relative have to take part? 
Taking part is voluntary. It is up to you to decide whether they are included within the 
study. If you do agree that they can be part of the study, you are free to change your 
mind at any time and without giving a reason. This will not alter their care in any way, 
now or at any stage in the future. 
 
What will happen to your relative if they take part? 
 I will arrange to visit your relative in their home in order to record their current 
medication and storage/administration arrangements – this will be in the 
presence of a carer (formal or unpaid). 
 If formal carers are involved, records relating to medication administration will 
be accessed (with the consent of the care provider) 
 Their carers will be interviewed (interview questions attached) 
 
 
Can I participate in the research? 
If you have current or past experience of managing the medication for your relative 
and/or seeing the impact on them then your participation would be most welcome - 
this can be noted on the consent form. 
  
 
Will the research result in changes to my relative’s medication? 
Although I am a pharmacist, I am not wishing to access medication information with the 
purpose of undertaking a medication review. 
However, if in the course of the research I notice an issue (or an issue is highlighted to 
me) I will ensure that you and any formal carer are made aware and that appropriate 
action is then taken (e.g. appointment made with the GP). 
 
 
What are the possible benefits of taking part? 
There is very little known about the impact medication can have on the lives of people 
with learning disabilities and their carers. It is possible that the findings will allow 
pharmacists, doctors and carers to better help other people with learning disabilities in 
the future. 
 
There is no direct benefit to the individual participants. However, I hope that all the 
participants will enjoy the experience of being involved with, and contributing to, local 
research.  
 
Will our contribution to this study be kept confidential?  
 
All the information collected during the course of the research will be kept confidential. 
All raw data will only be stored in password protected files within the Robert Gordon 
University. Once the data is anonymised the information will be held on the 
researcher’s laptop in password protected files until the thesis is completed. At this 
stage it will be deleted from the researcher’s laptop.  
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All participants’ responses will be anonymised. 
 
Confidentiality will only ever be breached is if any information indicating an adult 
protection issue is revealed. As required by law, adult protection concerns would be 
passed on to a suitable manager of the formal Care Provider organisation and/or the 
appropriate Local Authority’s Adult Protection team who would then assess the 
situation. After discussion with yourself and other relevant parties, a decision would be 
reached about the appropriateness of including some or all of the data gathered in the 
case study or whether the person (and therefore all associated data) should be 
withdrawn from the study. 
 
 
 
What will happen to the results of the research study? 
 I will send you a short report of the findings.  
 The full findings of the study will become the researcher’s thesis and selected 
sections may be published in a health care journal and presented at a 
conference.  
 
 
Who is organising and funding the research? 
I am doing this research as part of my Doctorate of Professional Practice at the Robert 
Gordon University which is funded by NHS Education for Scotland (NES) and Pharmacy 
Research UK (PRUK). 
 
 
Who has reviewed the study? 
 The wording of this information sheet and the consent form has been reviewed 
by CASPA and the Robert Gordon University’s ethical review panel. 
 The aims and intentions of the study have been reviewed by academic experts 
and approved by the Robert Gordon University’s ethical review panel. 
 
 
What if there is a problem? 
If you have any concern about this study and/or the researcher please contact: 
Dr Katie MacLure (Senior Research Fellow and Lecturer) 
School of Pharmacy and Life Sciences 
Robert Gordon University -Aberdeen  
k.m.maclure@rgu.ac.uk  
xxxxxx 
 
Thank you for your time and consideration in reading this information sheet.  If you have further 
questions about this study please contact me on xxxxxx or j.m.macleod1@rgu.ac.uk   
 
 
Supervisors:Dr Katie MacLure k.m.maclure@rgu.ac.uk ; Prof Derek Stewart d.stewart@rgu.ac.uk  
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Appendix 2.6 Guardian Consent Form 
 
 
 
Exploring the medication related experiences 
of adults with learning disabilities. 
Researcher:   Joan MacLeod   
Email: j.m.macleod1@rgu.ac.uk  
Phone:  xxxxxx 
RELATIVE/WELFARE 
GUARDIAN CONSENT 
FORM 
 
Area of Consent Initials 
1. I confirm that I have read the information sheet v1.2 dated 
11thOct2016for the above named study. I have had the 
opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
 
2. I understand that participation in this study is voluntary and 
that I am free to withdraw my relative/ward from the study at 
any time, without giving any reason, without my or their care 
or legal rights being affected 
 
 
3. I understand that the researcher will be: interviewing carers 
involved in the care of my relative; accessing my relative’s 
medication; accessing any medication records kept by formal 
carers (with their consent) for my relative; taking a photo of 
the medicines and how they are organised. In addition, data 
collected during the study may be looked at by the researcher 
and her supervisors and I grant them permission to do so. 
 
 
4. I understand that anonymised data from the study may be 
looked at by regulatory authorities (e.g. Local Authority; RGU 
Exam Board) if appropriate. 
 
 
5. I understand that data collected during the study will be used 
for research purposes including publication of anonymised 
findings and quotations. I grant copyright permission on the 
understanding that the confidentiality of my relative will be 
protected. 
 
 
6. I agree to allow my relative to be included in the study. 
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I would like to be interviewed as part of the research study:    YES / NO 
 
If yes, please provide details of how you would prefer to be contacted below: 
 
 
Please now complete the appropriate section  
 
 
For Relatives 
I confirm that as [insert relationship]  
……………………………………………………………………………………………                                                                                   
I am the nearest relative for [insert name of person] 
……………………………………………………………………. 
and that no other nearest relative or welfare Guardian exists. 
 
Name: 
 
Date: 
Signature:  
 
Contact Number: 
 
 
For Welfare Guardians 
I confirm that I am the welfare Guardian for [insert name of person] 
……………………………………………………………………………………………………………. 
 
Name: 
 
Date: 
Signature:  Contact Number: 
 
 
 
Researcher Signature: 
 
 
Date: 
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Appendix 2.7 Carer Information Sheet 
 
 
 
Exploring the medication related experiences 
of adults with learning disabilities. 
 
  
 
 
 
 
 
 
 
CARER  
(Formal or Unpaid)  
INFORMATION SHEET 
 
 
 
Dear [carer name] 
 
You are invited, as the carer of a person with learning disabilities, to take part in a 
research study to find out about the impact of regular medication on the lives of people 
with learning disabilities and their carers (formal and unpaid). Please read this letter so 
you understand why the research is being done and what involvement would be required. 
If anything is unclear, or if you would like more information, please just ask. 
 
 
 
What is the purpose of the study? 
I [Joan] am a pharmacist and am interested in finding out about the experiences of 
people with learning disabilities with their regular medication. I am doing this by 
generating case studies of 6 -10 individuals with learning disabilities. In each case study I 
plan to detail the medication related burden, the medication related beliefs and 
medication taking practice of that individual.  
 
 
Why have I been chosen? 
You are/were a regular carer for one of the people with learning disabilities included in 
this study.  
  
 
 
 
 
Researcher:   Joan 
MacLeod  
Email: 
j.m.macleod1@rgu.ac.
uk  
Phone:  XXXXXX 
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Do I have to take part? 
Taking part is voluntary. If you do agree to take part, you are free to change your mind 
at any time and without giving a reason.  
 
 
What will happen if I take part? 
 I will interview you with regards to your experiences of your client/relative’s 
experience with medication (questions attached) 
 If your client/relative has capacity, you may be asked to be present [as an 
advocate] while I interview your client/relative  
 Formal Carers: Only information relating to the individual participating will be 
requested and included in the study i.e. you will not be asked to provide 
information on other clients in your service. 
 
 
Will the research result in changes to the person’s medication? 
Although I am a pharmacist, I am not wishing to access medication information with the 
purpose of undertaking a medication review. However, if in the course of the research I 
notice an issue (or an issue is highlighted to me) I will ensure that the person and their 
primary carer is made aware and that appropriate action is then taken (e.g. 
appointment made with the GP). 
 
 
What are the possible benefits of taking part? 
There is very little known about the impact medication can have on the lives of people 
with learning disabilities and their carers. It is possible that the findings will allow 
pharmacists, doctors and carers to better help other people with learning disabilities in 
the future 
 
There is no direct benefit to the individual participants and to you as an organisation. 
However, I hope that all the participants will enjoy the experience of being involved 
with, and contributing to, local research.  
 
 
Will our contribution to this study be kept confidential?  
 
All the information collected during the course of the research will be kept confidential. 
All raw data will only be stored in password protected files within the Robert Gordon 
University.  
 
Once the data is anonymised the information may also be held on the researcher’s 
laptop in password protected files until the thesis is completed. At this stage it will be 
deleted from the researcher’s laptop.  
 
All participants’ responses will be anonymised. 
 
 212 
Confidentiality will only ever be breached if current or previously unknown adult 
protection issue(s) are revealed and/or the safety of the person was at risk.  
 
As required by law, adult protection concerns would be passed on to a suitable manager 
of the formal Care Provider organisation and/or the appropriate Local Authority’s Adult 
Protection team who would then assess the situation. After discussion with all relevant 
parties, a decision would be reached about the appropriateness of including some or all 
of the data gathered in the case study or whether the person (and therefore all 
associated data) should be withdrawn from the study. 
 
 
What will happen to the results of the research study? 
 I will send you a short report of the findings.  
 The full findings of the study will become my doctoral thesis and selected 
sections may be published in a health care journal and presented at a 
conference.  
 
 
Who is organising and funding the research? 
I am doing this research as part of my Doctorate of Professional Practice at the Robert 
Gordon University which is funded by NHS Education for Scotland (NES) and Pharmacy 
Research UK (PRUK) are funding the research. 
 
 
Who has reviewed the study? 
 The wording of this information sheet and the consent form have been reviewed 
by CASPA and the Robert Gordon University’s ethical review panel. 
 The aims and intentions of the study have been reviewed by academic experts 
and approved by the Robert Gordon University’s ethical review panel. 
 
 
What if there is a problem? 
If you have any concern about this study and/or the researcher please contact: 
Dr Katie MacLure (Senior Research Fellow and Lecturer) 
School of Pharmacy and Life Sciences 
Robert Gordon University -Aberdeen  
k.m.maclure@rgu.ac.uk  
 
 
Thank you for your time and consideration in reading this information sheet.  If you 
have further questions about this study please contact me on  XXXXXX  or 
j.m.macleod1@rgu.ac.uk   
 
 
Supervisors: Dr Katie MacLure k.m.maclure@rgu.ac.uk ; Prof Derek Stewart 
d.stewart@rgu.ac.uk  
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Appendix 2.8 Carer Consent Form 
 
 
 
 
Exploring the medication related experiences 
of adults with learning disabilities. 
 
 
Researcher:   Joan MacLeod   
Email: j.m.macleod1@rgu.ac.uk  
Phone: XXXXXX 
 
 
CARER (FORMAL OR 
UNPAID) CONSENT 
FORM 
 
Area of Consent 
 
Initials 
1. I confirm that I have read the information sheet v1.2 dated 
11thOct2016for the above named study. I have had the opportunity 
to consider the information, ask questions and have had these 
answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw from the study at any time, without giving any reason, 
without my care or legal rights being affected 
 
3. I understand that data collected during the study may be looked at 
by the researcher and her supervisors and I grant them permission 
to do so. 
 
4. I understand that data from the study may be looked at by 
regulatory authorities (e.g. Local Authority; RGU Exam Board) if 
appropriate. 
 
5. I understand that data collected during the study will be used for 
research purposes including publication of anonymised findings and 
quotations. I grant copyright permission on the understanding that 
my confidentiality will be protected. 
 
6. I agree to take part in the study.  
 
 Name Signature  Date  
Participant    
Researcher    
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Appendix 3.1 CASE 01N - PILOT 
 
Case01N-Pilot is a 46-year old Caucasian male who has severe LD. He is described by his carer as 
having profound and multiple learning disabilities (PMLD). He is deaf and non-verbal as a result of 
Usher syndrome and requires help with all tasks of daily living. He is also diagnosed with epilepsy.  
 
His carer was willing to participate in the research but the care workers were unable to participate 
throughout the duration of the planned fieldwork. The interview was therefore used as a pilot for 
the interview schedule and the data not included in the study. No further information was obtained. 
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Appendix 3.2 CASE 02N - ANNA 
 
Personal Details 
Anna is a 26-year-old Caucasian female who has severe LD and is almost non-verbal. She was 
diagnosed with Global Development Delay of unknown cause as a baby. Although she is 
independently mobile she requires help with all tasks of daily living. She alternates month about 
between living with her parents and living in a respite home with around the clock care worker 
support.  Her carers/care workers gave the following descriptions of her: cheeky monkey; 
understands more than we give her credit for; happy; content; sweet; child-like; likes to help; 
sometimes difficult to interpret; knows what she wants from her life. 
 
Medical History 
 
Active Medical Conditions Comments/Notes 
Epilepsy (tonic-clonic) 
 
 First seizure at 9 months; started properly age 5-6 years 
 Seizure frequency is increasing (~3 per month) 
 
Dysplasia of front temporal lobe 
(stroke damage) and right-sided 
weakness 
 
 Diagnosed at 9 years of age 
 A scarred area in the left temporal lobe is the focal point for her seizures but 
as she has prolonged seizures, the area of damage gets bigger 
 
 
Past Medical Conditions Comments/Notes 
Dental extractions  
Pityriasis versicalor  
 Urinary tract infections  
 
Medication History  
 
Current Prescribed Medication Indication Comments/Notes 
Midazolam (Epistatus) 10mg/ml 
oromucosal solution 
1ml as per protocol 
Acute epileptic 
seizure 
 To be given as detailed in her care plan 
 See Case02NPhoto01 and Case02Nphoto02 for 
excerpts of that care plan 
 
 
Case02Photo01: Midazolam careplan-01   
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Case02Photo02: Midazolam careplan-02 
Lamotrigine (Lamictal) dispersible 
tablets 
250mg (2x100mg + 2x25mg) 
morning and night 
 
Epilepsy  
Topiramate (Topamax) 100mg 
tablets 
One in the morning and night 
Epilepsy  Case02N Letter from neurologist 2012 (in care 
workers’ file): ‘She has been topiramate at higher 
doses in the past (200mg BD) but by that dose we felt 
it was affecting her cognition…’ 
 Also, querying side-effect of hair loss 
Lacosamide (Vimpat) 200mg 
tablets 
One in the morning and night 
 
Epilepsy  
Evra patch  
(ethinylestradiol 33.9 microgram 
per 24h + norelgestromin 203 
microgram per 24h) 
One patch weekly for 3 weeks 
then one week patch free 
 
Control of menstrual 
cycle 
 Addition of Evra adversely affected epilepsy control 
 Led to the addition of topiramate and lacosamide 
Fluticasone furoate (Avamys) 
27.5 micrograms/dose nasal 
spray  
Two sprays in the morning 
 
Sinus problems  
Duraphat (fluoride 5000 ppm) 
toothpaste 
Use morning and night 
 
To strengthen tooth 
enamel 
 
Paracetamol 250mg/5ml 
suspension  
20ml when required up to four 
times a day 
 
Pain  
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Past Prescribed Medication Indication Comments/Notes 
Diazepam rectal tubules Acute epileptic 
seizure 
 Replaced by midazolam 
Phenytoin Epilepsy  Case02N Letter from neurologist 2012 (in care 
workers’ file): ‘…when she was given phenytoin 
[Anna] became very flushed’ 
Carbamazepine (Tegretol) Epilepsy  Stopped as it was ineffective 
Sodium Valproate (Epilim)  Epilepsy  Stopped because of side-effects: increased terror and 
fear 
Levetiracetam (Keppra) Epilpesy  Controlled the epilepsy but had to be stopped 
because of side-effects: increased anxiety, agitation, 
anger 
Antibiotics Infections  
Ibuprofen liquid Short term 
pain/fever 
 
Tramadol Impacted wisdom 
teeth/extraction 
 Abrupt withdrawal caused behavioural problems that 
resulted in short term use of riperidone 
 Case02N Letter from neurologist 2011 (in care 
workers’ file): ‘…mum said to me that she thought 
she knew what had caused [Anna]’s extreme 
breakdown in behaviour… rapid withdrawal of 
tramadol and dihydrocodeine’ 
Dihydrocodeine Impacted wisdom 
teeth/extraction 
Risperidone  Breakdown in 
behaviour 
 Associated with rapid withdrawal of tramadol and 
dihydrocodeine 
Miconazole shampoo  Pityriasis versicalor  Used as a lotion on the body. Left on overnight 
according to prescriber’s instructions but caused 
serious skin irritation 
Fexofenadine tablets Skin sensitivity from 
miconazole  
 Used until skin desensitised 
Doublebase gel Skin sensitivity from 
miconazole  
 Used until skin desensitised 
Clotrimazole (Canesten) 1% 
cream 
 
Sweat rash under the 
breasts 
 Care workers used a topical product aide memoire to 
help administration – see Case02NPhoto03 
 
 
Case02NPhoto03: Topical product aide memoire 
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Over the Counter (OTC) 
Medication 
Indication Comments/Notes 
Paracetamol 250mg/5ml 
suspension (Calpol Six Plus)  
20ml when required up to four 
times a day 
Pain  Care workers require written permission from GP to 
administer any paracetamol that was not prescribed – 
see Case02NPhoto04 below 
 
 
Case02NPhoto04: GP authorisation to administer bought 
paracetamol suspension  
Simple Linctus Sore throat/cough 
and cold 
 Care workers require written permission from GP to 
administer any simple linctus that was not prescribed 
– see Case02NPhoto05  
 
 
Case02NPhoto05: GP authorisation to administer bought 
simple linctus 
 
Medication Management  
 
Ordering of prescriptions  Parents order repeat prescriptions 
Taking prescriptions to 
pharmacy  
 Local pharmacy collects repeat prescriptions from surgery 
 Parents or care worker would take acute prescription to pharmacy 
Collecting medication 
from pharmacy 
 Parents or care worker collect medication from local pharmacy 
Administration  Responsibility for administration lies with parents when at home and with care 
workers when in respite home 
 Care workers are required to have Medication Administration Record (MAR) charts to 
record all administration – see Case02NPhoto06 
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Case02NPhoto06: Medication administration record chart  
 Midazolam has a specific protocol for administration – see Case02Photo01 and 
Case02Photo02 
 
Storage in family home  Extra boxes of medicines are stored in a kitchen cupboard above the worktop and the 
medicines in use are stored on the kitchen window sill - see Case02NPhoto07 and 
Case02NPhoto08 
 
 
Case02NPhoto07: Storage of extra medicines at home (kitchen cupboard)   
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Case02NPhoto08: Storage of medicines in use at home (kitchen window sill)   
 
Storage in respite home  Medication is stored in Anna’s bedroom in a locked cabinet – see Case02NPhoto09 
 
 
Case02NPhoto09: Storage of medicines in respite home (bedroom cupboard) 
Other Travel bag for emergency midazolam – see Case02NPhoto10. 
 
 
Case02NPhoto10: Travel bag for emergency midazolam  
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Appendix 3.3 CASE 03N - PAUL 
 
Personal Details 
Paul is a 31-year-old Caucasian male who has profound and multiple learning disabilities (PMLD) as a 
result of oxygen deprivation at birth. He is visually impaired, non-verbal and unable to mobilise 
independently. He lives in a small residential unit with other adults with PMLD where there is 
around the clock care. His care workers gave the following descriptions of him: cheeky; 
unpredictable; challenging; vocal; charming; lovable; sad scamp; complicated; frustrating; knowing – 
he knows what is going on. 
 
Medical History  
 
Active Medical Conditions Comments/Notes 
Cerebral Palsy  Has contractures which are painful 
 
Behavioural problems –
agitation/rage, screaming 
vocalisation, making himself sick  
 At the point of data collection, Paul’s behavioural problems were of such a 
severity, it was putting his placement at risk 
 There were concerns that if he was hospitalised and in a shared ward 
environment he would require to be heavily sedated for his own wellbeing 
and to allow staff to cope 
 Case03N Letter from Clinical Psychologist, 2013 (in care workers file): 
‘[Paul]’s level of learning disability means that he requires a clear and 
predictable routine…Constipation can be linked to challenging behaviour…It 
is unlikely that his behaviour is caused by one factor’ 
Reflux/vomiting  His reflux/vomiting was so severe that a PEG tube required to be inserted 
for feeding 
 Despite the PEG tube, Paul still vomits 
 Staff had kept a record of the number of instances of vomiting in the last 8 
months: March (11); April (13); May (16); June (15); July (20); August (8); 
September (17); October (9) 
 The vomit varies in volume; often just a small amount of phlegm; 
sometimes blood present 
 Sometimes the vomiting is linked to agitation; Paul often calms down 
quickly afterwards 
 There were four recorded instances of medicines being visible in the vomit 
in the last eight months 
 Case03N Email from Dietician, 2016 (in formal care workers file): ‘The 
reason he is NBM [nil by mouth] in the first place is because of the 
reflux/agitation.’ 
Has PEG (percutaneous endoscopic 
gastrostomy) tube in situ  
 Paul is fed overnight (Nutrison) and has all his medication administered via 
the PEG tube except for his Gaviscon which is administered orally 
Constipation 
 
 
Heart valve problems 
 
 
 
Past Medical Conditions Comments/Notes 
None mentioned   
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Medication History 
 
Current Prescribed Medication Indication Comments/Notes 
Omeprazole 40mg dispersible tabs 
One at breakfast and bedtime via PEG tube 
 
Reflux  
Gaviscon Advance liquid 
20ml up to four times daily ORALLY 
Reflux  From the administration records, 
it is nearly always given in the 
morning and at bedtime and 
given ~33% of the time at lunch 
and tea times. 
Macrogol (Laxido) sachets 
One sachet at breakfast and bedtime via 
PEG tube 
 
Constipation  
Paracetamol 500mg soluble tabs 
One or two tablets up to four times a day 
when required via PEG tube 
 
Pain/fever  Rarely required 
Risperidone 1mg/ml liquid 
1ml at breakfast and bedtime via PEG tube 
Behavioural issues  Paul’s behaviour has been a 
serious issue for ~10 years 
 
Baclofen 10mg tabs 
Half a tablet three times daily via PEG tube 
Cerebral palsy – contractures 
and muscle spasticity 
 New – had only been started on 
this a month previously 
 
 
Past Prescribed Medication Indication Comments/Notes 
Fluoxetine 
 
Depression  
Haloperidol  Behavioural issues  Stopped because of side effect 
of profuse sweating and no 
benefit to behaviour 
Diazepam liquid  
(as part of a wider de-escalation procedure) 
 
Behavioural issues 
 
 
 Case03N Letter from Consultant 
Psychiatrist 2016 (in formal care 
workers file): ‘Currently on 
diazepam 4mg a day…staff 
however reported that the 
introduction of diazepam has not 
made much of a difference…nor 
the recent increase in the dose of 
risperidone.’ 
Domperidone  
 
Reflux  
Laxative suppositories 
 
Constipation  
Senna liquid 
 
Constipation  
Cocodamol dispersible tablets 
 
Pain   
 
Over the Counter (OTC) Medication Indication Comments/Notes 
None    
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Medication Management  
 
Ordering of prescriptions  Manager or depute manager are responsible for ordering, organising and 
collecting all medication 
 
Taking prescriptions to 
pharmacy  
Collecting medication from 
pharmacy 
Administration  All care workers are trained to administer Paul’s medicines via his PEG tube (and 
Gaviscon orally) 
 Senior care workers will train new care workers; information resources available 
in Paul’s folder – see photo Case03NPhoto1 
 
 
Case03NPhoto01: Information available to care workers (PEG administration) 
 
 Written protocol for administration of ‘when required’ medicines availabe to 
carers – see Case03NPhoto2 
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Case03NPhoto02: ‘When required’ medicine protocols  
Storage  All medicines in use are stored in a locked cabinet in Paul’s room – see 
Case03NPhoto3 
 If there is any excess medication, it is stored in a locked cabinet in the general 
office 
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Case03NPhoto03: Medicine storage (bedroom)  
Other  
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Appendix 3.4 CASE 04N - JAMIE 
 
Personal Details 
Jamie was a Caucasian male who had PMLD; at the time of his death he was 21 years of age. He was 
adopted at the age of 8 months and lived with his adoptive parents (his primary carers) all his life. 
His regular care worker also acted as his Citizen Advocate.  His carer and care worker gave the 
following descriptions of him: a people person; insightful and understanding; he soothed people and 
he made people feel good in his company; loving; caring.  
 
Medical History 
 
Active Medical Conditions Comments/Notes 
Quadriplegic cerebral palsy   Loss of muscle tone; contractures; dystonia (occasional); scoliosis; instances 
of aspiration; excess salivation 
 His distorted body shape exacerbated health issues 
Epilepsy (absence, partial and tonic-
clonic) 
 
 Had seizures from birth 
Chronic gastrointestinal issues 
including: gagging, reflux and 
constipation.  
[PEG tube in situ] 
 Serious digestive issues from birth and feeding as a young child was a slow 
process 
 A PEG tube was put in place age 6 years – from this point all medicines 
were given via the PEG tube 
 Fundoplication occurred age 6years and was repeated again later in life 
Asthma and general breathing 
problems from scoliosis 
 Nearer the end of his life, Jamie required oxygen and a continuous positive 
airways pressure (CPAP) ventilator 
 
Hayfever   
 
Carnitine deficiency   Diagnosed in his teens 
 
Electrolyte imbalance 
 
 
Excess salivation 
 
 
Kidney stones  Had regular scans 
 
 
Past Medical Conditions Comments/Notes 
Widespread herpes infection age 6 
years 
 
 Caused gastro-intestinal ulceration which confirmed the requirement for a 
PEG tube 
 
Depression   Circles of discontent – physical illness affecting mental wellbeing which 
then causes increased physical illness 
 Caused restless sleep 
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Medication  
 
Regular Prescribed Medication  
(in last 3 months of life) 
Indication Comments/Notes 
Sodium Valproate (Epilim) 100mg crushable tablets 
5 tablets twice daily via PEG tube 
 
Epilepsy  Allergic to the red dye in Epilim 
liquid 
 
Clonazepam 500mcg tabs  
2 in the morning and 1 at night via PEG tube 
Epilepsy  Had reduced down to this dose 
 Stopping had been unsuccessful 
 
Midazolam (Epistatus) 10mg/ml oromucosal solution  
1ml as per protocol when required 
Epilepsy  Had trialled original formulation 
of midazolam but the 
dose/delivery caused 
bradycardia 
Omeprazole (Losec) 40mg MUPS tablets 
One in the morning via PEG tube 
 
Reflux  
Ondansetron (Zofran) 4mg/5ml 
5ml twice daily via PEG tube 
 
Reflux/sickness  
Gaviscon Advance liquid 
5-10ml up to four times a day when required via PEG 
tube 
 
Reflux  
Macrogol (Movicol)sachets  
One sachet in the morning via PEG tube 
 
Constipation  
Benefiber powder 
15ml to be added to Ketocal feed 
 
Constipation   
Paracetamol 500mg soluble tablets 
One and a half tablets up to four times a day when 
required via PEG tube 
 
Pain  
Diclofenac (Voltarol) 50mg suppositories 
One to be inserted rectally when required 
 
Dystonia- pain  Only required in last year of life 
 
Cetirizine 5mg/5ml solution 
5ml twice daily via PEG tube 
 
Hayfever   
Hyoscine (Scopolamine) 1.5mg patch 
One patch to be applied every 48 hours 
 
Excess salivation  
Sando K 1000mg effervescent tablets 
Two at night via PEG tube 
 
Body salts  
Sodium Chloride 50mg/5ml solution 
5ml in the morning via PEG tube 
 
Body salts  
Budesonide (Pulmicort) [strength not specified] 
nebules  
One to be inhaled in the morning 
 
Asthma  
Salbutamol [strength not specified] nebules  
One to be inhaled when required 
 
Asthma  Caused tachycardia 
Carnitor 30% solution 
3.3ml in the morning via PEG tube 
 
Carnitine deficiency   
Ketocal powdered food  
200mg +500ml boiled water +500ml filtered water  
250ml bolus at night the 900ml overnight 
Food  For the last 7 years of his life he 
was on a ketocal (high fat) diet 
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Midazolam via syringe driver Palliative care  An ulcer developed around entry 
site of needle 
Morphine via syringe driver 
 
Palliative care   
 
Past Prescribed Medication Indication Comments/Notes 
Baclofen – oral and intrathecal Loss of muscle 
tone/contractures 
 Side effect of excess drowsiness/reduced 
cognition at one point 
 Intrathecal baclofen (via a continuous pump) was 
installed in Jamie’s mid-teens 
 Long term side effect was arachnoiditis 
(adhesions up the spinal canal) 
Oxygen Breathing problems 
from distorted body 
shape 
 Also had CPAP ventilator 
Variety of anti-epileptic 
medication including lamotrigine  
 
Epilpesy  Was careful to stick to a brand as generics 
affected seizure control 
Rectal diazepam Epileptic seizure  Replaced with buccal midazolam 
 
 
Over the Counter (OTC) Medication Indication Comments/Notes 
None noted   
 
Medication Management  
 
Ordering of prescriptions  Parents 
Taking prescriptions to 
pharmacy  
Collecting medication from 
pharmacy 
Administration  Mainly parents but carer (employed under direct payments) would administer 
medication if required 
Storage  A locked box/medication chest where current medication was stored 
 Excess medication was stored in his bedroom 
 Emergency medication was stored in the chest and in his bedroom 
 Toolbox converted to medication box for travel 
Other  
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Appendix 3.5 CASE 05N - ROB 
 
Personal Details  
Rob is a 20-year-old Caucasian male who has PMLD as a result of Emanuel syndrome, a 
chromosomal disorder. He has hearing impairment and wears a hearing aid in one ear; visual 
impairment and wears glasses; and is non-verbal. As part of a formal shared care agreement, Rob 
now lives with his ‘second parents’ in his ‘second home’ but returns to his family home every other 
weekend and for some holidays. His carer and care workers gave the following descriptions of him: 
cheeky; strong-willed; determined; quirky; very loving; an absolute joy. 
 
Medical History  
 
Active Medical Conditions Comments/Notes 
Emanuel Syndrome 
(also known as chromosome 11/22 
translocation or partial trisomy 
11/22) 
 
 Emanuel syndrome is a chromosomal disorder; most affected individuals 
have severe to profound intellectual disability (US Department of Health 
and Human Services 2017) 
Chronic gastrointestinal issues 
including: gagging, reflux and 
constipation 
[PEG tube in situ]  
 Started at puberty. PEG tube was put in place mid teens 
 All medication administered via the PEG tube but Jamie still takes some 
food orally 
 Small amount of liquid Nutrison feed given overnight to maintain weight 
 Lack of mobility and fluid intake contributing factors to constipation 
Epilepsy   Started at puberty. Initially tonic-clinic; now mainly complex partial 
 Photosensitive 
Scoliosis and muscoskeletal issues 
 
 Multiple operations to hip, leg, ankle, feet to improve mobility 
Excess salivation 
 
 
 
Past Medical Conditions Comments/Notes 
Cleft palate (sub-mucosal)   Caused drainage problems from ears 
Ear infections  Has had grommets inserted several times 
 Attends audiology clinic regularly and has ears cleaned out 
Stomach ulcer  From stress of routine change – having to stay indoors during a prolonged 
winter. 
Meningitis  
Rotavirus  
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Medication History  
 
Current Prescribed Medication Indication Comments/Notes 
Sodium Valporate (Epilim) 200mg/5ml liquid 
15ml twice daily via PEG tube 
 
Epilepsy   
Lamotrigine (Lamictal) 25mg dispersible 
tablets 
Four tablets twice daily via PEG tube 
 
Epilepsy  
Midazolam (Epistatus) 10mg/ml oromucosal 
solution 
1ml as per protocol 
 
Epileptic seizure   
Lansoprazole 15mg fastab  
One tablet twice daily via PEG tube 
Reflux  Recently changed from 
omeprazole 20mg/5ml liquid – 
10ml in the morning 
 Omeprazole tablets had clogged 
up the PEG tube 
Ranitidine 150mg/10ml liquid  
10ml twice daily via PEG tube 
 
Reflux  
Domperidone 1mg/ml liquid 
20ml twice daily via PEG tube 
 
Reflux  Had tried to reduce and stop but 
had to restart for symptom 
control 
Gaviscon Advance liquid 
5ml twice daily via PEG tube 
 
Reflux   Often used after mealtimes 
Macrogol (Movicol) sachets 
One at night via PEG tube 
 
Constipation   
Lactulose liquid 
10ml twice daily via PEG tube 
 
Constipation   
Paracetamol 250mg/5ml liquid  
15ml up to four times a day when required 
via PEG tube 
 
Occasional pain   
Hyoscine (Scopalamine) 1.5mg patch  
One patch to be applied every 72h 
 
Excess salivation   Less effective on day 3 
Maxitrol eye ointment 
Apply round stoma area when required  
Over-granulation of stoma 
tissue 
 Maxitrol contains 1 ml 
suspension contains 1 mg 
dexamethasone, 6000 IU 
polymyxin B sulfate, 3500 IU 
neomycin sulfate (as base) 
 
Past Prescribed Medication Indication Comments/Notes 
Antibiotics (liquid) Ear infections   
Senna Constipation   
Dioralyte Hydration during illness  
 
Over the Counter (OTC) Medication Indication Comments/Notes 
None noted.    
 
  
 231 
Medication Management  
 
Ordering of prescriptions  Care worker 
 Taking prescriptions to 
pharmacy  
Collecting medication from 
pharmacy 
Administration 
Storage – Care Worker’s home  Medicines stored in locked cabinet in kitchen – see photos Case05NPhoto1 and 
Case05NPhoto2 
 
 
Case05NPhoto01 – Closed medicine cabinet (kitchen)  
 
 
Case05NPhoto02 – Open medicine cabinet (kitchen) 
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 Extra boxes and new supplies are stored in a bedroom, in plastic boxes, at care 
worker’s home – see Photos Case05NPhoto3 and Case05NPhoto4 
 
 
Case05NPhoto03: Storage of extra boxes/new supplies-01  
 
 
Case05NPhoto04: Storage of extra boxes/new supplies-02 
 Case05NCareW01: ‘When I take him away…on holiday what I’ve got is…a big 
toolbox and I put all the medicines in that… omeprazole liquid, we had to keep it 
cool. And what we did was, we had a cool box that we could plug into the car…’ 
 
Storage – family home  Case05NCarer02: ‘We’ve got a utility room so they’re in a shelf above in the 
utility room away from everybody else.’ 
 Case05NCarer02[in reference to travel]: ‘Everything goes into a bag. Basically, 
we’ve got a plastic tub with all the syringes in it and it’ll go into a separate 
carrier bag with all the stuff. And then I lay out his medication.’ 
Other  
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Appendix 3.6 CASE 06C - MARK 
 
Personal Details  
Mark is a 54-year-old Caucasian male with moderate LD caused by Fragile X syndrome, a genetic 
condition. His capacity is limited but he is able to communicate verbally. He has his own room in a 
housing support facility and there are always care workers available. He receives scheduled support 
from care workers for most of his daily activities (washing, dressing, eating, activities). His carers 
gave the following description of him: sociable; likeable; happy; good sense of humour; great 
memory; loves Star Wars and the Welsh rugby team. 
 
Medical History 
 
Active Medical Conditions Comments/Notes 
Fragile X syndrome   Fragile X syndrome is a genetic condition that causes a range of 
developmental problems including learning disabilities and cognitive 
impairment (US Department of Health and Human Services 2017) 
Anxiety 
 
 
Eczema  
 
 
 
Past Medical Conditions Comments/Notes 
None noted   
 
Medication 
 
Current Prescribed Medication Indication Comments/Notes 
Fluoxetine 20mg capsules 
Two in the morning  
 
Anxiety and mood  Has successfully controlled his 
outbursts 
Clonazepam 0.5mg tablets 
Half a tablet in the morning and at 
lunchtime 
 
Anxiety/agitation   Will also take a dose before he 
has to attend the doctor or 
dentist 
Paracetamol 500mg tablets 
One or two tablets up to four times daily 
when required 
 
Pain  
Deramalo bath emollient  
Use in the bath when required 
 
Eczema  Flare-ups possibly linked to 
anxiety 
Ultrabase cream 
Apply morning and night  
 
Eczema   
 
Past Prescribed Medication Indication Comments/Notes 
Clobetasone butyrate (Eumovate) 0.05% 
cream 
Apply once or twice daily when required  
Eczema   Moderately potent steroid 
 
Over the Counter (OTC) Medication Indication Comments/Notes 
None noted    
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Medication Management  
 
Ordering of prescriptions  Key worker or another care worker 
 Taking prescriptions to 
pharmacy  
Collecting medication 
from pharmacy 
 The pharmacy delivers medication to the residential unit 
Administration  Routine is very important to Mark and he will remind the care workers to help him 
with his medicines if they are ever late 
 Mark self-administers as his care workers supervise. Care workers only help Mark 
apply his Ultrabase cream and record this on a MAR chart – see Case06CPhoto1 
 
 
Case06CPhoto01: MAR chart 
 
 Mark’s routine is included in his care plan – see Case06CPhoto2 and Case06CPhoto3 
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Case06CPhoto02: Care plan excerpt-01 
 
 
Case06CPhoto03 - Care plan excerpt-02 
 
 His ability to self-administer is also noted in his hospital passport – see 
Case06CPhoto04 
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Case06CPhoto04: Hospital passport excerpt  
 
Storage  Medication stored in a locked cupboard in Mark’s bedroom – see Case06CPhoto5 
 
 
Case06CPhoto05: Medicines storage (bedroom)   
 
Other Carers keep Patient Information Leaflets (PILs) for reference – see Case06CPhoto06 
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Case06CPhoto06: Referenced PILs 
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Appendix 3.7 CASE 07C - FIONA 
 
Personal Details  
Fiona is a 46-year-old Caucasian female who has mild-moderate LD (cause unknown). For the 
majority of everyday decisions, including medication, she is deemed to have capacity but the Local 
Authority has guardianship for particular decisions. Her mum lives locally and they have regular 
contact. She lives in her own flat within a small housing support unit for adults with LD; a care 
worker is always available around the clock. Care workers supervise her self-administering her 
medicines twice daily and support her with her finance. Fiona describes herself as enjoying her 
independence but needs company. She also enjoys craft work, decorating and going to the bingo 
with her mum. 
 
Medical History 
 
Active Medical Conditions Comments/Notes 
Pain (hip)  See information from care plan in Case07CPhoto1 
 
 
Case07CPhoto01: Care plan  
 
Depression/anxiety 
Constipation 
Dry skin 
 
Past Medical Conditions Comments/Notes 
Indigestion/heartburn  
Fungal infections (skin)  Possibly linked to not washing and drying properly 
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Medication History 
 
Current Prescribed Medication Indication Comments/Notes 
Cocodamol 30/500 effervescent 
tablets 
Two tablets twice daily 
 
Hip pain   Had previously been prescribed as two tablets four times 
daily 
 Concerns over dependence raised and dose reduced to 
twice daily 
Fluoxetine 20mg capsules 
Two in the morning 
 
Depression and 
anxiety  
 Initially prescribed as 20mg daily; then increased to 40mg 
Lactulose solution 
10mls twice daily 
 
Constipation   
Doublebase cream 
Apply after shower 
 
Dry skin  
 
Past Prescribed Medication Indication Comments/Notes 
Omeprazole 10mg capsules  
One in the morning when required 
Indigestion  
Fexofenadine 120mg tablets 
One in the morning when required 
Skin irritation   
Daktacort cream 
Apply twice a day when required 
Sweat rash beneath breasts  
 
Over the Counter (OTC) Medication Indication Comments/Notes 
Hyoscine (Kwells) 300mcg tab Travel sickness  
 
Medication Management 
 
Ordering of prescriptions  Care Workers 
 Taking prescriptions to 
pharmacy  
Collecting medication 
from pharmacy 
 Pharmacy delivers medication to the care workers at the residential unit 
Administration  Her care workers keep the key to the locked cupboard containing her medication but 
Fiona self-administers all her medication as detailed in her care plan (see 
Case07CPhoto2) and hospital passport (see Case07CPhoto3) 
 
 
Case07CPhoto02: Medication section of care plan   
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Case07CPhoto03: Medication section of hospital passport 
 
 Fiona has a set routine for taking her medicines: ‘I get up, answer my front door, they 
give me a key, I open my cabinet, I take out my box of co-codamol, my fluoxetine, my 
lactulose. ‘Cause I know that’s the three that I take in the morning. I fill my glass with 
water, put my two co-codamols in it. It makes a hissing noise which is good. I take my 
two fluoxetine at the same time ‘cause it’s easier to swallow. Then my lactulose. 
That’s in the morning. And at night I’ve only my lactulose and co-codamol at night-
time.’ 
 
Storage  Fiona has her oral medicines stored in a locked cupboard in her kitchen – see 
Case07CPhoto04 
 
 
Case07CPhoto04: Medication storage in kitchen  
 
 Her Daktacort is stored in her fridge 
 Fiona has a particular glass that she uses for her cocodamol – see Case07CPhoto5 
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Case07CPhoto05: Dedicated glass for taking dispersible co-codamol 
 
 Fiona also has particular measuring cups for her liquid medicines – see 
Case07CPhoto07 
 The cup on the left (with the larger numbers) is preferred to the one on the right. 
 
Case07CPhoto07: Measuring Cups  
 
Other  Two different types of packaging for cocodamol – see Case07CPhoto08 
 Fiona finds the foil ones easier to open  
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Case07CPhoto08: Two brands of cocodamol 
 
 Care workers do a stock check of all medicines on a Sunday 
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Appendix 3.8 CASE 08C - RUTH 
 
Personal Details  
Ruth is a 55-year-old Caucasian female with mild LD and has capacity to make decisions for herself 
(including medication). She lives alone in a flat that is part of a supported housing complex for adults 
with LD; children and grandchildren live locally and she has contact with most of them. Although she 
has worked previously she does not at present. Care workers supervise her taking her morphine 
tablets twice daily but Ruth is responsible for all her other medicines. Care workers also support her 
in arranging activities and with some aspects of personal care; support is minimal compared with 
other residents in the complex. Ruth enjoys going to the cinema, seeing her grandchildren and 
daughter, and going out for coffee. 
 
Medical History  
 
Active Medical Conditions Comments/Notes 
Depression/anxiety   Admitted to hospital for 2 years due to suicidal ideation before coming to 
current flat 
 Potential for self-harm when feeling stressed or anxious 
 Problems with low mood and pain recorded in sleep diary in previous 12 
months– see Case08CPhoto01 
 
 
Case08CPhoto01: Problems with low mood evidenced in sleep diary  
 
Insomnia  Evidence of attempts to gain insight into sleep patterns (see 
Case08CPhoto02) and to regulate hypnotic use (see Case08CPhoto03) over 
last 12 months 
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Case08CPhoto02- Information on sleep pattern   
 
 
Case08CPhoto03: Attempt to regulate/reduce hypnotic use  
Osteoarthritis & chronic pain   Back, pelvis and knees 
 
Hiatus hernia  Had endoscopy and colonoscopy done within last 12 months 
 
Constipation 
 
 
Irritable Bowel Syndrome (IBS) and 
intestinal polyps 
 
 
Hypothyroid  
 
 
Iron deficiency  
 
 
Asthma  Quiescent 
 
Allergy to diclofenac (Voltarol) gel 
and ibuprofen gel 
 
 Caused bronchospasm and skin irritation 
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Past Medical Conditions Comments/Notes 
UTIs   Infrequent 
Impacted wax  
 
Medication History 
 
Current Prescribed Medication Indication Comments/Notes 
Duloxetine 60mg capsules 
One in the morning and bedtime 
 
Depression/pain  About to begin dose reduction as 
requested by specialist 
Pregabalin (Lyrica) 200mg capsules 
One capsule three times daily 
 
Pain  
Morphine (MST) MR tablets 
[1x10mg + 1x30mg] twice daily 
 
Pain   
Paracetamol 500mg tablets 
Two tablets four times daily  
 
Pain   
Zopiclone 7.5mg tablets 
One at night 
 
Insomnia  Has been on 3.75mg and 15mg 
in the past 
L-thyroxine tablets  
[1x25mcg + 1x50mcg] in the morning 
 
Hypothyroid  
Ranitidine 300mg tablets 
One tablet twice daily  
 
Hiatus hernia  Had been 150mg twice daily 
Metoclopramide 10mg tablets 
One tablet three times a day 
 
Hiatus hernia  Tried and failed to reduce dose 
Gaviscon Advance liquid 
10ml up to four times a day 
 
Hiatus hernia  
Docusate 100mg capsules 
Two capsules twice daily  
 
Constipation  Exacerbated by MST and iron 
Ferrous sulfate (Ferrograd) 210mg tablets 
One in the morning 
 
Anaemia   Didn’t like the taste of liquid 
preparation 
Hyoscine (Buscopan) 10mg tablets 
One tablet three times daily   
 
IBS  
Piroxicam gel 
 
Sore muscles/joints   Mentioned by carers but not 
seen or mentioned by Ruth 
Sodium hyaluronate (Clinitas)  
eye drops 
 
Dry eyes  Seen in bedroom but not 
mentioned by Ruth 
 
Past Prescribed Medication Indication Comments/Notes 
Cerumol ear drops Impacted wax  
Ibuprofel topical gel Back pain  Adverse drug reaction 
Omeprazole capsules Hiatus hernia  Changed to ranitidine 
Macrogol (Laxido) sachets  Constipation   
Diazepam tablets Anxiety  
Dihydrocodeine tablets Pain   
Tramadol capsules Pain   
Amitriptyline tablets Pain   Replaced with pregabalin 
Peppermint oil capsules IBS  
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Salbutamol inhaler Asthma  
Beclometasone inhaler Asthma  
Simple linctus Sore throat   
Doublebase cream Dry skin   
Sodium Cromoglycate (Opticrom) 
allergy eye drops 
Sore eyes   
Antibiotics  UTIs  
 
Over the Counter (OTC) Medication Indication Comments/Notes 
Tums tablets Indigestion  
Deep Freeze gel Back pain  
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Medication Management 
 
Ordering of prescriptions The supplying pharmacy. 
Taking prescriptions to 
pharmacy  
Pharmacy collect from the surgery. 
Collecting medication from 
pharmacy 
Pharmacy deliver to the care workers at the supported housing unit. 
Administration  Ruth self administers all her medicines except the MST without any supervision 
by the care workers 
 The majority of medicines are packed in a pharmacy filled MCA – see 
Case08CPhoto04 
 
 
Case08CPhoto04: Pharmacy-filled MCA  
 In the morning, Ruth moves all these tablets into her own pillbox (see 
Case08CPhoto05) and self-administers from this 
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Case08CPhoto05: Ruth’s own pill-box  
 
 Ruth has a particular routine with her medicines as described by her carers, 
Case08CCarer04: ‘She takes her tablets the same way every day. It’s the same 
tablets go – just say it’s the blue one first, and then the green ones and then the 
white ones. She does that every day. That’s the way she takes her tablet.’ 
 Case08CCarer02: ‘She’s got a lined-up routine thing going on I’ve noticed. 
Sometimes she’s got them lined-up waiting for the time to take the.’ 
 Ruth’s MST is stored in a medisafe and the carers supervise her access to the 
MST 
 Even though it is not legally required, the carers maintain a CD register 
 
Storage  Ruth stores all her medicines (except for her MST) in her bedroom – see 
Case08CPhoto06 
 
 
Case08CPhoto06: Storage of medicines (bedroom)  
 
 MST is stored in a locked safe in her hall cupboard – see Case08CPhoto07 
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Case08CPhoto07: Storage of MST (hall cupboard) 
Other  
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Appendix 3.9 CASE 09C - DONALD 
 
Personal Details  
Donald is a 29-year-old Caucasian male who has autism and mild LD. He lives alone in a tenement 
flat; in that tenement other flats are rented out to adults with LD. His parents live on the other side 
of the city and he sees them at least once a week. Donald works for 2 hours/week in a nearby office. 
He receives 20 hours of care worker support each week and it fits around what he has on that week. 
His care worker makes sure he is eating properly, budgeting appropriately and general 
housekeeping; his care workers are not involved with any aspect of his medication. Donald states 
that what is important to him is volunteering with a number of groups, working, and getting enough 
sleep. 
 
Medical History 
 
Active Medical Conditions Comments/Notes 
Autism 
 
 
Depression/ seasonal affective disorder 
 
 Diagnosed age 18/19y 
Anxiety 
 
 
Asthma 
 
 Diagnosed age 14y 
Eczema 
 
 From birth 
Hayfever 
 
 From birth  
 
Past Medical Conditions Comments/Notes 
None mentioned   
 
Medication  
 
Current Prescribed Medication Indication Comments/Notes 
Mirtazapine 30mg tablet 
One at night  
 
Depression   Weekly dispense 
Venlafaxine (Efexor) 75mg XL capsule 
One in the morning  
 
Depression/anxiety   Weekly dispense 
Salbutamol 100mcg inhaler 
Two puffs when required 
 
Asthma  
Beclometasone 100mcg and salmeterol 6mcg 
(Fostair) inhaler 
Two puffs morning and night  
 
Asthma   
 
Past Prescribed Medication Indication Comments/Notes 
Co-codamol 30/500 tablets 
Two tablets up to four times a day when 
required 
Pain   
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Over the Counter (OTC) Medication Indication Comments/Notes 
None mentioned    
 
Medication Management  
 
Ordering of prescriptions  Donald will order his prescriptions 
Taking prescriptions to 
pharmacy  
 The pharmacy collect the prescriptions from the GP surgery 
Collecting medication from 
pharmacy 
 Donald goes to the pharmacy himself to collect the medication 
Administration  Donald self-administers without any supervision from care workers 
Storage  Medicines stored in drawer in kitchen – see Case09CPhoto01 
 
 
Case09CPhoto01: Medicines storage (kitchen)   
 
Other  
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Appendix 3.10 CASE 10C - SUSAN 
 
Personal Details  
Susan is a 59-year-old Caucasian female who lives in a flat in a supported housing complex (city 
location); she had been in at least 5 other places before that. She has mild-moderate LD (cause 
unknown) and has visual impairment from only having one working eye. Both her parents have died 
and she only has contact with one of her siblings. She receives scheduled care worker support once 
a fortnight to assist her with shopping and general activities. She has capacity for everyday decisions 
and self-manages her medication. For Susan, the things that are important to her are: feeling secure 
(as she does in her current accommodation); going to her drama group on a Wednesday; and 
dolphins – she swam with dolphins on a trip to Florida. 
 
Medical History 
 
Active Medical Conditions Comments/Notes 
Hypertension  
 
 
Heartburn/ indigestion  
 
 
Urinary frequency, urgency, and 
urge incontinence 
 
 Despite medication, still has to wear incontinence pads 
Irritable bowel syndrome? 
 
 Complains of stomach pains, wind and occasional diarrhoea 
Hip pain/ mobility issues 
 
 Requires a frame to walk 
Visual Impairment  
 
 Only has one eye 
 
Past Medical Conditions Comments/Notes 
Hormonal/uterine problems  Problems with bleeding; had a hysterectomy 
Urinary tract infections (UTIs)  
 
Medication History  
 
Current Prescribed Medication Indication Comments/Notes 
Aspirin 75mg dispersible tablets  
One in the morning  
 
Primary prevention?   No recollection of a myocardial 
infarction or stroke 
Amlodipine 10mg tablets 
One in the morning  
 
Hypertension   
Ramipril 2.5mg capsules  
One in the morning  
 
Hypertension   
Lansoprazole 30mg capsules  
One in the morning 
 
Heartburn/ indigestion   
Mirabegron MR 50mg capsules 
One in the morning 
 
Urinary frequency, urgency, 
and urge incontinence 
 Still suffers from urinary 
incontinence despite medication 
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Solifenacin 5mg tablets 
One in the morning  
 
Urinary frequency, urgency, 
and urge incontinence 
Loperamide 2mg capsules 
One when required after loose stool  
 
Diarrhoea   
 
Past Prescribed Medication Indication Comments/Notes 
Hormonal therapy  Pre-hysterectomy   
Antibiotics UTIs  
 
Over the Counter (OTC) Medication Indication Comments/Notes 
Gaviscon double action sachets  Indigestion   
Hyoscine 0.3mg tabs  Travel sickness  
Vitamins (cod liver oil)    
Aspirin tablets Pain   
 
Medication Management  
 
Ordering of prescriptions  Care Worker in housing support unit orders Susan’s prescriptions 
Taking prescriptions to 
pharmacy  
 Pharmacy collects prescriptions from the GP surgery 
Collecting medication from 
pharmacy 
 Pharmacy delivers medication to Susan 
Administration  Susan self-administers her medication without formal carer support; she gets all 
her regular medication in an MCA 
Storage  Susan keeps her MCA on a pull out shelf in the kitchen (see Case10CPhoto01) 
and original packs of medicines in a plastic container beside the microwave in 
the kitchen (see Case10CPhoto02) 
 
 
Case10CPhoto01: Medicine storage-01 (kitchen)  
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Case10CPhoto02: Medicines storage-02 (kitchen)  
 
Other  
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Appendix 3.11 CASE 11C - DAVID 
 
Personal Details 
David is a 68-year-old Caucasian male who describes himself as having LD. However, his learning 
disability actually came about from a motorbike accident when he was a teenager that left him 
partially paralysed and brain damaged. He has memory problems and described himself as ‘dead 
slow’. Although it can be argued that he does not have LD as defined by the British Psychological 
Society (2000), he identifies with that sub-group of the general population and so has been included. 
David worked as a handyman for most his life but had to retire early because of an increasing 
frequency of epileptic seizures. He has lived alone in a flat in a supported housing unit for the last 30 
years. David receives support several times a week from a support worker; he manages his 
medication independently. Of most importance to David are: his security; his art – he enjoys 
sketching and painting and would like to attend a local art class; and being fit and independent. 
 
Medical History 
 
Active Medical Conditions Comments/Notes 
Epilepsy (petit mal)  Started after his motorbike accident 
 Was controlled earlier on in his life but not in his later working life – 
resulted in him having to take early retirement 
Osteoporosis 
 
 
Low body weight 
 
 Involvement of dietitian  
 
Past Medical Conditions Comments/Notes 
Brain injury/ haemorrhage after 
motorbike accident 
 Right-sided causing left-sided weakness 
Fractured neck of femur   Fell in a local shop 
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Medication History 
 
Current Prescribed Medication Indication Comments/Notes 
Alendronate 70mg tablet 
One tablet weekly 
 
Osteoporosis  Takes on a Monday  
Accrete D3 tablet 
One tablet twice daily 
Osteoporosis  
Lamotrigine 200mg tablet 
One tablet twice daily  
 
Epilepsy   
Ensure Plus 
Two drinks daily  
 
Low body weight  
Paracetamol 500mg tablets 
Two tablets when required  
General aches/pains  David decants his paracetamol from a pack into 
a tub that was previously for vitamins – see 
Case11CPhoto01 Paracetamol storage 
 
 
Case11CPhoto01 Paracetamol storage 
 
 
Past Prescribed Medication Indication Comments/Notes 
Senna 7.5mg tablets 
Two tabs morning and night 
Constipation  Not required regularly  
Aqueous cream Dry skin  On repeat prescription list but 
David never mentioned 
Other anti-epileptic medication   Couldn’t remember the names 
 
Over the Counter (OTC) Medication Indication Comments/Notes 
Calcium and vitamin D tablets  Supplement  Knew that he now had prescribed calcium 
and vitamin D so was no longer taking 
Magnesium 187.5mcg tablets Supplement  Couldn’t remember why he had bought 
these  
 
Strepsils lozenges  
Sore throat Propolis lozenges 
Tyrozet lozenges  
Lemsip Max sachets Cough/cold 
Ibuprofen 200mg tablets Pain relief 
Paracetamol 500mg tablets 
Bonjela oral gel Sore mouth 
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Medication Management  
 
Ordering of prescriptions  Orders his own medication 
Taking prescriptions to 
pharmacy  
 Pharmacy collects the prescriptions from the GP surgery 
Collecting medication from 
pharmacy 
 Pharmacy delivers his medication to his flat 
Administration  David self-administers his own medication 
 He has his own system for organising his medication 
 He puts his twice daily lamotrigine into his own medication box and keep a strip 
of his Accrete D3 beside it (see Case11CPhoto02) 
 
 
Case11CPhoto02: David’s system for organising his lamotrigine and Accrete  
 
 He then uses his old medication box (see Case11CPhoto03) for other 
medication/vitamins he needs to take that day 
 
 
Case11CPhoto03: David’s system for organising other medicines/vitamins  
Storage  David stores his medicines in the kitchen in two locations – see Case11CPhoto04 
and Case11CPhoto05 
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Case11CPhoto04: Medicine storage-01 (kitchen)  
 
Case11CPhoto05: Medicine storage-02 (kitchen)  
 
Other  
 
 
